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Summary 
Chronic lymphocytic leukaemia (CLL) is the most prevalent leukaemia of the 
Western world, and despite the recent evolution in clinical treatment of the 
disease, it remains incurable.  Although current therapies such as allogeneic 
hematopoietic stem cell (HSC) transplantation have been successfully used to 
treat CLL, this is an option for only a minority, as most CLL patients are diagnosed 
over the age of sixty and cannot withstand the harsh transplantation procedures. 
Combination chemotherapy, such as fludarabine and cyclophosphamide, has 
been shown to significantly improve response rate and prolonged remission in CLL 
patients, however, no improvement in overall survival has been observed. Patients 
eventually relapse due to re-emergence of minimal residual disease (MRD). 
Therefore it is critical that further clinical therapies are investigated in order to 
eliminate MRD, and offer hope to patients that are unresponsive to current 
treatments.   
CLL is marked by the presence of the accumulation of long-lived mature 
monoclonal B cells in peripheral lymphoid organs, bone marrow and peripheral 
blood with the specific phenotype of CD19hi, CD5+, CD23+ and IgMlo that resist 
apoptosis. The in vivo accumulation of leukaemic lymphocytes is highly facilitated 
by interactions of CLL cells with other cells present in their microenvironment, 
including stromal cells and soluble factors such as IL4.  Studies have established 
a variety of mechanisms potentially responsible for disease progression in CLL, 
including chromosomal abnormalities and intrinsic defects in the apoptotic 
machinery due to higher levels of the anti-apoptotic protein Bcl-2 family member 
proteins Bcl-2 and Mcl-1, thus making this disease extremely heterogeneous.  
Although the apoptotic machinery is certainly dysregulated in CLL, it is not simply 
a disease of a clonal accumulation of B cells, rather, proliferation is occurring as 
well as apoptosis, accounting for up to 2% of the clone size per day. CLL B cell 
proliferation centres exist within lymph nodes (LN) and bone marrow (BM) where B 
cells receive signals from their B cell antigen receptor (BCR) to proliferate, 
generating a very aggressive form of the disease.  In addition, evidence suggests 
that stimulation through the BCR plays a pivotal role in pathogenesis of CLL since 
CLL B cells have a phenotypic profile of B cells activated by antigen interaction 
and a genetic expression profile of antigen experienced B cells.  
During the course of our studies assessing the impact of modulating protein kinase 
C (PKC) signaling in B cell development in vitro or in vivo, we developed a unique 
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model system to investigate the mechanisms underlying the induction of CLL.  
Introduction of full length, catalytically inactive PKCα (PKCα-KR) into HSCs 
derived from wild type mouse fetal liver (FL), and subsequent culture of the cells 
either in vitro or in vivo resulted in the generation of a population of B lymphocytes 
that are phenotypically similar to human CLL cells (CD19hi, CD5+, CD23+, IgMlo). 
PKCα-KR-expressing FL cells also expressed enhanced proliferative capacity over 
untransduced cells and were refractory to apoptosis.  These results indicate that 
the subversion of PKCα signaling acts as an oncogenic trigger for developing B 
lymphocytes. The aim of this project was to identify similarities between our 
murine CLL (mCLL) model and human CLL and investigate putative translational 
therapeutic targets.  The main findings of this study implicate PKCβII as an 
important survival and proliferation signal within mCLL.  Cyclin D1 is also 
upregulated within mCLL, linked to an increase in the proliferative capacity of 
mCLL cells, and is regulated through transcriptional repressor 4EBP1, which 
appears inactive in both mCLL and human CLL.  In addition, PKCα-KR transduced 
cells harbour the potential for lineage plasticity in a microenvironment-dependent 
manner, whereby PKCα-KR B cells lineage switch to T cells upon Notch ligation.  
The reprogramming occurs via a reduction in B cell specific genes and an 
upregulation of T cell specific genes, implicating the deregulation of PKCα 
activity/expression as a potential mechanism for lineage trans-differentiation 
during malignancies. Importantly, in human CLL, PKCα is downregulated at the 
transcript and protein levels implicating it a tumour suppressor, highlighting the 
translational capacity of our CLL mouse model. 
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1.1 Normal B cell development and function 
1.1.1 Summary of B cell development 
B cell development is characterized by a series of steps marked by the 
upregulation or downregulation of specific genes that regulate differentiation, 
proliferation, migration, survival and apoptosis (Honjo & Neuberger 2004). At each 
stage of B cell development, gene rearrangements lead to either successful or 
unsuccessful immunoglobulin (Ig) protein chain products, allowing the cell to 
proceed to the next stage of development or to apoptose respectively (Murphy et 
al. 2008).   It is crucial that a B cell expresses only one receptor specificity, and is 
therefore strictly monitored by inherent checkpoints to avoid dysfunctional 
development (Murphy et al. 2008). Therefore an immature B cell that binds self-
surface antigen is removed through negative selection in the BM.  A mature B cell 
bound to foreign antigen is activated and eventually gives rise to plasma and 
memory cells (Murphy et al. 2008).   
1.1.2 B cell development  
Pluripotent haematopoietic stem cells (pHSCs) develop into lymphoid progenitors 
that can generate B, T and NK cells and are phenotypically Lin-CD27+ckithi Sca-1+ 
within the mouse and Lin-CD34+CD38- within the human (Honjo & Neuberger 
2004; Nagasawa 2006) (Figure 1.1). Within the BM microenvironment lie stromal 
cells that provide cell-to-cell contact through cell adhesion molecules and their 
ligands and also secrete necessary cytokines and chemokines for the subsequent 
differentiation into B cells.  Multipotent progenitor cells (MPPs) express cell-
surface receptor tyrosine kinase called Flt-3 in human (Flt-3/Flk-2 in mice) that 
binds Flt-3 ligand on stromal cells.  Through Flt-3 signaling, an MPP differentiates 
to a common lymphoid progenitor (CLP) that can give rise to both B and T cells 
(Honjo & Neuberger 2004).  Flt-3 signaling together with activity of transcription 
factor PU.1 (also known as spleen focus forming virus (SFFV) proviral integration 
oncogene SPI1) induces expression of the interleukin-7 receptor (IL7R) in both 
human and mouse.  IL7 secreted by the stromal cells is important for the 
development of B and T cells in mice (Honjo & Neuberger 2004).  In human, 
although IL7R is expressed on HSCs from the BM and foetal liver (FL), stem cells 
within human cord blood (CB) that are CD34+CD38-CD7+ do not express IL7R, 
indicating that it may not be necessary in human B cell development (Hao et al. 
2001; Milne & Christopher J Paige 2006; Hoebeke et al. 2007).  In addition to IL7, 
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stem-cell factor (SCF) is another cytokine that stimulates growth of the 
haematopoietic lineage and B cell progenitors (Honjo & Neuberger 2004).  SCF is 
a membrane bound cytokine that interacts with receptor tyrosine kinase ckit 
(CD117) on precursor cells.  Stromally secreted stromal cell-derived factor 1 (SDF-
1), also known as chemokine CXCL12 is also important in B cell development at 
this stage for retention of B cell precursors within the BM (Honjo & Neuberger 
2004). CLP are marked by surface expression of CD45+Lin-ckitlo Sca-1lo in mouse 
and CD34+CD38+CD10- in human (Honjo & Neuberger 2004; Nagasawa 2006) 
(Figure 1.1).  At this point of development definitive B cell fate is specified by 
activity of E2A and early B cell factor (EBF) (see Section 1.1.4).  
The CLP gives rise to the pre-pro-B cell, where Ig rearrangement begins with the 
heavy-chain locus driven by recombination activation genes (RAG)s (Figure 1.2). 
Phenotypically pre-pro-B cells are ckit-B220+Flt-3+CD43+BP-1- and heat stable 
antigen (HSA/CD24)- in mouse and CD34+CD38+CD19+CD10- in human (Figure 
1.1) (Nagasawa 2006).  Ig heavy chain (IgH) rearrangement begins with the 
coming together of diverse (D) to joining (J)H regions at both alleles of the IgH locus 
(Figure 1.2). However these cells are not decisively B cells, as DH-JH gene 
rearrangements are also found in T, NK and myeloid cells (Honjo & Neuberger 
2004). As the lymphoid progenitors continue differentiation toward the B cell fate, 
some cells begin to express Igα (CD79a).  In addition transcription factors paired-
box-protein-5 (PAX5) and aiolos are expressed within this population, and Id 
genes repressed (Honjo & Neuberger 2004). 
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Figure 1.1 B cell development: surface protein expression 
 
At this point the cell becomes a pro-B cell that begins rearrangement of variable 
heavy chain (VH) gene segment to DJH on one chromosome (Honjo & Neuberger 
2004)(Figure1.2).   If this rearrangement is unsuccessful, rearrangement on the 
other allele begins.  Phenotypically pro-B cells are characterized as 
CD19+ckit+B220+Flt-3-CD43+BP-1-HSA+ in mouse and CD34+CD38+CD19+CD10+ 
in human (Figure 1.1) (Nagasawa 2006; Igarashi et al. 2002). 
Terminal deoxynucleotidyl transferase (TdT) is an enzyme that is expressed by 
pro-B cells.  By adding non-templated nucleotides at the joints in between 
rearranged gene segments, TdT aids in the diversity of the BCR repertoire.  Once 
V(D)J has rearranged, the rearranged heavy chain (IgVH) must be functionally 
tested.  The heavy chain is incorporated into a receptor along with two surrogate 
proteins that have similar structures to the light chains (which have not yet 
rearranged) (Ogawa et al. 2000; Gounari et al. 2002).  Expression of these two 
surrogate proteins: λ5 and VpreB are induced by E2A and EBF.  Alongside these 
surrogate proteins, Igα (CD79α) and Igβ (CD79b) are two other necessary proteins 
expressed by pro-B cells that are crucial components of the pre-B cell receptor 
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(pre-BCR) (Honjo & Neuberger 2004). Unlike λ5 and VpreB, Igα and Igβ are also 
necessary for the formation of the BCR.   
Formation of the pre-BCR marks the transition between a pro-B cell toward a large 
pre-B cell population which is CD19+ckit-B220+Flt-3-CD43-BP-1+HSA+ in mouse 
and CD34-CD19+CD10+ in human (Figure 1.1) (Nagasawa 2006; Murphy et al. 
2008). Signaling via the pre-BCR involves key molecules such as B cell linker 
protein (BLNK) and Bruton’s tyrosine kinase (Btk), and ensures that only one of 
the two heavy chain alleles are expressed in a cell, a process termed ‘allelic 
exclusion’.  Allelic exclusion involves a reduction in expression of RAG1 and 
RAG2 and reduction in access to heavy chain locus to the recombinase 
machinery.  Pro-B cell to large pre-B cell transition is also marked by a 
proliferation event, whereby the population of cells that have successfully formed 
the pre-BCR expands before it becomes a population of small pre-B cells. 
Expression of VpreB and λ5 is turned off at this point (Grawunder et al. 1995) 
through pre-BCR signaling via Igα/Igβ, spleen tyrosine kinase (SYK) and BLNK 
(Melchers 2005).   
 
Modified from Murphy et al. 2008 
Figure 1.2 V(D)J Recombination  
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Large proliferating pre-B cells eventually stop dividing and light chain 
rearrangement re-occurs.  At this point TdT is activated in human cells (but not in 
mouse) (Honjo & Neuberger 2004; Payne & Crooks 2007).   
Light chain rearrangement is initiated by the reactivation of RAG proteins.  Each 
small pre-B cell can generate a unique rearranged light chain, thus again enlarging 
the overall pool of B cells with different antigen specificities.  Since light chain loci 
lack D segments, rearrangement occurs by VJ joining (Figure 1.2). Once light 
chain rearrangement is successful on both alleles, a light chain pairs with a µ 
chain forming an intact IgM that is expressed on the cell surface and the cell 
enters the immature B cell stage. Allelic and isotypic exclusion occur after light 
chain rearrangement to produce B cells expressing only one type of light chain: κ 
or λ. Immature B cells are found in BM and spleen and express IgM but not IgD on 
their surface. They also continue to express RAG1, RAG2, and AA4.1, whereas 
CD21 and CD23 are not yet expressed (Honjo & Neuberger 2004).  If immature B 
cells express autoantigen specific BCR, arrest in differentiation is initiated and 
apoptosis follows.  On the other hand, low avidity to autoantigen can result in 
positive selection of immature B cells into the B1 cell compartment in the mouse, 
or periphery for human (Honjo & Neuberger 2004). Separate B1 and B2 
compartments found in the mouse are yet to be identified in human (see section 
1.1.2.1) (Payne & Crooks 2007). An immature B cell passes through a transitional 
stage (see section 1.1.2.2) where it can be positively selected for and allowed to 
mature, now expressing both IgM and IgD. A mature B cell bound to foreign 
antigen is activated and eventually gives rise to plasma and memory cells (Murphy 
et al. 2008). 
1.1.2.1 B1 versus B2 cells 
In mouse, B1 cells consist of B1a and B1b cells, which differ based on surface 
phenotype whereby B1a cells are IgMloIgDlo/-CD5+ and B1b cells are IgMhiIgDlo/-
CD5lo/-. B2 cells are IgMloIgDhiCD5- (Hayakawa & Hardy 2000).  B1 cells are 
thought to be derived from FL, whereas B2 cells are of adult BM origin.  B1 cells 
are found within spleen, pleural and peritoneal cavities and can express CD11b 
within the peritoneal cavity (Berland & Wortis 2002).  Two models exist that 
explain the origin of a B1 and B2 cells.  In the single lineage model, B1 and B2 
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cells are thought to derive from two distinct committed precursors, and are 
therefore distinct lineages.  In the layered model, B1 cells are thought to develop 
as a result of antigen-driven differentiation and selection (Berland & Wortis 2002).  
B1 cells are thought to develop as a result of B cells encountering repetitive 
antigens during neonatal life, whereas B2 cells develop as a result of B cells being 
exposed to exogenous antigens during adult life.  In this model, B2 cells can 
transition into B1 cells through BCR stimulation (Herzenberg 2000).  However, 
Montecino-Rodriguez and colleagues show that B1 and B2 progenitors are distinct 
subsets based on CD138 and MHC class II molecule expression during early B 
cell development (Montecino-Rodriguez et al. 2006; Tung et al. 2006). 
1.1.2.2 Transitional B cells  
Between BM immature B cells and peripheral mature B cells exist a subset of 
transitional B cells, termed transitional 1 (T1) and transitional 2 (T2) cells.  The 
transitional stage is a key juncture where developing B cells gain access to the 
spleen, start responding to T-cell help and become insensitive to negative 
selection.  Transitional B cells still resemble their BM counterparts (Chung et al. 
2003).  They are still susceptible to negative selection and are HSAhighAA4.1+, 
express surface IgM at higher levels and CD22 and B220 at lower levels 
compared to mature B cells.  Phenotypically, T1 B cells are AA4.1+IgM+IgD-
CD21loCD23- whereas T2 B cells IgMhiIgDhiCD21+CD23+.  Allman et al describe a 
T3 subset which is similar to T2 but expresses sIgM at lower levels than T2 cells 
(Allman et al. 2001).   
When immature B cells exist in the BM, they emigrate to the spleen via terminal 
branches of central arterioles and enter the red pulp, penetrating the marginal 
zone sinuses and reaching the periarteriolar lymphoid sheath (PALS).  T1 cells are 
limited to the outer PALS where the T-cell-B cell interphase lies, whist T2 cells 
migrate toward B cell follicles, most likely due to their high surface expression of 
chemokine receptor CXCR5 compared to T1 cells (Chung et al. 2003).  Whereas 
mature B cells induce proliferation upon BCR engagement, T1 cells do not 
proliferate and are vulnerable to apoptosis.  It is unclear whether T2 cells 
proliferate and are resistant to apoptiosis following BCR engagement (Loder et al. 
1999; Allman et al. 2001; Su & Rawlings 2002; Petro et al. 2002; Chung et al. 
2002; Chung et al. 2003).  However, with T-cell help, T2 B cells do proliferate 
when stimulated and evade BCR-induced apoptosis, unlike T1 cells (Chung et al. 
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2002).  Both T1 and T2 cells, however, are capable of processing and presenting 
antigen like mature B cells.  Therefore the transition from T1 to T2 is key in their 
subsequent development into mature B cells as T2 cells are more responsive to 
positive selection pressures in comparison to T1 cells.   
1.1.2.3 Marginal zone B cells 
Marginal zone (MZ) B cells are IgMhiIgDlowCD21hiCD23- cells that can be found 
within the outermost portion of the white pulp within the spleen, in tonsil 
subepithelial areas, dome regions of Peyer patches and within the subcapsular 
portions of the LN (Chiorazzi & Ferrarini 2011).  MZ B cells are capable of a T-cell 
independent response to bacterial polysaccharides and can carry either 
unmutated or mutated IgV rearrangements (Weill et al. 2009).  In human, 70-80% 
of MZ B cells have mutated IgVH rearrangements (Chiorazzi & Ferrarini 2011).   
MZ B cells can undergo IgVH mutations and Ig isotype switching during responses 
in MZ areas. Activation-induced deaminase (AID) has been postulated by some to 
be responsible for inducing IgV mutations in MZ B cells, although some argue that 
AID cannot be detected in splenic MZ B cells (Chiorazzi & Ferrarini 2011; 
Willenbrock et al. 2005). A more accepted explanation is migration of B cells that 
have acquired mutations and undergone class switch recombination (CSR) within 
the germinal centre (GC) into the MZs.  MZ B cells have been demonstrated to be 
antigen-experienced as confirmed by evidence of clonal expansion of IgMhiIgDlow 
IgV unmutated B cells.  Also, IgV mutated MZ B cells are capable of diversification 
and expansion within the MZ (Dono et al. 2000; William et al. 2002; Dono et al. 
2007).  Within MZ areas, IgG or IgA expressing B cells are found, termed switched 
memory B cells, that use mutated IgVH genes and are most likely of post-GC origin 
(Chiorazzi & Ferrarini 2011). 
1.1.3 The germinal centre reaction 
If a foreign antigen invades the system, CD4+ helper T cells are activated by 
antigen-presenting cells in the periphery (Melchers 2005).  These activated T cells 
travel into the perpheral lymphoid organs where the antigen activates resting 
mature B cells, forming GCs where centroblast and centrocyte B cells proliferate.  
After a few days, a GC becomes visible with histology and is marked by the 
presence of a light zone, rich in follicular dendritic cells (FDCs) and a dark zone 
filled with a compact pool of centroblasts  (Figure 1.3).   Within the GC, CD40 on B 
cells binds to CD40 ligand (CD154) on helper T cells and AID is expressed.  AID 
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induces somatic hypermutation (SHM) in VH and VL regions of Ig, induces CSR via 
switch regions and induces replacement of V-region encoding segments (Melchers 
2005).   
 
Modified from Küppers 2005 
Figure 1.3 The germinal centre reaction 
 
The Igs on these B cells are now hypermutated and express IgH classes other 
than IgM (such as IgG, IgE or IgA) (Klein & Dalla-Favera 2005).  These cells can 
become long-living memory B cells that have high affinity to that particular antigen 
that will in turn get reactivated if the same/similar antigen invades the system 
(Klein & Dalla-Favera 2005).  The hypermutated sIg-expressing B cells can also 
turn into high-affinity antibody-secreting plasma cells.  Both memory and plasma 
cells exit the GC and return to the BM (Melchers 2005). Alternatively if a B cell 
does not exhibit high affinity to an antigen, it is unlikely to survive, resulting in 
apoptosis.   
SHM of mature B cells in response antigen stimulation by T cells not only leads to 
hypermutation of Ig VH and VL regions and Bcl-6 gene, but occasionally also other 
genes that are actively transcribed within the GC which can in turn lead to 
malignancies. For example, in diffuse large cell lymphoma, genes such as c-
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myelocytomatosis viral oncogene (c-myc),  proto-oncogene serine/threonine-
protein kinase (pim-1) and PAX5 are also hypermutated (Melchers 2005).   
1.1.4 Transcriptional Control  
The decision of a lymphoid progenitor to become a B or T cell is controlled by the 
Ikaros gene which controls downstream target genes RAG, TdT, IgH and IgL chain 
genes and Igα (Honjo & Neuberger 2004).  B cell commitment specifically, is 
initially mainly dependent on two transcription factors: the basic-helix-loop-helix 
protein E2A and EBF.  E2A gene has two isoforms: E12 and E47 generated by 
alternate splicing.  IL7 signaling promotes E2A expression that cooperates with 
PU.1 to induce EBF expression (Murphy et al. 2008). Together these transcription 
factors induce expression of B cell specific proteins and thus B cell fate.  In fact, 
absence of E2A negatively affects B lineage differentiation. E2A-/- mice do not 
rearrange Ig at the DH-JH nor VL-JL level (Bain et al. 1994; Zhuang et al. 1994; Lin 
& Grosschedl 1995; Sigvardsson et al. 1997; Kee & Murre 1998).  Transcript 
levels of RAG1, RAG2, CD19, Igα, Igβ, VpreB, λ5 and PAX5 are reduced or 
abolished when E2A is downregulated.  In addition, E2A isoform E47 induces 
expression of TdT and IgH chain locus (Choi et al. 1996).  Also, deficient EBF 
expression in mice results in a B cell developmental block similar to E2A-/- mice 
(Lin & Grosschedl 1995).  
Although E2A and EBF are important initially in B cell development, they are not 
sufficient to push B cell precursors to develop pre-BCRs and functional BCRs.  
Expression of transcription factor PAX5 is crucial to B cell development (Honjo & 
Neuberger 2004).  It is expressed in all stages of B cell development apart from 
plasma cells (Urbánek et al. 1994; Busslinger & Urbánek 1995).  In PAX5-/- mice B 
cell development stops at the pro-B stage (Urbánek et al. 1994).  These cells 
express VpreB and λ5 genes, Igα and Igβ, RAG1 and RAG2, octamer transcription 
factors 1 and 2 (Oct1; Oct2), sex-determining region Y-box 4 (Sox-4), PU.1, 
Ikaros, E2A and EBF (Honjo & Neuberger 2004). PAX5-/- cells do not initiate VH to 
DH-JH rearrangement as normal pro-B cells and cannot therefore generate large 
pre-B cells that express the pre-BCR.  Therefore, these cells cannot rearrange VL-
JL and form immature or mature B cells.   
PAX5 is not only necessary for B cell commitment, but also for the maintenance of 
B cell identity during subsequent differentiation (O’Brien et al. 2011).  PAX5 
activates the transcription of a number of downstream genes responsible for pre-
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BCR signaling as well as other transcription factors that ensure B cell identity.  
More specifically, PAX5 regulates expression of pre-BCR components: V-DJ 
recombined IgH chain alongside surrogate light chains VpreB and λ5, and the Igα/β 
dimmer.  Co-receptor CD19 which is responsible for positive amplification of pre-
BCR signaling is also regulated by PAX5, alongside BLNK and phospholipase C 
gamma (PLCγ)2 (Holmes et al. 2007).  Signaling through the pre-BCR results in 
pre-B cell proliferation, activation of Igκ and allelic exclusion of the IgH locus.   
Expression of Aiolos which in turn represses λ5 resulting in termination of pre-BCR 
signaling, is also regulated by PAX5.  In addition to activating B cell specific 
genes, PAX5 represses genes that are not B cell specific such as macrophage 
colony-stimulating factor (M-CSF) receptor encoding gene Csf1r important in 
macrophage development, Notch homolog-1 (Notch1) important in T cell 
development, and Flt3 which is important in early haematopoietic progenitors and 
early B cell development but downregulated during B cell commitment (Holmes et 
al. 2007).  Therefore, PAX5 is a key regulator in the B cell gene expression 
program. 
1.2 Chronic Lymphocytic Leukaemia  
CLL is a disease characterised by the monoclonal expansion of mature B cells that 
highly express surface protein markers CD5 and CD23, and downregulate 
monoclonal sIgM.  Gene expression profiling data has highlighted the idea of 
phenotypic homogeneity within CLL, implicating transformation of a normal B cell.   
A B cell count of 5 x 109/L for 6 months or longer is used as a benchmark for CLL 
prognosis. Chromosomal abnormalities that are present in 80% of CLL cases are 
identified via fluorescence in situ hybridization (FISH), and are good predictors of 
progression (Desai & Pinilla-Ibarz 2012).   Levels of β2-microglobulin and soluble 
CD23, lymphocyte doubling time, evidence of infiltration into the BM and 
lymphadenopathy, splenomegaly or hepatomegaly are also considered when 
assessing progression (Desai & Pinilla-Ibarz 2012).   Mutational status of IgVH 
genes as well as surrogate markers ZAP70 and CD38 are also good determinants 
of disease stage (Rassenti et al. 2008).   
Clinical staging is carried out using the Rai or Binet staging system (Desai & 
Pinilla-Ibarz 2012).  Patients with the most advanced stage in either staging 
system have a 1-2 year median survival time whereas lowest stage CLL patients 
have a medium survival of more than 10 years (Rai et al. 1975; Binet et al. 1981).   
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Classically, CLL was considered a disease of accumulation rather than 
proliferation, because within the accumulation department (blood), most CLL cells 
are arrested in G0/G1 phase of cell cycle (Caligaris-Cappio & Hamblin 1999).  
However, current opinion highlights the importance of proliferative compartments 
within CLL, where cells are not resting yet actively proliferating and apoptosing 
(Messmer et al. 2005), eradicating the idea that CLL is a static disease, but rather 
dynamic.  In fact, proliferation centres within the BM and LN of CLL patients 
display an aggregate of dynamic CLL cells that eventually make their way into the 
accumulation department (Granziero et al. 2001).  Within proliferation centres are 
prolymphocytes and paraimmunoblasts surrounded by CD4+ CD40L+ T cells.  Of 
interest, stimulation of CD40 on CLL B cells through CD154 (CD40L) induces 
proliferation of otherwise resting CLL B cells (Buske et al. 1997; Kitada et al. 1999; 
Fluckiger et al. 1992) in vitro.  This microenvironment mimicking system also 
allows for the upregulation of survivin, chemokine (C-C motif) ligand 17 (CCL17) 
and 22 (CCL22) which are characteristic of CLL cells within proliferation centres 
(Ghia et al. 2001; Granziero et al. 2001).  Antigen stimulation together with T cell 
help, thus aids in clonal expansion of leukaemic cells which eventually accumulate 
within the blood through additional stromal help (Caligaris-Cappio & Ghia 2007).  
Proliferation compartments are a unique feature of CLL that other B cell 
malignancies do not share.  Interestingly, however, in rheumatoid arthritis and 
multiple sclerosis, these proliferation centres do exist, substantiating the idea that 
a CLL cell is in fact antigen-experienced (Messmer et al. 2005), perhaps self-
antigen-experienced due to the auto-immune characteristics of these two 
diseases.  
1.2.1 IgVH mutational status  
CLL cells have been demonstrated to be heterogeneous in terms of molecular and 
functional features such as clinical course (Klein et al. 2001; Caligaris-Cappio & 
Ghia 2007). While some CLL patients require immediate therapeutic intervention, 
others may never need therapy.  The most prominent feature of CLL intraclonal 
heterogeneity arises from the two distinctive CLL subtypes based on IgVH gene 
mutational status.  One group of CLL patients carries unmutated IgVH genes, while 
the other carries mutated IgVH genes.  The two subsets have remarkable 
differential clinical outcomes whereby unmutated IgVH carrying patients display a 
worse overall prognosis than mutated IgVH carrying patients (Hamblin et al. 1999; 
Damle et al. 1999).  CD38 expression and 70 kDa zeta associated protein 
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(ZAP70) positivity are another two distinguishing features within CLL patients, 
whereby patients that express CD38 and are ZAP70+ display a worse overall 
disease course (Damle et al. 1999; Crespo et al. 2003; Wiestner et al. 2003) (see 
sections 1.2.2 and 1.2.3).  In fact, unmutated CLL cases have higher expression of 
ZAP70 and CD38 and can better activate key signal transduction pathways in 
response to BCR activation (see Section 1.2.5). Unmutated IgVH CLL cells also 
display greater proliferative capacity than mutated CLL cells (Klein et al. 2001; 
Rosenwald et al. 2001; Wiestner et al. 2003),  supported by different telomere 
lengths (Damle et al. 2007; Messmer et al. 2005; Roos et al. 2008).   In addition 
unmutated CLL cells are more likely to carry harmful genetic lesions such as 
11q23 and 17p13 deletion (Kröber et al. 2002; Oscier et al. 1997; Stilgenbauer et 
al. 2007; Shanafelt et al. 2006).   
At a functional level, intraclonal heterogeneity is also evident when CLL cells are 
stimulated through the BCR, CD40 or CD5 (Chen et al. 2002; Lanham et al. 2003; 
Moreau et al. 1997; Klein et al. 2001; Hamblin 2002; Hamblin et al. 1999; Damle et 
al. 1999; Crespo et al. 2003; Wiestner et al. 2003; Law et al. 1994; Zupo et al. 
2000; Zupo et al. 1996; Lankester et al. 1995). There are also differences in 
expression of genes when considering different locations of a CLL cell within the 
body such as BM, LN and blood (Caligaris-Cappio & Ghia 2007).  CLL cells 
residing within the proliferation centres, for example, have differential expression 
of survivin, CCL-17 and CCL-22 (Granziero et al. 2001).  CD38 expression may 
also vary, whereby it is more present on CLL cells that have infiltrated the BM than 
those circulating within blood (Ghia et al. 2003). 
1.2.2 Prognositic marker ZAP70 
ZAP70 is a member of the ZAP70 protein tyrosine kinase family (of which SYK is 
another member) involved in T cell activation (Klein & Dalla-Favera 2005). When 
the T cell receptor (TCR) is engaged, ZAP70 interacts with immunoreceptor 
tyrosine-based activation motifs (ITAM) sequences of the TCR ζ-chains resulting 
in recruitment and activation of downstream signaling kinases (Au-Yeung et al. 
2009).  In normal B cells, it is exclusively expressed on mature tonsillar activated B 
cells and only transiently expressed in pro-B to pre-B cell transition (Schweighoffer 
et al. 2003).  In CLL, its expression is used as a surrogate marker for the level of 
IgV gene mutation status, and thus as a predictor of clinical outcome (Crespo et al. 
2003; Orchard et al. 2004). In concordance with this, stable expression of ZAP70 
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was shown to be correlated to 93% of unmutated CLL cases (Crespo et al. 2003; 
Wiestner et al. 2003). A study of 307 CLL patients revealed that ZAP70+ patient 
groups displayed a signifiantly shorter median time from diagnosis to treatment 
compared to ZAP70- CLL patients implicating ZAP70 to be a strong predictor of 
need for treatment in CLL (Rassenti et al. 2004).   
1.2.3 Prognostic marker CD38 
CD38 is a non lineage-restricted transmembrane glycoprotein that can function as 
an ectoenzyme, with the ability to catalyze cyclic ADP-ribose synthesis and 
dyrolysis that functions as a receptor.   CD38 was originally also thought to be 
indicative of mutational status, whereby 30% of unmutated CLL cases investigated 
in one study expressed CD38 (Damle et al. 1999).  More recently, no such 
association has been demonstrated (Poeta et al. 2001; Damle et al. 1999; D’Arena 
et al. 2001), however IgVH mutational analysis together with ZAP70 expression 
and CD38  expression can collectively prove to be of greater prognostic value than 
these factors individually (Morilla 2008; Giudice et al. 2005).  
1.2.4 MicroRNA (miRNA)  
Recent studies have highlighted the fact that CLL is a disease with substantial 
alterations of miRNA expression.  miRNA gene expression profiles of normal 
versus CLL CD5+ cells revealed a significant proportion of differently expressed 
miRNAs including miR-183, miR-190, miR-24-1, miR-203, miR-16-1 and miR-15a 
all of which are down-regulated in CLL (Calin et al. 2004).  Patients with 13q14 
deletions have a better prognosis compared with patients with complex 
cytogenetic changes (Döhner et al. 2000).  In addition 13q14.3 deletions are 
associated with the mutated subset of CLL which is also indicative of a good 
prognosis (Oscier et al. 2002). A comparative analysis of CLL samples either 
carrying or not carrying a 13q14 deletion revealed that miR-16-1, miR-24-2, miR-
195, miR-203, miR-220, mirR221 were expressed at significantly lower levels and 
miR-7-1, miR-19a, miR-136, miR-154, miR-217 are expressed at significantly 
higher levels within the 13q14 deletion carrying patients (Calin et al. 2004). When 
mutated versus unmutated CLL subsets were analysed, five miRNAs were 
differentially expressed (miR-186, miR-132, miR-16-1, miR-102, miR-29c), 
highlighting the prognosis potential of miRNAs (Calin et al. 2004; Calin et al. 
2005). 
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1.2.5 BCR Signaling in CLL  
A stereotyped CDR3 is most commonly found within unmutated CLL cases, 
however 10% of mutated cases may carry an identical BCR.   The notion of 
antigen exposure in CLL is underlined by the CLL cell’s signature of BCR-
mediated stimulation (Damle et al. 2002).  Signaling through the BCR is variable in 
CLL, where some cases, mostly unmutated have a significantly higher ability to 
signal through the BCR than their mutated counter parts (Lanham et al. 2003; 
Lankester et al. 1995). Intracellular regions of BCR components CD79a and 
CD79b contain ITAMs that interact with intracellular tyrosine kinases such as SYK 
and LYN (Zenz et al. 2010).  These kinases in turn activate downstream pathways. 
The ability to transduce a BCR-mediated signal may depend on molecules such as 
ZAP70, HIS, CD38, or IgVH mutational status (Figure 1.4) (Zenz et al. 2010).  For 
example, CLL cells that have unmuated IGVH genes and are ZAP70+ are 
stimulated through their BCR, resulting in recruitment of SYK and ZAP70 which 
phosphorylate and activate downstream targets BTK, phosphoinositide 3-kinase 
(PI3K), BLNK, PLCγ which in turn activate pro survival and anti-apoptotic signaling 
pathways such as protein-threonine protein kinase Akt, nuclear factor kappa B 
(NF-κB), extracellular regulated mitogen activated protein kinase (ERK) and 
mammalian target of rapamycin (mTOR) (Figure 1.4) (Zenz et al. 2010).    
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Modified from Zenz et al. 2010 
Figure 1.4 Signaling in CLL.  
 
Constant BCR stimulation by low-affinity antigen could in fact lead to an overall 
worse prognosis associated with the unmutated CLL group through induction of 
survival and growth of the leukaemic clone (Caligaris-Cappio & Ghia 2007).  On 
the other hand, in patients that have a better overall survival rate, a high-affinity 
self-antigen could also cause selection of a responsive clone, but would however 
lead to receptor desensitization and an anergic state (Melchers & Rolink 2006; 
Caligaris-Cappio & Ghia 2007).  
Among the most common genetic alterations leading to a good prognosis is the 
deletion of tumour suppressor region 13q14. The 13q14 cluster contains miR-
15a/16 which targets B cell CLL/lymphoma 2 (Bcl-2) anti-apoptotic protein, adding 
to the complexity of good and bad prognostic markers. Downregulation of DAPK1 
through epigenetic silencing is another genetic alteration leading to a bad 
prognosis (Zenz et al. 2010).  The interactions of CLL cells with their environment 
composing of soluble factors (such as vascular endothelial growth factor (VEGF)α, 
SDF1 and IL-4) and stromal cells and T cells (expressing CD40L) also contributes 
to pathogenesis through upregulation of anti-apoptotic proteins myeloid cell 
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leukaemia sequence 1 (Mcl-1), Bcl-2 and survivin (Figure 1.4) (Zenz et al. 2010).    
Targeting BCR signaling has therefore been a major focus in CLL therapy with use 
of specific inhibitors, antisense therapy or BCR interference. 
1.2.6 SHM and CSR 
Ever since the discovery that CLL B cells express remarkably low levels of sIgM, 
the role of the BCR has been a feature of CLL research.  As discussed above, in 
normal B cell development antigen stimulation leads to activation which in turn 
induces proliferation and differentiation, eventually generating an antigen-specific 
memory B cell or plasma cell.  In CLL, the role of chronic antigen stimulation has 
been highlighted as an aid in malignant transformation (Mackay & Rose 2001).  In 
other lymphomas, constant bacterial or viral stimulation has been shown to be a 
cofactor in disease development (Jelić & Filipović-Ljesković 1999; Ferreri et al. 
2004).  In addition BCR sequencing studies have underlined the role of antigen 
encounter in CLL (Stevenson & Caligaris-Cappio 2004a).  SHM, normally a post 
antigen encountering event, occurs in at least half of CLL patients (Fais et al. 
1998). This process generates long-lived, high-affinity antibody producing memory 
B cells from a naïve B cell precursor (Wabl et al. 1999). It is usually thought to 
occur within GCs in a T-cell dependent manner (Berek et al. 1991; MacLennan 
1994a), however it can also occur in a T-cell independent manner and outside of 
GCs (William et al. 2002) (as discussed in section 1.2.10.2).  
SHM is characterised by insertions/duplications or deletions within the sequence 
of the variable region of the BCR.  Since it is a common phenomenon in normal, 
neoplastic or autoreactive B cells (Caligaris-Cappio & Ghia 2007), it is therefore 
difficult to associate SHM with CLL cells in particular, with the exception of CLL 
IgHV3-21 expressing cells where a specific deletion was found in all stereotyped 
receptor cases (Tobin et al. 2003).  In addition CLL cases show a bias toward 
certain IgVH genes and the complementarity-determining region 3 (CDR3) 
sequences.  CDR3 sequences are unique for each B cell and its progeny and 
define BCR specificity. However, more than 20% of unrelated CLL cases in both 
mutated and unmutated CLL carry identical or closely homologous CDR3 
sequences on IgH and IgL chains (Tobin et al. 2003; Widhopf et al. 2004; Tobin et 
al. 2004; Ghiotto et al. 2004; Messmer et al. 2004; Stamatopoulos et al. 2007; 
Ghia et al. 2005). This remarkable statistic implies that the CLL clone is selected 
for through recognition of a limited set of particular antigens (Caligaris-Cappio & 
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Ghia 2007).   Antigen stimulation has also been implicated in the progression of 
CLL.  For example, the CDR3 sequence a patient carries may correlate to overall 
clinical outcome.  Patients with V3-21 carrying a short HCDR3 have an overall bad 
outcome regardless of mutational status (Ghia et al. 2005).  In patients carrying 
the VH1-69 gene, two unmutated subsets display opposite clinical outcomes, 
whereby VH1-69/D2-2/J6 patients have a short lifespan compared to VH1-69/D3-
10/J6 patients that live significantly longer (Stamatopoulos et al. 2007).  In 
contrast, VH4-39 also predominates among the unmutated cases, whereas VH3-
23, VH4-34 and VH3-07 predominates within the mutated CLL subgroup (Oppezzo 
& Dighiero 2005).   
CSR and SHM allow a B cell to mature, however during the various stages of 
maturation, B cells become susceptible to abnormal development and generation 
of diverse forms of leukaemia (Fu et al. 1978). There are various mechanisms 
employed  by CSR in isotype switching (Oppezzo & Dighiero 2005) such as 
deletional recombination between DNA-switch regions, duplication of sister 
chromatids and trans-splicing (Oppezzo & Dighiero 2005). These mechanisms can 
sometimes lead to the production of double isotype expression in the same cell.  
Similarly, in CLL, some sub-populations of B cells express clonal isotype switch, 
whereby different isotypes sharing same hypervariable domains are found within 
the same cell due to trans-splicing or duplication of sister chromatids mechanisms 
(Oppezzo & Dighiero 2005). VH rearrangement genes within these cells remain 
unmutated, indicating that CSR can occur without SHM (Siekevitz et al. 1987; 
Sideras et al. 1989).  Normally, CSR is thought to follow SHM within the GC 
(Oppezzo & Dighiero 2005; Sideras et al. 1989; Siekevitz et al. 1987).  Therefore 
the process of differentiation and diversification are not necessarily interconnected 
(Siekevitz et al. 1987; Sideras et al. 1989). 
1.2.7 Role of antigen in CLL 
V(D)J gene recombination of Ig loci, along with SHM and CSR after antigen 
encounter allow for the generation of many different BCR specificities against an 
array of exogenous pathogens.   However, 20 percent of CLL patients share a 
restricted BCR repertoire with almost identical Ig sequences (Darzentas et al. 
2009).  Over-usage of Ig genes VH1-69, VH4-34, VH3-7 and VH3-21 in CLL and 
similar CDR3 regions in patients that were geographically distributed became 
apparent in CLL research (Fais et al. 1998; Potter et al. 2003; Widhopf et al. 2004; 
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Ghiotto et al. 2004; Tobin et al. 2004; Messmer et al. 2004). Ig light chain 
repertoire was also demonstrated to be frequently restricted and presented 
homogeneity within κ and λ CDR3 regions (Widhopf et al. 2004; Ghiotto et al. 
2004; Tobin et al. 2004; Tobin et al. 2003).  Because of the minimal likelihood of 
randomly selecting two B cells that harbour almost identical Ig rearrangements, 
CLL’s Ig repertoire restriction and CDR3 composition could probably not occur by 
chance.  Therefore this implicates antigen selection of CLL cells, conferring a 
tumour cell’s growth advantage. In mucosa-associated lymphoid tissue (MALT) 
lymphoma and Burkitt’s lymphoma, infectious agents such as Helicobacter and 
Epstein-Barr virus (EBV) respectively have been implicated in development of 
disease (Wotherspoon et al. 1991; Vereide & Sugden 2009).  In CLL, history of 
pneumococcal pneumonia has been linked with increased risk for CLL (Anderson 
et al. 2009; Landgren et al. 2007).  Nevertheless, some studies indicate that a 
number of CLL monoclonal antibodies, similarly to natural antibodies, can 
recognize molecular structures existing in bacterial and apoptotic cells (Chu et al. 
2008; Myhrinder et al. 2008; Catera et al. 2008), providing an alternative 
explanation to antigen selection of CLL clones.  Therefore, CD5+ CLL cells were 
implicated to be derived from a subset of cells producing natural antibodies that 
have a function as scavengers of apoptotic debris as well as binding to bacterial 
cell structures.   Collectively these data indicate that antigen/autoantigen, 
apoptotic cells and microbial pathogens can synergistically drive CLL 
pathogenesis by constantly stimulating the BCR.  
1.2.8 Role of the Microenvironment 
Ex-vivo culture of CLL B cells without stroma results in spontaneous apoptosis, 
thus highlighting the role of the microenvironment within CLL (Lagneaux et al. 
1999; Chiorazzi & Ferrarini 2003). Within BM and secondary lymphoid tissues CLL 
cells interact with stromal cells and matrix, leading to increased survival, 
proliferation, CLL-cell homing, tissue retention and drug resistance of CLL cells 
(Burger 2011).  Among the cells that make up the microenvironment are nurse-like 
cells (NLCs), mesenchymal stromal cells and T cells (Figure 1.5).  CLL cells also 
express chemokine receptors and adhesion molecules that allow for contact with 
NLCs or BM stromal cells (BMSCs) (Burger 2011).   
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Figure 1.5 The microenvironment in CLL 
1.2.8.1 Role of NCL and BMSCs 
NLCs protect CLL cells from spontaneous or drug-induced apoptosis, whereas 
BMSCs provide a nourishing niche where CLL cells are protected from cytotoxic 
agents (Burger et al. 2000; Tsukada et al. 2002).  Co-culture of CLL cells with 
NLCs results in increased NFκB activation and upregulation of target genes CCL3 
and CCL4 (Burger et al. 2009; Herishanu et al. 2011).  NLCs secrete chemokine 
(C-X-C motif) ligand 12 (CXCL12 or SDF-1) and CXCL13, platelet/endothelial cell 
adhesion molecule 1 (CD31), plexin B1 (PLXNB1), B cell activating factor (BAFF), 
a proliferation-inducing ligand (APRIL) and vimentin (Figure 1.5) (Burger 2011).   
NLCs also attract CLL cells through secretion of CXCL12 and CXCL13 whereas 
BMSCs secrete CXCL12 (Burger 2011).   G-protein coupled chemokine receptors 
(GPCRs) CXCR4 and CXCR5 on CLL cells bind to CXCL12 and CXCL13 
respectively.   CXCR4 (CD184) is highly expressed on CLL cells and regulates cell 
chemotaxis, actin polymerization, and migration over vascular endothelium and 
under BMSCs (Burger 2011).   BCR signaling downregulates CXCR4 and 
upregulates chemotaxis toward CXCL12 and CXCL13 (Quiroga et al. 2009; Vlad 
et al. 2009).  Compared to ZAP70- cells which are correlated to a better prognosis, 
ZAP70+ cells which are correlated to higher responsiveness to BCR stimulation 
and worse prognosis, survive better in response to CXCL12 (Richardson et al. 
2006; Chen et al. 2002).  In addition, ZAP70+ and CD38+ CLL cells display higher 
levels of chemotaxis toward CXCL12 (Richardson et al. 2006; Deaglio et al. 2007).  
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CXCR5 (CD185) binds to chemokine CXCL13, regulating lymphocyte homing and 
situating within the lymph follicles (Burger 2011).    Deleting CXCR5 in mice results 
in an absence of inguinal LNs and a defect in development of primary follicles and 
GCs within the spleen and Payer patches (S. N. Mueller & R. N. Germain 2009).  
Like CXCR4, CXCR5 is highly expressed on CLL cells.  When CXCR5 is 
stimulated with CXCL13, an activation of PI3Ks, and ERK signaling occurs leading 
to actin polymerization, chemotaxis and endocytosis (Bürkle et al. 2007).   Other 
receptors including CXCR3 and CCR7 are also expressed on CLL cells and are 
important in lymphoid tissue homing.   
NLCs highly express CD31 which is the ligand for CD38 expressed by normal B 
and T cells and poor prognosis CLL cells (Deaglio et al. 2005). In vitro co-culture 
of CLL cells with murine fibroblasts expressing CD31 resulted in proliferation of 
CLL cells (Deaglio et al. 2005).  Increased proliferation was shown to correlate 
with upregulation of survival receptor CD100 and down regulation of CD72 which 
is an inhibitory receptor on CLL cells (Deaglio et al. 2005).  Integrins such as VLA-
4 (CD49d) work in concert with chemokine receptors to establish cell-cell 
adhesions (Deaglio et al. 2005).   
1.2.8.2 Role of T cells 
T cells have also been implicated as necessary components of the CLL 
microenvironment.  CLL is marked by a dysregulation of T lymphocyte function 
that may correlate to clinical features in CLL such as hypogammaglobulinaemia 
and autoimmune haemolytic anaemia (Mellstedt & Choudhury 2006).  CD4+ and 
CD8+ T cells are elevated during CLL progression and display oligoclonality 
(Mellstedt & Choudhury 2006; Serrano et al. 1997).  Within proliferation centres 
where CLL cells reside, CD38+ CLL cells co-localize with activated CD4+ T cells, 
suggesting that these T cells may play a role in the CLL clone’s expansion (Patten 
et al. 2008). Within a CLL-transfer model where CLL cells were injected into 
immunodeficient mice, activated CD4+ T cells were demonstrated to support CLL-
cell proliferation (Bagnara et al. 2011).   
CLL cells are also activated through interactions of CD40 with CD40L present on T 
cells, a member of the tumour necrosis factor (TNF) family, along with BAFF, and 
APRIL (Burger 2011).  Activation through CD40L, BAFF and APRIL leads to 
immune recognition, increased survival and increased outgrowth of CLL cells. 
Binding of BAFF can occur via BAFF receptor (BAFF-R) or interaction with 
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receptors B cell maturation antigen (BCMA) or transmembrane activator and 
calcium modulator and cyclophilin ligand-interactor (TACI) on a CLL cell (Mackay 
et al. 2003).  APRIL also interacts with BCMA and TACI (Mackay et al. 2003).  
BAFF overexpression leads to increased B cell proliferation and autoimmunity in 
mouse models (Shanafelt et al. 2010), whereas overexpression of APRIL leads to 
a B-1 lymphoproliferative disorder similar to human CLL (see section 1.2.12). 
BAFF and APRIL have been shown to protect CLL cells from drug-induced and 
spontaneous apoptosis in vitro (Nishio et al. 2005), by activating the canonical 
NFκB pathway (Endo et al. 2007).  In addition, analysis of serum levels of APRIL 
in CLL patients revealed elevated expression compared to normal B cells, and 
negatively correlated to survival (Nishio et al. 2005).  In addition, activation of the 
BCR on CLL cells leads to cytokine secretion which may attract other cells to the 
microenvironment (Ghia et al. 2002; Burger et al. 2009). 
1.2.9 Genetic homogeneity 
CLL cells exhibit exceptionally high genetic homogeneity indicative of their clonal 
outgrowth (Klein et al. 2001; Caligaris-Cappio & Ghia 2007). In fact, unsupervised 
hierarchical gene expression cluster studies of CLL cases displayed a common 
gene expression profile, independent of mutational status of CLL or expression of 
surrogate marker CD38 (Klein et al. 2001; Rosenwald et al. 2001; Dürig et al. 
2003). Therefore, although genotypic and clinical differences exist between the 
two subgroups of CLL, CLL represents a homogenous disease (Klein & Dalla-
Favera 2005).  It is therefore unlikely that the hypothesis stating that different 
origins of CLL are based on different subgroups of CLL is correct.  Genetic 
homogeneity indicates that all CLL B cells derive from a common precursor (Klein 
& Dalla-Favera 2005).  Microarray analyses of CLL compared to other lymphoma 
subtypes demonstrated that the CLL signature is very distinct from that of other 
lymphomas (Rosenwald et al. 2001; Wang et al. 2004; Jelinek et al. 2003).  CLL 
specific genes that were identified include ZAP70 and exchange protein activated 
by cyclic AMP (EPAC) (Klein et al. 2001; Tiwari et al. 2004).  Another observation 
within the CLL signature was the comparatively low expression of cycle-associated 
genes as compared to normal and transformed B cells analyzed (Klein et al. 
2001).  However, the source of the cells analysed does not represent cells from 
proliferation centres within lymphoid organs and thus may have led to a 
generalization of all CLL cells, regardless of location within the body (Chiorazzi & 
Ferrarini 2003).  
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When a supervised gene expression analysis was conducted on the data set, a 
small set of genes were discovered that were different between the two mutational 
subgroups of CLL (Klein et al. 2001; Rosenwald et al. 2001).  Another study 
investigated gene expression differences between CD38+ and CD38- CLL cases, 
and found very few differences (Dürig et al. 2003).  Within this study, an 
unsupervised clustering did identify some gene profile differences between two 
subgroups: one with a more favourable outcome and one with a less favourable 
outcome (Dürig et al. 2003).  Another group identified genetic differences 
according to patient survival and clinical staging (Stratowa et al. 2001).  Similarly, 
Jelinek et al demonstrated the presence of a set of genes that are distinguishable 
between low risk and high risk patients based on Rai stage (Jelinek et al. 2003).  
However, Klein and Dalla-Favera point out complications with the above studies 
(Stratowa et al. 2001; Dürig et al. 2003) arising from lack of CLL B cell purification 
prior to analysis and lack of independent panel validation (Klein & Dalla-Favera 
2005).    
1.2.10 Origin of a CLL cell 
To date, there is no consensus as to the normal cell counterpart to CLL, however 
evidence suggests that it is an antigen-experienced B cell (Chiorazzi & Ferrarini 
2011).  It is also unclear whether a single or multiple normal precursors evolved 
into a CLL cell. 
As mentioned above (section 1.2.1), CLL can be divided into two patient 
subgroups with distinct clinical courses based on mutational status of IgVH genes.  
This finding gave rise to the hypothesis that unmutated and mutated CLL clones 
come from distinct cellular origins.  CLL IgVH repertoire is non-random and is 
different in unmutated versus mutated CLL subsets.  IgVH repertoire between 
normal and CLL cells is also different.  The higher frequency of poly/auto-reactive 
BCRs, particularly within unmutated CLL cases and retention of BCR signaling in 
unmutated CLL suggest that specificity of antigen-binding and capacity of the BCR 
to signal both influence clonal expansion, resulting in increased tumour survival 
and growth (Chiorazzi & Ferrarini 2011).  However, microarray gene expression 
studies suggest that although the CLL cell gene profile differs from the normal B 
cell, very few genetic differences exist between unmutated and mutated CLL cells 
implying a single cell of origin (section 1.2.9).   
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1.2.10.1 CD5 expression 
One of the notable features of a CLL cell is high expression of CD5. CD5 is 
normally considered a T-cell molecule that inhibits signaling in T cells (Brossard et 
al. 2003).  Mouse B1 cells have been implicated to be the mouse equivalent of the 
human CLL cell of origin because of their high expression of CD5 (Caligaris-
Cappio et al. 1982).  B1 cells within the mouse are responsible for producing 
multireactive antibodies and lack the ability to form GCs and undergo isotype class 
switching (Montecino-Rodriguez & Dorshkind 2006). Unlike murine CD5+ B cells, 
human CD5+ B cells do not respond to T-independent antigens and do not 
produce autoreactive antibodies (Chiorazzi & Ferrarini 2003; Hervé et al. 2005). In 
adult mice, these B1 cells remain constant in numbers and can clonally expand 
(Stall et al. 1988).   
Mouse B1 CD5+ cells express unmutated IgV genes (Kocks & Rajewsky 1989), 
similar to healthy human CD5+ B cells as demonstrated by single cell PCR of 
CD5+ B cells from healthy individuals (HBrezinschek et al. 1997; Fischer et al. 
1997; Geiger et al. 2000). CLL cells, however can express both unmutated and 
mutated IgVH genes, therefore a CD5+ B cell cannot alone be considered a 
precursor to all CLL. Therefore, Fischer et al made an assumption that IgV 
mutated CLL cells derive from CD5+ B cells that only occasionally proliferate and 
mutate their Ig genes in the GC reaction (Fischer et al. 1997).  These assumptions 
were based on the canonical B cell development pathway where unmutated IgV B 
cells are naïve B cells and somatically mutated B cells are memory B cells (Klein & 
Dalla-Favera 2005).   
Some argue that expression of CD5 is a consequence of activation requirements 
(Wortis et al. 1995). Although high expression of CD5 on CLL cells is a constant 
occurrence, CD5 can serve as an activation marker within CD5- B cells and CD5+ 
B cells can downregulate CD5 upon activation (Morikawa et al. 1993; Caligaris-
Cappio et al. 1989).  In addition, some healthy older individuals (above 65) carry a 
small population of CLL-like CD5+CD19+ cells within circulating blood (Ghia et al. 
2004; Rawstron et al. 2002). 
Studies ruled out CD5+ B cells as the normal counterpart to the CD5+ CLL B cell 
through gene expression profile analysis that demonstrated that CD5+ B cells 
derived from cord blood displayed a very different profile than CLL B cells (Klein et 
al. 2001; Rosenwald et al. 2001).  However, CD5+ B cells from cord blood may be 
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different from adult CD5+ B cells (Klein & Dalla-Favera 2005).  Therefore CD5 
cannot alone be used as a distinguishing marker of B-CLL. However, high 
expression of CD5 coupled with low expression of CD20 is characteristic of CLL 
(Rawstron et al. 2001).  
1.2.10.2 Marginal Zone B cell/Memory B cell 
Another speculative suggestion for the origin of a CLL cell is the MZ B cell 
(Chiorazzi & Ferrarini 2003; Klein & Dalla-Favera 2005).  In most GC 
malignancies, chromosomal translocation occurs within the GC, and since CLL B 
cells lack chromosomal translocations, it is therefore possible that they are derived 
from post-GC MZ B cells in which Ig class switching and SHM are no longer active 
(Figure 1.6) (Klein & Dalla-Favera 2005). Of note, a small subset of CLL cells can 
class switch.  Gene expression analysis of CLL cells compared to different subsets 
of normal B cells indicated high similarity of CLL cells with CD27+ memory B cells 
found in the tonsil (Klein et al. 2001).  Indeed, IgM-expressing CD27+ B cells also 
respond to T-independent antigens, eluding to their MZ B cell identity (Dono et al. 
2001; Werner-Favre et al. 2001).  In mouse and human cells, SHM was 
demonstrated to occur outside of the GC and in a T-independent manner (Weller 
et al. 2004), and therefore the origin of a CLL cell may not lie within the GC (Figure 
1.6).  In addition, other studies (Weller et al. 2004; Kruetzmann et al. 2003) 
indicate the possibility of somatically mutated IgM-expressing B cells generated in 
an antigen-independent fashion, and elude to the idea that SHM can give rise to a 
diversified pre-immune repertoire (Klein & Dalla-Favera 2005).  These T-
independent IgM+ IgV mutated cells are generated in the spleen through an 
unknown pathway (Kruetzmann et al. 2003; Weller et al. 2004).   
However CD27 can be found on B cells other than post-GC memory B cells 
reacting to T-dependent antigens (Klein & Dalla-Favera 2005).  CD27+ B cells can 
carry unmutated IgV genes, however CD27- B cells are IgM+IgD+ and thus naïve in 
Ig status.  Therefore CD27+ cells can be: classical GC-generated memory B cells; 
antigen experienced B cells reacting to T-independent antigens; or somatically 
mutated B cells generated in a T-cell dependent or independent manner.  Since all 
of these cells reside within the MZ of peripheral lymphoid organs, they can be 
referred to as MZ B cells (Klein & Dalla-Favera 2005).  
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Modified from Klein & Dalla-Favera 2005 
Figure 1.6 Speculative origins of a CLL cell 
 
The above arguments support the hypothesis that MZ B cells derived from T cell 
dependent/independent stages of development are the normal counterpart to the 
human CLL B cell.  Indeed, CD27 is often expressed on tumour cells of human B 
cell malignancies (Oers et al. 1993).  Since CLL B cells display a restricted IgV 
gene repertoire (in both mutated and unmutated subsets) and antigen selection 
occurs within mutated CLL subsets, it can be concluded that antigen stimulation 
plays an important role within CLL pathogenesis (section 1.2.7).  Interestingly, 
hairy-cell leukaemia (HCL) cells also resemble CD27+ B cells in terms of gene 
expression profile (Basso et al. 2004).  In addition, like CLL cells, HCL cells lack 
chromosomal translocation (Haglund et al. 1994; Sambani et al. 2001). This leads 
to the hypothesis that CLL and HCL cells arise from a similar precursor, a CD27+ 
MZ or a memory B cell (Klein & Dalla-Favera 2005).   
1.2.10.3 Antigen-experienced B cell 
The complexity of understanding the origin of a CLL cell arises from the lack of 
unique molecular abnormality in CLL, lack of balanced chromosomal translocation 
and CLL’s long natural history (Caligaris-Cappio & Ghia 2007). The low levels of 
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sIg may imply that a CLL cell has been exposed to antigens (Chiorazzi & Ferrarini 
2003).  However, this anergy-related feature of CLL cells does not mean that BCR 
signaling is impaired as demonstrated by the ability to stimulate some CLL cells in 
vitro through sIgM (Lanham et al. 2003; Chen et al. 2002). CLL B cells express 
activation markers, express transcripts of many cytokines and secrete some as 
seen in activated B cells (Caligaris-Cappio & Ghia 2007).  Therefore, it is plausible 
to consider that a CLL cell’s normal equivalent is an antigen-experienced B cell, 
especially within the somatically mutated IgV gene carrying CLL cases (see 
section 1.2.7) (Rajewsky 1996; MacLennan 1994) (some studies highlight that 
somatically mutated IgM-expressing cells can be generated in an antigen-
independent manner).  In fact, telomere expression and length studies 
demonstrate that some CLL cells, particularly of the unmutated subset, display a 
history of cell division prior to leukaemic transformation, implying a post-antigen 
encountering event (Caligaris-Cappio & Ghia 2007).  Some believe that mutated 
IgV carrying B cells come from antigen experienced B cells whereas unmutated 
IgV carrying CLL B cells come from antigen-inexperienced, naïve B cells (Oscier 
et al. 1997; Fais et al. 1998; Hamblin et al. 1999; Küppers et al. 1999). However, 
as discussed above (section 1.2.10.2) others have demonstrated through 
microarray studies comparing mutated versus unmutatated CLL subsets that both 
subsets display an antigen-experienced memory B cell phenotype (Klein et al. 
2001).  Collectively interpretations of studies done to date have not resulted in a 
clear answer as to the origin of a CLL cell, but have certainly highlighted the 
complexity of understanding the initiating factors leading to this very 
heterogeneous disease.   
1.2.11 CLL prognosis and Current Therapies 
As CLL is a heterogeous disease and presents with a highly variable clinical 
course, some patients need immediate treatment whilst others do not need 
treatment at all (Yuille et al. 2000).  Traditionally, alkylating agents such as 
chlorambucil or cyclophosphamide have been used to treat CLL. Monoclonal 
antibody therapies in combination with chemotherapy have proven to be much 
more effective and increase progression-free survival (PFS) and overall survival 
(OS) (Desai & Pinilla-Ibarz 2012).   
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1.2.11.1 Single Agent Chemotherapy/Monotherapy 
Chlorambucil, an alkylating agent has been the standard in CLL treatment for over 
four decades however response is variable between 30-70% within previously 
untreated patients (Desai & Pinilla-Ibarz 2012).  Treatment of previously untreated 
CLL patients with single agent fludarabine, a purine analog, has resulted in 
superior overall response (OR) and complete remission (CR) rates when 
compared to alkylating agents alone (Rai et al. 2000; Leporrier et al. 2001; 
Eichhorst et al. 2009).  It was also shown to be better than combination regimens 
cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) or 
cyclophosphamide/doxorubicin/prednisone (CAP) in inducing CR rates but overall 
survival did not improve (Leporrier et al. 2001). It is important to note that patients 
with p53 (17p) dysfunction are often refractory to purine analogues such as 
fludarabine, thus making treatment very difficult (Döhner et al. 1995).  
Bendamustine is another alkylating agent that is similar structurally to both 
alkylating agents and purine analogs.  It restores p53 function by activating DNA-
damage stress response, and downregulates mitotic checkpoint regulation genes 
(Desai & Pinilla-Ibarz 2012). Phase III clinical trial of previously untreated CLL 
patients with bendamustine versus chlorambucil demonstrated improved OR/CR 
rates over chlorambucil but no improvement of OS rate (Desai & Pinilla-Ibarz 
2012). 
1.2.11.1.1 Monoclonal Antibodies 
Targeting CD20 and CD52 with monoclonal antibodies rituximab and 
alemtuzumab has been popular in CLL therapy.  Rituximab, which targets CD20, 
has been shown to be more effective in previously untreated patients as CD20 
levels subside with treatment (Desai & Pinilla-Ibarz 2012).  In addition, CD20 is 
present in plasma of CLL patients which interferes with treatment (Huhn et al. 
2001; Byrd et al. 2001; O’Brien et al. 2001).  Therefore single agent monotherapy 
with rituximab is not as effective as rituximab and chemotherapy combined.  
Alemtuzumab targets CD52 and has been demonstrated to induce cell death of 
CLL cells in vitro (Mone et al. 2006). When compared to chlorambucil alone 
OR/CR rates increased drastically (83/24% for alemtuzumab versus 56/2% for 
chlorambucil) (Hillmen et al. 2007).  However, more than half of alemtuzumab 
treated patients developed cytomegalovirus (CMV) reactivation compared to 2% 
within the chlorambucil arm (Hillmen et al. 2007).  Newer monoclonal antibodies 
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such as ofatumumab and GA-101 are currently being tested for improved 
effectiveness over rituximab or alemtuzumab (Desai & Pinilla-Ibarz 2012) 
1.2.11.2 Combination Therapies 
Combination therapy of purine analogs and alkylating such as FC resulted in 
improvements in OR, CR and PFS over fludarabine monotherapy  (Eichhorst et al. 
2006; Flinn et al. 2007; Catovsky et al. 2007).  However, patients subjected to FC 
therapy often developed neutropenias (Desai & Pinilla-Ibarz 2012).  Combination 
therapy of fludarabine and rituximab in one study demonstrated evidence of 
synergy where OR/CR rates of combination therapy increased over fludarabine 
alone  (84/38% for combination therapy versus 63/20% for fludarabine 
monotherapy) (Byrd et al. 2005).   
FCR was shown to increase CR and OR rates, and increase MRD negative-status 
over FC treatment alone but not in patients harbouring a 17p/11q deletion.   
Other combination therapies are being investigated including FCR/Alemtuzumab, 
Cladribine/Rituximab, and Bendamustine/Rituximab among others, in order to 
generate a therapy that is more effective and less toxic than other combination 
therapies (Desai & Pinilla-Ibarz 2012).   
1.2.11.3 Small molecule inhibitor therapies 
Newer treatments targeting the BCR within CLL and the microenvironment have 
been a key focus in current therapy development. SYK inhibitors (such as 
Fostamatinib R788), BTK inhibitors (such as PLC32765), PI3δ inhibitors (such as 
CAL101), and CXCR4 antagonists (such as Plerixafor) have all shown to be 
effective in targeting CLL cells (Burger 2011). In summary, CLL therapy is evolving 
to increase OS, PFS, OR and decrease MDR, however no current therapy is 
100% effective.  Although CLL still remains incurable, new knowledge in CLL 
biology is leading to novel therapies that may prove beneficial.  
1.2.11.3.1 Inhibiting PKCβ 
Recent studies have highlighted a role for PKCβII in CLL. BCR signaling is 
important to the survival of CLL cells and a key mediator is PKCβ that regulates 
deactivation of BTK and activation of IκB through phosphorylation events after 
engagement of the BCR (Abrams et al. 2007a).  PKCβII was shown to be 
overexpressed and enzymatically active in primary cells from CLL patients 
(Abrams et al. 2007; Abrams et al. 2010). Additionally, its activity correlates to 
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BCR engagement response in CLL, amplifying survival signals (Zent et al. 2010).   
Treatment of CLL cells with enzastaurin, a PKCβ inhibitor resulted in CLL cell-
specific apoptosis (Abrams et al. 2007; Holler et al. 2009).  Activation of PKCβII 
was shown to be stimulated with VEGF, contributing to the enhanced survival and 
malignant phenotype of CLL cells (Abrams et al. 2010).  In a murine model of CLL, 
the Eµ-TCL1 transgenic mouse model (see section 1.2.12), PKCβ was shown to 
be necessary for the development of CLL, as PKCβ-deficient TCL-1 transgenic 
mice did not develop CLL (Holler et al. 2009).  Therefore, inhibiting PKCβ may 
prove to be beneficial in treatment of CLL.   
1.2.11.3.2 Inhibiting mTOR Signaling 
 
mTOR proteins belong to a group of evolutionarily conserved serine/threonine 
protein kinases that regulate the balance between protein synthesis and 
degradation in response to intracellular energy and nutrients such as amino acids 
(Memmott & Dennis 2009; Raught et al. 2001) directing cell growth and 
proliferation. These processes contribute to tumour formation, and many cancers 
are characterized by abnormal activation of the mTOR signaling pathway 
(Memmott & Dennis 2009). In CLL, mTOR has also been demonstrated to be 
active (Aleskog et al. 2008).  
In vitro treatment of CLL cells with rapamycin showed anticancer activity (Aleskog 
et al. 2008) by inducing apoptosis (Hayun et al. 2009), and attenuating 
proliferation by induction of G1 arrest in cycling CLL B cells through 
downregulation of cyclins and survivin (Decker et al. 2003).  A Phase II pilot trial of 
advanced CLL patients with rapamycin analogue RAD001 (everolimus) was 
shown to be promising, however also demonstrated high toxicity (Thomas Decker 
et al. 2008).  Another study of 22 CLL patients demonstrated clinical responses 
and CLL cell mobilization in response to RAD001 treatment (Zent et al. 2010).  In 
the Eµ-TCL1 model, treatment of mice with rapamycin significantly prolonged life 
span.  Collectively targeting the mTOR pathway in combination with other agents 
may prove to be beneficial in CLL.   
1.2.12 Mouse Models of CLL 
1.2.12.1 Eµ-TCL1 mouse model 
TCL1 is an oncogene that was initially associated with T cell leukaemias through 
inversions/translocations at locus 14q32.1.  TCL1 rearranges with the TCR α/β at 
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locus 14q11 in a reciprocal manner.  When activated, TCL1 is associated with 
mature T cell leukaemias, preleukaemic conditions, and AIDS-related 
immunoblastic lymphoma plasmacytoid (IBLP) (Narducci et al. 1995; Thick et al. 
1996; Pekarsky et al. 2007; Teitell et al. 1999).  Activation of TCL1 is possibly due 
to inversions inv(14)(q11:q32) or translocation of t(14;14)(q11;q32) (Brito-
Babapulle & Catovsky 1991; Virgilio et al. 1994; Narducci et al. 2000).   In T cells, 
TCL1 is only expressed during the early stages of development at the double 
negative (CD4-CD8-) stage. In B cells, TCL1 is expressed in early pre-B cells, and 
IgM expressing cells and to some extent in GC B cells, but not in plasma cells 
(Pekarsky et al. 2007; Narducci et al. 2000).  
 
Modified from Pekarsky et al. 2007 
Figure 1.7 TCL mouse model of CLL 
 
 
TCL1 is involved in the Akt oncogenic pathway (Laine et al. 2000; Pekarsky et al. 
2007) which is important in proliferation, survival and death (Chan et al. 1999).  In 
particular Akt has been demonstrated to be important in the survival and 
proliferation of T and B cells (Chan et al. 1999).  As indicated in the Figure 1.7, 
PI3K is activated through growth and survival factors such as insulin, platelet-
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derived growth factor (PDGF) and epidermal growth factor (EGF) in the plasma 
membrane (Pekarsky et al. 2007). 
The two domains of Akt, the pleckstrin homology (PH) and kinase domain have 
distinct roles (Figure 1.7).  The PH domain binds phosphoinositides (PIP3) and is 
also responsible for protein-protein interactions and membrane recruitment 
whereas the kinase domain regulates Akt’s enzymatic activity. TCL1 and Akt have 
been demonstrated to physically interact through the PH domain of Akt.  When Akt 
binds to TCL1, there is an increase in kinase activity of Akt thereby implicating 
TCL1 as Akt’s co-activator  (Laine et al. 2000; Ahmed et al. 1993; Pekarsky et al. 
2000).  In addition TCL1 mediates Akt’s translocation into the nucleus (Pekarsky et 
al. 2000).     
When Akt binds to PIP3, it moves to the plasma membrane where it becomes 
activated through phosphorylation at residue Thr308 by 3’-phosphoinositide-
dependent kinase 1 (PDK1) and at residue Ser473 by mTOR.  The now active Akt 
phosphorylates  and thus regulates a variety of pro- and anti-apoptotic factors 
such as IκB kinase-α (IKKα) leading to NFκB activation, mTOR, the nerve growth 
factor IB (NGFIB) also known as Nur77, glycogen synthase kinase-3 (GSK3), Bcl-
2 pro-apoptotic family member Bad, and cyclin AMP-responsive element binding 
protein (CREB) among others (Figure 1.7) (Chan et al. 1999; Cross et al. 1995; 
Ozes et al. 1999; Mok et al. 1999; Pekarsky et al. 2007) 
When human TCL1 is expressed in mice under control of immature and mature B 
cell specific VH promoter enhancer IgH-Eµ (Bichi et al. 2002), it results in a 
pathogenesis similar to human CLL. Peripheral blood lymphocytes of Eµ-TCL1 
mice at 1-9 months displayed a characteristic CLL phenotype marked by the 
expression of CD5, and were also B220+/IgM+. Sorted peripheral blood malignant 
B cells displayed cell cycle arrest at G0/G1 phase, as seen in human CLL (Bichi et 
al. 2002).   By 6 months, an expansion of these cells was seen in all mice, but no 
signs of disease. Eventually all Eµ-TCL1 transgenic (10-20 months) exhibited an 
overall increased white blood cell count, enlarged LN, spleen, liver with evidence 
of malignant cell infiltrations that were TCL1 positive (Bichi et al. 2002). Analysis of 
Ig gene rearrangement demonstrated the presence of pre-leukaemic and leukemic 
clones, similar to human CLL (Bichi et al. 2002). Some mice exhibited 
lymphoadenopathy as seen in some cases of CLL (Bichi et al. 2002). Secondary 
non-haematological malignancies were also seen in Eµ-TCL1 mice similar to poor 
prognosis human CLL cases (Kyasa et al. 2004).   
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When TCL1 is expressed in mice within both B and T cells, a similar phenotype as 
the Eµ-TCL1 transgenic model is seen (Hoyer et al. 2002).  This TCL1 model 
shows evidence of accumulation of malignant B cells with increased proliferative 
capacity in vitro and higher survival capabilities in vitro compared to normal 
counterparts (Hoyer et al. 2002).  
Importantly, TCL1 protein is present in 90% of human CLL cases (of 213 patients 
studied) as assessed by flow cytometry, immunohistochemistry (IHC) and western 
blot (Herling et al. 2006).  In addition, TCL1 expression was shown to positively 
correlate to ZAP70 expression and was more frequent within the unmutated CLL 
subset (Herling et al. 2006).  As in human CLL, there is a bias toward VH11, VH12 
and VH4 gene usage in Eµ-TCL1 mice (Yan et al. 2006). In human CLL, the 
unmutated subset exhibits long CDR3 containing tyrosine and serine rich sections 
that favour polyreactivity (Pekarsky et al. 2007). VH1-69 and VH4-39 
rearrangements in particular, are always associated with poor outcome (Ghiotto et 
al. 2004). Similarly, within the TCL1 mouse, CDR3s also contain charged amino 
acids that are often not coded by germline D and JH segments (Pekarsky et al. 
2007). Collectively, the TCL1 mouse model is representative of the unmutated, 
more aggressive form of CLL.   
BCR signaling has also been demonstrated to play an important role within the 
TCL1 mouse model.  In fact, TCL1 mice that also had a PKCβ knockout failed to 
develop CLL even though they did develop an expanded CD5+ B cell population 
(Holler et al. 2009). The TCL1 transgenic mouse is the best known CLL mouse 
model to date and has been used as a tool to test pre-clinical drugs. Transformed 
lymphocytes from the Eµ-TCL1 mouse express Bcl-2, Mcl-1, DNA (cytosine-5-)-
methyltransferase 1 (DNMT1), PDK1 and are sensitive to agents currently used in 
therapy such as fludarabine and flavopiridol (Johnson et al. 2006). 
1.2.12.2 Simian virus 40 (SV40) large T antigen model 
SV40 is an oncogene that is able to transform a variety of cell types (Suda et al. 
1987; Ahuja et al. 2005) and has been associated with a number of cancers 
(Gazdar et al. 2002; Vilchez et al. 2003) including non-Hodgkin’s lymphoma 
(NHL).  It functions by inactivating p53 and Rb proteins thereby inducing genomic 
instability (White & Khalili 2004).  Introduction of SV40T gene under the control of 
IgH enhances results in increased proliferation of haemopoietic cells, similar to 
occurrences in myelodysplastic syndromes (Inoue et al. 1994).  Introduction of the 
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SV40T gene that lacked a promoter in the reverse orientation between IgH D and 
JH segments, led to the generation of a disease similar to human CLL (Brugge et 
al. 2009). 
The aim was to generate sporadic SV40 T antigen expression through 
homologous recombination in embryonic stem (ES) cells.  Briefly, SV40 large and 
small T antigen-coding unit was introduced in between DQ52 and JH1 in the IgH 
locus (Brugge et al. 2009). An extra copy of the Eµ enhancer was introduced in 
one construct.  Homologous recombination in ES cells was selected for and 
chimeric mice generated that carried the targeted IgH allele. Neomycin generated 
excision occured through the cre-loxP system.  The mice generated above were 
crossed with mice expressing Cre recombinase under control of CMV immediate 
early enhancer-chicken beta-actin hybrid promotor.  Mice expressing a single 
targeted allele were bred with C57BL/6 mice generating heterozygous offspring 
IgH.TEµ or IgH.T.  Analysis of 8-week old IgH.T, IgHTEµ or wild type mice revealed 
no difference in BM and spleen cellularity and no difference in proportions of B 
cells (different stages of B cell development and also different types of B cells 
such as follicular, MZ or spleen cells) (Brugge et al. 2009). 
In addition there was no bias of use of either targeted or wildtype IgH allele usage.  
SV40 T gene and protein expression in spleen was higher in the IgH.TEµ than 
IgH.T as expected due to Eµ promoter (Brugge et al. 2009).  No SV40T 
transcription/translation was evident within the wildtype mice. 
Interestingly, a subpopulation within the IgH.T and IgH.TEµ cohorts showed 
accumulation of monoclonal B cells.  These B cells phenotypically resemble 
human CLL by expression of CD19, CD5.  Leukaemia formation in these mice was 
evident within the blood, spleen and BM within 10 months. IgH.TEµ mice had 
higher incidence than IgH.T mice due to the extra copy of Eµ within the D-JH region 
which may be due to increased antisense transcription.   In addition, crossing of 
IgH.TEµ mice with p53-deficient background increased incidence of CLL.  Whereas 
p53-/- littermates developed T cell tumours, both IgH.T and IgH.TEµ mice biased 
toward B cell leukaemia. However, age of mice at evidence of malignancy 
increased with loss of 53, and tumour formation was not increased as a result of 
p53 loss. 
In some cases, it was demonstrated that usage of IgVH genes within the IgH.TEµ 
cohorts that developed leukaemia resembled unmutated human CLL whereas 
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characterisation of VH regions revealed predominantly germline sequences.  In 
other cases, high levels of hypermutation was seen with use of VHJ558.  Within 
the unmutated set, there was evidence of non random VH family usage (mostly 
VH11) and serine/tyrosine rich CDR3 regions.  Interestingly two mice expressed 
VH11 domains identical to those from a TCL1 CLL clone. 
Also, the unmutated group expressed AID at high levels, similar to human CLL 
whereas low AID expression was seen in the rest of the cases. AIDhi and AIDlow 
cases had similar transcription factor expression profiles supporting the idea that 
both subsets originate from a common post-GC cell. 
The authors suggest that the predominant use of VH11 in the IgH.TEµ leukaemic 
cells demonstrated that the cell of origin was not a CD5+ B-1 cell that had 
randomly transformed because only 10% of this B cell population use VH11.  The 
authors imply use of auto antigen-driven selection within the clonally expanded 
CD5+ B cells in aging mice that leads to disease. The fact that a number of CLL 
IgH.TEµ cases  demonstrated almost identical CDR3 regions was evidence of a 
restricted BCR repertoire. 
Collectively, the authors show a mouse model that is able to generate both 
mutated and unmutated forms of CLL with similarities to the TCL1 mouse model 
and human CLL in terms of characterization of the BCR (Brugge et al. 2009). 
1.2.12.3 miR15a/16-1 mouse model 
As previously discussed, deletions in chromosomal region 13q14 are common in 
CLL implicating that this region contains a tumour suppressor gene (Klein et al. 
2010).  Minimal deleted region (MDR) of 13q14 encodes the deleted leukaemia 
(DLEU2) gene, and the micro RNA cluster miR-15a/16-1 which are considered to 
be tumour suppressors, targeting anti-apoptotic proteins like Bcl-2, and have been 
shown to be downregulated in CLL (Calin et al. 2004).  DLEU2’s function is not 
well characterized because its sequence is not similar to any known non-coding 
RNA.  miR15a/16-1 cluster has been characterized as a negative regulator of 
proliferation and apoptosis (Calin et al. 2005). Deletion of the MDR of 13q14 leads 
to proliferation in both human and mouse B cells and can result in clonal 
lymphoproliferative disorders (Bandi et al. 2009; Calin et al. 2008; Klein et al. 
2010).  
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Klein et al developed a transgenic mouse that harboured conditional alleles that 
mimicked MDR deletion of miR-15a/16-1 or specifically deleted this region without 
any effect on DLEU2 (Klein et al. 2010).  Homozygous deletion of MDR region or 
miR-15a/16-1 did not have an effect on lymphocyte development in the early 
months, however at 12 months both cohorts displayed an expansion of 
CD5+B220low cells within the peritoneal cavity.  At 15-18 months, a clonal 
CD5+B220low population was evident within peripheral blood. Within a 
subpopulation of these mice infiltration of CD5+ B cells into lymphoid organs was 
evident, and histopathologically resembled human CLL.  These mice harboured 
enlarged splenic white pulp, smudge cells and aggregates of a clonal population of 
small lymphocytes in the BM similar to human CLL.  Collectively 42% of MDR-/- 
and 26% of miR-15a/16-1-/- cohorts at 15-18 months developed B cell 
lymphoproliferative disorders of clonal origin (Klein et al. 2010).   
MiR-15a/16-1-/- mice developed a milder disease than MDR-/- mice and had no 
apparent increase in survival than wild-type littermates, unlike MDR-/- mice that 
died earlier (Klein et al. 2010).  When miR-15a/16-1 and MDR was deleted 
particularly within B cells, development of clonal lymphoproliferations occurred in a 
B cell autonomous manner in both MDR-/- and mir-15a/16-1 cohorts. 
When IgV genes were sequenced within tumours of homozygous or heterozygous 
MDR and miR-15a/16-1 mice, CD5+ tumours harboured unmutated IgVH genes 
while CD5- NHL tumours harboured mutated IgVH genes, indicating that 
lymphoproliferation originated from B cells that have undergone T-cell dependent 
and independent antibody responses (Klein et al. 2010).  In addition, whereas the 
CD5- NHL tumours expressed HCDR3 regions that were variable, within the CD5+ 
B cell proliferations IgV gene usage was limited and showed similar HCDR3 
regions. Therefore CD5+ B cell lymphoproliferation in MDR-/- and miR-15a/16-1-/- 
mice can express antibodies that have stereotypical antigen binding regions, 
implying common or auto antigens within clonal expansion, similarly to human CLL 
(Ghia et al. 2008).   
Klein et al. also showed that miR-15a/16-1 cluster (and not DLEU2) negatively 
regulated proliferation of mouse and human B cell line I83E95 derived from human 
13q14-/- CLL) (Klein et al. 2010).  Importantly miR-15a/16 negatively regulates Bcl-
2 expression and the cluster’s downregulation results in an increase in Bcl-2, as 
seen in human CLL. 
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1.2.12.4 Bcl-2/TRAF3 mouse model 
TNF-receptor associated factors (TRAFs) belong to a family of adaptor proteins 
important in signal transduction pathways such as gene expression, proliferation 
and regulation of apoptosis (Zapata et al. 2004).  When deregulated, TRAFs can 
lead to generation of automimmiune and inflammatory diseases (Zapata et al. 
2004).  In NHL and CLL, TRAF1 is overexpressed and is associated with 
resistance to apoptosis (Wang et al. 1998; Arron et al. 2002; Lin et al. 2003).  
Zapata et al developed a transgenic mouse expressing Bcl-2 and TRAF2 mutant 
that lacks N’ terminus RING and zinc finger domains (TRAF2DN).  These mice 
develop B cell leukemia and lymphoma that is similar to human CLL, although 
over expression of Bcl-2 alone or TRAF2DN alone does cause polyclonal B cell 
expansion, but does not lead to lethal malignancies (Zapata et al. 2004). 
More specifically, transgenic mice overexpressing Bcl-2 and TRAF2DN develop 
extreme splenomegaly already evident at birth.  In addition these mice die at 
accelerated rates compared to single transgenic (Bcl-2 or TRAF2DN alone) 
cohorts. Histological analysis of double transgenic mice revealed an expansion of 
MZ with the presence of infiltrating small B cells.  In addition, double transgenic 
mice had infiltration of B220+ lymphocytes within major tissues and organs at 
much more invasive rates than single transgenic cohorts (Zapata et al. 2004).    
Phenotypic analysis of spleen lymphocytes from double transgenic mice revealed 
a significant population of B220medIgMhiIgDlowCD21low-nullCD23nullCD11blow B cells.  
CD5 was also expressed on most splenic B cells from double transgenic mice.   In 
addition, blood counts were up to 167x106 B cells/ml in double transgenic mice 
compared to wild-type counts of 4x106 B cells/ml indicative of leukemia 
development ( Zapata et al. 2004).     
Analysis of double transgenic cohorts assessed for levels of expression of 
adhesion molecules indicative of elevated invasiveness revealed increased 
expression of CD54 (intercellular adhesion molecule-1), CD29 (β1 integrin) , 
CD49d (α4 integrin) and CD11a (LFA-1) compared to Bcl-2 single transgenic and 
wild-type cohorts (Zapata et al. 2004).  Additionally, analysis of IgH gene 
rearrangements in double transgenic cohorots revealed clonal origin of B cells.  
Assessment of proliferation, cell cycle and apoptosis within double transgenic 
cohorts revealed that B cells from transgenic cohorts had comparable proliferation 
rates but had much higher ability to resist apoptosis when treated with 
chemotherapeutic drugs compared to single transgenic and wild-type cohorts 
  38 
(Zapata et al. 2004).   
1.2.12.5  APRIL mouse model 
APRIL is a protein that stimulates proliferation of tumour cells in vitro (Medema et 
al. 2003), is expressed in a number of nonhaematopoietic carcinoma cell lines and 
tumour samples, and in haematopoietic cells (Hahne et al. 1998; Kelly et al. 2000; 
Novak et al. 2002; Litinskiy et al. 2002; Pradet-Balade et al. 2002; Deshayes et al. 
2004).  Its role in tumour growth is highlighted by studies in colon and lung 
carcinomas (Rennert et al. 2000).  In CLL, APRIL was found to be expressed in a 
small percentage of patients by one group (Novak et al. 2002), and in all CLL 
cases but at comparative levels to normal B cells by another group (Kern et al. 
2004).  Analysis of APRIL levels in sera of CLL versus normal donors through 
ELISA revealed elevated expression in CLL patients (Stein et al. 2002; Planelles 
et al. 2004) 
When transgenic mice were generated overexpressing APRIL, there was evidence 
of thymus-independent humoral immune responses (both type 1 and type 2) (Stein 
et al. 2002).  At 6-12 weeks, no difference in B1/B2 cell ratio was seen in APRIL 
transgenic mice, however as the mice aged a significantly higher percentage of B1 
cells was seen in the peritoneal cavity of APRIL mice (and not spleen) compared 
to control littermates.  APRIL mice also exhibited higher IgA serum levels, 
indicative of B1 cell activity.  The B1 cells found within the peritoneum were also 
CD5+, and accumulated over time similarly to the human CLL phenotype.  By 9-12 
months, 40% of APRIL mice displayed enlargement of and increase in cell number 
of mesenteric lymph nodes (mLN) or Peyer’s patches (PP).  Older APRIL mice 
also displayed a highly disorganized splenic architecture and B cell infiltration 
(Stein et al. 2002).  B and T cell populations within aged APRIL mice had 
expanded within mLN, and there was evidence of activation.   Expansion within 
mLN was concluded to be due to lymphocyte hyperactivation leading to 
hyperplasia (Planelles et al. 2004). Expanded mLNs also harboured B1 cells that 
were phenotypically CD5+CD19+IgMdimB220dimCD23- and therefore imply higher 
activation status due to downregulation of surface IgM. Furthermore, ex-vivo 
culture of B1 cells from APRIL mice and control littermates revealed that B1 cells 
from APRIL mice had a survival advantage, surviving longer ex-vivo (Stein et al. 
2002).   
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1.2.12.6 New Zealand Black mouse model 
Unlike the previous models discussed, the New Zealand Black (NZB) mouse 
model is not induced by expression of exogenous genes (Scaglione et al. 2007).  It 
is an age-associated expansion of malignant CD5+ B1 clones (Scaglione et al. 
2007).  IL-10 has been associated with the expansion of these malignant B cells 
that first go through a monoclonal B cell lymphocytosis (MBL)-like stage before 
developing into a disease that resembles human CLL.  Of note, MBL can be a 
precursor in human CLL but may also never develop into CLL (Salerno et al. 
2010).   NZB model also develops a mild form of autoimmunity (Scaglione et al. 
2007). As in human CLL, miR-15a/16-1 tumour suppressive cluster is altered.  
Although within human CLL it is usually deleted, within the NZB mouse, it is 
mutated making it structurally unstable and unable to fully mature (Raveche et al. 
2007).  Interestingly, a similar point mutation was reported in 2 cases of human 
CLL (Calin et al. 2005). Restoring miR-16 levels in NZB mice allows for enhanced 
sensitivity to drug treatment (Coll-Mulet et al. 2006).  Within the NZB a side 
population of stem-like cells was found and implicated to be the CLL progenitor 
cell (Tárnok et al. 2010).   
1.2.12.7 miR-29 mouse model  
miR-29 targets a number of oncogenes including TCL1, Mcl-1, and cyclin-
dependent kinase 6 (CDK6) and is thought of as a tumour suppressor in some 
systems (Pekarsky et al. 2006; Zhao et al. 2010; Mott et al. 2007) and a tumour 
promoter in others (Gebeshuber et al. 2009; Han et al. 2010).  Analysis of miR-29 
expression revealed that it is up-regulated in unmutated CLL compared to mutated 
CLL and normal B lymphocytes (Santanam et al. 2010).  Generation of a 
transgenic mouse over-expressing miR-29 under the Eµ promoter led to a model 
of CLL whereby there was evidence of an expanded CD5+ population.  In 
particular, at 2 months 85% of Eµ-miR-29 transgenic mice harboured a CD5+ B 
cell population that rose to 100% at 2 years of age.  Enlarged spleen and liver 
were a common feature of the Eµ-miR-29 cohorts and 20% developed frank 
leukemia and died.  Some evidence of clonality of B cells was also demonstrated 
within the Eµ-miR-29 cohorts, however only 5 were examined and 3 showed clonal 
outgrowth of B cells (Santanam et al. 2010).   
Histological analysis of blood smears from wild type mice and high-grade CLL Eµ-
miR-29 mice revealed the presence of increased number of atypical and malignant 
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lymphoid cells, including smudge cells within the Eµ-miR-29 cohorts.  Eµ-miR-29 
also displayed distorted splenic architecture coupled with an increase in cyclin D1 
expression.  The authors suggest that the CLL phenotype in the Eµ-miR-29 model 
is not only due to accumulation, yet also to active proliferation of CD5+B220+ cells 
within the BM, LN and spleen.  In fact, BrdU analysis of Eµ-miR-29 versus wild 
type mice reveals a higher percentage of proliferating B220+CD5+ B cells. The Eµ-
miR-29 mice also developed hypogammaglobulinemia that is a common 
occurrence in CLL patients. Crossing of Eµ-TCL1 mice with Eµ-miR-29 mice 
revealed an even more aggressive phenotype, with an increase of 40% in 
CD5+CD19+ splenic B cells in the double transgenic compared to Eµ-TCL1 alone, 
suggesting that miR-29 can contribute to the pathogenesis of CLL independently 
of TCL1 (Santanam et al. 2010). 
Although there are clear disadvantages in using murine models such as 
differences from pathogenesis of human disease and differences between 
microenvironment of mouse and human, they are nevertheless important tools in 
understanding human disease, particularly in light of the heterogeneity of the 
human disease.  They can be used to study initiation and development of a CLL, 
and characterize novel therapeutic targets that may prove beneficial in treatment 
of the disease.  Although no model to date exactly emulates human disease, all 
models have furthered our understanding of human CLL and may reflect the 
heterogeneity of CLL.  
1.3 The Protein Kinase C Family 
The PKC family comprises of nine closely related serine/threonine kinase isoforms 
that have evolutionarily conserved structural features.  PKCs belonging to the 
mammalian family share common catalytic domains (Figure 1.8), but differ in their 
regulatory domain which dictates the co-factors required for their activation.  The 
isoforms are subdivided into three main groups: conventional, novel and atypical 
PKCs.  Conventional PKCs (α, βI, βII and γ) are activated by phospholipids, 
diacylglycerol (DAG) and Ca2+ binding (Figure 1.8).  Novel PKCs (δ, ε, η, and θ) 
do not require Ca2+ for activation, but are still dependent on phospholipids and 
DAG.  Finally, atypical PKC isoforms (ζ and ι/λ) are activated independently of 
Ca2+ and DAG (Newton 2001; Rosse et al. 2010).  
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Figure 1.8 The structure of PKCs 
 
1.3.1 Regulators of PKCs 
GPCR or receptor tyrosine kinases (RTK) are activated resulting in PLC regulated 
generation of inositol triphosphate (IP3) and DAG from cell membrane 
phospholipids (Griner & Kazanietz 2007).  IP3 releases Ca2+ from the sarcoplasmic 
reticulum (or other intracellular stores) which primes conventional PKCs.  Before a 
PKC is activated, it must undergo a process of maturation involving a series of 
phosphorylation steps (Figure 1.9) (Griner & Kazanietz 2007).  The first 
phosphorylation step of a PKC is mediated by PDK1 and occurs at the activation-
loop site.  This first phosphorylation step exposes the turn and hydrophobic motifs 
within the C terminal. The PKC now autophosphorylates, leading to increased 
stabilization of the enzyme and maturity.  The mature yet still inactive PKC is now 
released into the cytosol awaiting activation (Griner & Kazanietz 2007).  Upon 
increase in levels of intracellular Ca2+ and DAG, Ca2+ binds the C2 domain of 
classical PKCs and DAG binds the C1 domain conferring a high-affinity interaction 
between the membrane and the PKC resulting in a conformational change that 
results in release of the pseudosubstrate from the substrate-binding site, thus 
releasing this domain for binding of actual substrates, serine/threonine 
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phosphorylation and activation of signaling effectors that lie downstream (Colón-
González & Kazanietz 2006).  Novel PKCs are not pre-targeted by Ca2+ but have 
higher affinity to DAG (Giorgione et al. 2006).   
 
Figure 1.9 Activation of cPKCs 
 
1.3.2 PKCs: Tumour Promoters or Suppressors? 
PKCs are ubiquitously expressed and necessary for regulation of processes in 
normal cells such as proliferation, apoptosis, differentiation and migration (Newton 
2001; Tan & Parker 2003). PKCs are not only a target of tumour promoting phorbol 
esters which act as DAG analogues, but have also been linked to oncogenes such 
as RAS, FOS and myc, placing PKCs at the core of cancer signaling pathways 
(Griner & Kazanietz 2007).  Indeed, expression of specific PKCs is dysregulated in 
a number of cancers (Griner & Kazanietz 2007; Michie & Nakagawa 2005). PKCs 
have also been implicated in mitogenesis, survival and transformation (Griner & 
Kazanietz 2007).  Overexpression of PKCβI and PKCγ in murine fibroblasts causes 
a malignant transformation of these cells and enhances tumorigenesis in nude 
mice (Bredel & Pollack 1997). Overexpression of PKCβII in colon cancer causes 
hyperproliferation of colonic epithelium and increased carcinogenesis (Griner & 
Kazanietz 2007). In fact inhibiting PCKβ with enzastaurin has shown to effectively 
induce apoptosis in or stop the proliferation of cancerous cells in colon cancer, T 
cell lymphoma, glioma and thyroid cancer (Griner & Kazanietz 2007). Therefore 
PKC inhibition has been a key focus in cancer therapy to date.  
However, not all PKCs act as tumour promoters.  Sometimes, where one isoform 
acts as a tumour promoter, another acts as a tumour suppressor.  For example, 
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some isoforms like PKCε and PKCδ can have opposing roles in proliferation, 
survival and tumour promotion.  PKCε acts as a tumour promoter, whereas PKCδ 
has been shown to have tumour suppressive qualities such as delivery of anti-
proliferative and apoptotic signals in various cell types (Griner & Kazanietz 2007). 
Similarly, overexpression of PKCβII in mice stimulates the proliferation of colon 
epithelial cells and is an early promoting factor in colon carcinogenesis (Gökmen-
Polar et al. 2001), whereas PKCα expression is usually decreased (Dupasquier et 
al. 2009).  
1.3.3 PKCα 
A single isoform can serve completely opposing roles in a system-dependent 
manner. For example, PKCα is upregulated in a variety of human cancers such as 
breast, gastric, prostate and brain cancers, implicating it as a tumour promoter in 
these cancers (Griner & Kazanietz 2007; Michie & Nakagawa 2005).  In 
melanoma, PKCα activation is associated with increased tumour cell proliferation, 
invasiveness and decreased differentiation (Lahn & Sundell 2004; Krasagakis et al. 
2004). Similarly, in breast cancer cells, PKCα expression has been linked to 
increased aggressiveness and invasiveness (Tan et al. 2006; Lønne et al. 2010).  
Moreover, PKCα and PKCβI antisense depletion studies in gastric cancer cells 
demonstrated reduced size and rate of tumour formation and anchorage-
independent growth (Griner & Kazanietz 2007). Such studies have led to the 
development of pharmacological agents targeting the expression or activity of 
PKCα, however clinical trials results have not been encouraging (Martiny-Baron & 
Fabbro 2007; Tortora & Ciardiello 2003; Mackay & Twelves 2007; Cripps et al. 
2002).  However, the expression or function of PKCα has been found to be 
downregulated in thyroid, pituitary, epidermal, pancreatic, colon cancers (Kahl-
Rainer et al. 1994; Alvaro et al. 1997; Detjen et al. 2000; Gökmen-Polar et al. 
2001; Tibudan et al. 2002; Neill et al. 2003)  as well as in CLL (Alkan et al. 2005; 
Abrams et al. 2007) suggesting that in these cancers PKCα may act as a tumour 
suppressor.  Overexpression of PKCα in melanocytes results in attenuated 
proliferation (Bredel & Pollack 1997).  In a carcinogen-induced colon cancer mouse 
model, expression of PKCα decreases (Gökmen-Polar et al. 2001). Similarly, within 
the ApcMin/+  mouse model of colorectal cancer PKCα expression is decreased 
(Nakashima 2002), and crossing of ApcMin/+  mice with PKCα-/- mice resulted in 
development of more aggressive tumours within mice that died earlier than their 
PKCα-proficient counterparts (Oster & Leitges 2006; Leitges 2007). Another mouse 
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colorectal cancer study showed that PKCα transcription is repressed by the SOX9 
transcription factor in proliferating intestinal epithelial cells in vitro and in vivo 
(Dupasquier et al. 2009), generating the cancerous phenotype.  Collectively, these 
studies underline the fact that a single isoform can have either tumour promoting or 
tumour suppressive roles, stressing the importance of differential regulation of PKC 
isoforms in distinct cell contexts.  
Importantly, subversion of PKCα signaling through expression of dominant-
negative PKCα (PKCα-KR) in lymphoid progenitor cells has led our laboratory to 
develop a murine model of CLL ( Nakagawa et al. 2006).  Therefore, within our 
model of CLL, PKCα acts as a tumour suppressor.  The aim of this project was to 
investigate events downstream of PKCα subversion during the initiation and 
development of disease and to draw links to human CLL. The following thesis will 
therefore characterize a previously established CLL model in order to gain further 
understanding of human CLL with the following aims: 
 
Aims: 
1. Elucidate similarities between human CLL and the mCLL model; 
2. Investigate properties of mCLL cells and define molecular events occurring 
downstream of subversion of PKCα signaling; 
3. Evaluate the lineage plasticity potential of mCLL cells. 
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2.1 Plasmids and cell lines 
2.1.1 Plasmids 
All plasmids encoding PKC mutants were a kind gift from Dr. Jae-Won Soh. 
Briefly, PKCα-KR was generated by introducing a point mutation in the full length 
PKCα cDNA at lysine (K) 368 in the ATP-binding site, changing it to arginine (R), 
the denomination PKCα-KR. The mutant was introduced into the backbone 
plasmid pHACE (Figure 2.1 top; Soh et al. 1999) at the EcoRI site.  pHACE was 
derived from pcDNA3 (Invitrogen, Paisley, UK; summary of supplier’s addresses 
can be found in Table 2.1), modified to contain a C-terminal HA tag. The 
constitutively active PKCβI and PKCβII isoforms (PKCβI-CAT and PKCβII-CAT) 
were generated by deletion of the respective gene’s regulatory domain, and were 
introduced into the backbone pHANE (Figure 2.1 bottom; Soh et al, 1999) at the 
EcoRI restrictin site.  pHANE was derived from pcDNA3 but modified to contain an 
N-terminal HA tag.  The full-length, wildtype PKCβI and PKCβII (PKCβI-WT and 
PKCβII-WT) were introduced into the pHACE and pHACB backbone (Figure 2.1 
top; Figure 2.2 top) at the EcoRI site (into pHACE) and BamHI site (into pHACB) 
respectively. Like pHACE, pHACB was generated by altering pcDNA3 to contain a 
C-terminal HA tag.   
Retroviral constructs were generated by subcloning of wildtype and mutated 
isoforms into the retroviral backbone MIEV (Figure 2.2, bottom). MIEV contains 5’ 
and 3’ long terminal repeats (5’LTR, 3’LTR) flanking a cytomegalovirus (CMV) 
promoter and green fluorescent protein (eGFP) driven by an IRES sequence.  
LTRs are used by viruses to insert their genetic information into the genome of the 
host, whereas the IRES sequence allows for initiation of translation of messenger 
RNA (mRNA).  PKCα-KR, PKCβI-CAT and PKCβII-CAT were cloned into MIEV at 
BglII-NotI restriction enzyme sites (Figure 2.3 top). PKCβI-WT was cloned into 
MIEV at XhoI, NotI (Figure 2.3 bottom). PKCβII-WT was excised out of pHACB 
with XhoI, EcoRV and subcloned into MIEV at XhoI, SnaBI (Figure 2.4).  MIEV-
CyclinD1 was created by subcloning CyclinD1 from pCMV-Sport6 (Bioscience 
LifeScience Ltd., Nottingham, UK; Figure 2.5 top) into MIEV at EcoRI, NotI sites 
(Figure 2.5 bottom). All inserts were cloned into MIEV 5’ of the internal-ribosomal 
entry site (IRES), allowing for the bicistronic expression of the specific gene of 
interest with GFP and effective tracking.   
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2.1.2 Cell Lines 
2.1.2.1 PT67 retroviral packaging cells 
PT67 cells (ClonTech, Saint-Germain-en-Laye, France) are NIH/3T3 fibroblasts 
that express gag, pol, and env genes to continuously produce retrovirus packaged 
into an amphotropic envelope 10A1 capable of infecting most mammalian cells 
after co-transfection with a retroviral vector (Miller & Chen 1996). PT67 cells were 
cultured in DMEM medium (10% FBS (Invitrogen), 100 U/ml penicillin, 100 µg/ml 
streptomycin, 50 µM β-ME (Sigma-Aldrich, Dorset, UK) and 2 mM L-glutamine 
(Invitrogen)) at 37°C in a humidified incubator containing 5% (v/v) CO2.   
2.1.2.2 GP+E.86 retroviral packaging cells 
GP+E.86 cells are NIH/3T3 fibroblast cells that were modified to contain gag, pol, 
and env genes to continuously produce an ecotropic virus after co-transfection 
with a retroviral plasmid.  For safety reasons, the gag, pol and env genes were 
initially separated onto two different plasmids and their Ψ packaging sequence 
was deleted, alongside the 3’ LTR to ensure replication incompetent virus 
(Markowitz et al. 1988). GP+E.86 cells were cultured in DMEM medium at 37°C in 
a humidified incubator containing 5% (v/v) CO2.   
2.1.2.2.1 Generation of retroviral packaging lines 
PT67 cells were transfected with retroviral vectors generated above (section 2.1.1) 
using lipofectamine or CaCl2.  Virus was collected after 48 hr, filtered through a 
0.45 µm filter, ultracentrifuged at 24 000 g for 2 hr at 4°C and used to transduce 
GP+E.86 cells. GFP+ GP+E.86 cells were sorted twice using BD FACSAria (BD 
Biosciences, Oxford, UK) and subsequently used to continuously generate virus 
for retroviral transduction of lymphoid progenitors (Figure 2.6). 
2.1.2.3 OP9 cells 
OP9 cells are a murine stromal cell line generated from newborn B6C3F2 op/op 
mouse calvaria (Kodama et al. 1984) with a mutation in the gene encoding for M-
CSF, thus resulting in the lack of secretion of functional M-CSF (Nakano 1995).  
OP9 cells support the differentiation of ES cells into B cells when co-cultured with 
cytokine IL7 and β-mercaptoethanol (β-ME) (Nakano et al. 1994; Nakano 1995) 
and have since been used to differentiate FL cells into B cells under similar 
conditions. OP9 cells were cultured in complete medium: α-MEM (Invitrogen) 
containing 20% foetal bovine serum (FBS) (Invitrogen), 100 U/ml penicillin, 100 
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µg/ml streptomycin, 50 µM β-ME, 2 mM L-glutamine, 10 mM HEPES, 1 mM 
Sodium Pyruvate and 10 µg/ml gentamycin (Invitrogen) at 37°C in a humidified 
incubator containing 5% (v/v) CO2.   
2.1.2.4 OP9-DL1 cells 
OP9-DL1 cells are OP9 cells that have been modified to ectopically express the 
Notch ligand delta-like-1 (DL1) (Schmitt & Zúñiga-Pflücker 2002). During 
lymphocyte development, Notch receptors and their ligands are important 
regulators of T cell linage commitment, and in particular, Notch1 has been shown 
to be critical in T cell development (Wang et al. 2006).  Following the addition of 
Flt3L and IL7 (PeproTech, London, UK), OP9-DL1 cells preferentially support T 
cell differentiation of ES cells and FL stem cells. OP9-DL1 cells were cultured in 
complete medium at 37°C in a humidified incubator containing 5% (v/v) CO2. 
2.2 Tissue culture 
All tissue culture was conducted under sterile conditions using a laminar air flow 
hood.  Tissue culture consumables were purchased from Fisher Scientific U.K. 
and Greiner Bio-One Ltd unless otherwise stated.  
2.2.1 Preparation of HPCs from FL cells 
Single cell FL suspensions were created via crushing of FL extracted at day 14 of 
gestation and filtering through a 70 µM nylon mesh (Biodesign Inc., NY, USA) 
followed by a wash in DMEM media (4 min, 324g, RT). Complement-mediated 
lysis was carried out using anti-CD24 antibody, and incubating cells with low-lox 
rabbit complement (Cedar Lane, ON, Canada) at 37ºC for 30 min.  Thereafter, a 
discontinous density gradient centrifugation over Lympholyte-Mammal (Cedar 
Lane) was performed for 30 min (623g; RT) in order to extract all viable CD24-/low-
HPCs.  Viable HPCs were then washed in DMEM medium for 5 min (324g) once 
before subsequent use.   
2.2.2 Retroviral transduction of HPCs 
Retroviral GP+E.86 packaging lines expressing PKCα-KR (GP+E.86-PKCα-KR) or 
MIEV empty retroviral vector (GP+E.86-MIEV) were plated at 60% confluence one 
day prior to retroviral transduction in 6-well plates.  Packaging lines were 
incubated with mitomycin C (10 µg/ml) for 3 hr at 37°C, and subsequently washed 
twice with DMEM. Single cell suspensions of prepared FL were re-suspended in 
complete medium supplemented with 10 ng/ml polybrene, 5 ng/ml IL7 and Flt3L 
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and were co-cultured with packaging cell lines for overnight transduction prior to 
being placed on an in vitro B cell generation system (OP9).  
2.2.3 In vitro B cell generation system  
OP9 stromal cells were plated at 60% confluence one day prior to FL co-culture. 
FL:OP9 co-culture was maintained in complete medium supplemented with 10 
ng/ml IL7 and Flt3L with a change of media every second day, and a change of 
OP9 layers every fourth day. After day 5 of FL:OP9 co-culture Flt3L was removed 
from the medium (Figure 2.7 top).  
2.2.4 In vitro T cell generation system 
OP9-DL1 cells were plated at 70% confluence one or two days prior to FL co-
culture.  Pro-B cells or HSCs were sorted from FL:OP9 co-cultures and 
subsequently co-cultured with DL1 cells in complete medium supplemented with 5 
ng/ml IL7 and Flt3L. Medium was changed every 2 days and OP9-DL1 layers were 
replaced once per week (Figure 2.7 bottom).  
2.2.5 Isolation of HSC, pro-B and T cells from FL in vitro cultures 
FL cells were transduced overnight with MIEV or PKCα-KR retroviral packaging 
lines in complete medium and thereafter labelled with fluorochrome conjugated 
antibodies (B220-PE, CD45-PerCP, Sca1-PE-Cy7, CD117-APC, CD19-APC-Cy7) 
and a lineage cocktail of biotin-conjugated antibodies (CD3ε, CD4, CD8, CD11b, 
Gr1, NK1.1 and Ter119) and visualized by streptavidin (SA) -conjugated Pacific 
blue (Invitrogen) (refer to Table 2.2 for list of FACS antibodies used). HSC 
populations were sorted by gating on: GFP+Lin-CD45+B220-CD19-CD117hiScaIhi 
and subsequently co-cultured with OP9 cells in complete medium supplemented 
with 10 ng/ml IL7 and Flt3L for 9 days. Late pro-B populations were then sorted 
from day 9 HSC:OP9 co-cultures by gating on: GFP+Lin-
CD45+B220+CD19+CD117+ and subsequently cultured on OP9-DL1 stromal layers 
in complete medium supplemented with 5 ng/ml IL7 and Flt3L.   B lineage cells 
(CD19+ B220+ Lin-) were sorted from both MIEV and PKCα-KR cultures and CD19-
B220- CD90.2+ CD25+ Lin- cells were sorted from PKCα-KR-cultures.  
2.2.6 Drugs and Inhibitors 
Details of the stock concentrations, manufacturers and storage conditions of all 
drugs and inhibitors used are listed in Table 2.8.  
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Phorbol-12-myristate-13-acetate (PMA; Sigma-Aldrich) is a polyfunctional 
diterpene phorbol that is an activator of PKC (Saitoh & Dobkins 1986) and is 
known as a widespread tumour promotor in cancer (O’Brien et al. 1975). 
Ionomycin (Iono) (Sigma-Aldrich) is an ionophore that is used to raise intracellular 
Ca2+ levels and is often used in combination with PMA to stimulate the activation 
of PKCs.  Hispidin (Sigma-Aldrich) is a fungal metabolite that inhibits PKCβI and βII 
isoforms.  Enzastaurin, a synthetic bisindolylmaleimide, inhibits PKCβ by binding 
to the ATP-binding site and was a kind gift from Eli Lilly (Eli Lilly and Co. Ltd, 
Hampshire, UK). Rapamycin (rapa) is an inhibitor of mammalian mTOR by 
associating with its intracellular receptor FKBP12 and was purchased from 
Calbiochem.  Okadaic Acid (OA) is an potent inhibitor of protein serine/threonine 
phosphatase A (PP2A) and was also purchased from Merck (Merck Chemicals 
Ltd., Nottingham, UK).   
2.2.6.1 In vitro drug treatment 
B cells were carefully harvested from FL:OP9 co-cultures and centrifuged over 
Lympholyte-Mammal prior to drug treatments. 1 x 106 cells per condition were 
plated in complete medium and treated with drug or vehicle control for 24 or 48 hr.  
2.2.6.2 In vivo drug treatment 
Enzastaurin was re-suspended in D5W (5% dextrose in water) and dosed by oral 
gavage (0.2 ml per dose) with 80 mg/kg daily in order to approximate the plasma 
concentrations achieved clinically as suggested by Eli Lilly. Mice were dosed for 
14-21 consecutive days and maintained on a normal diet.  
2.3 In vivo models 
2.3.1 RAG-/- and ICR mice 
All animal work was carried out in accordance with regulations set by the Animals 
Scientific Procedures Act 1986 (ASPA, 1986).   Imprinting control region (ICR) 
mice purchased from Harlan UK Ltd (Harlan UK Ltd., Blackthorn, UK) and RAG1-/- 
mice were used, and were maintained at the University of Glasgow Central 
Research Facilities.  ICR mice are an outbred strain of Swiss mice established by 
Hauschka and Mirand in 1973 (Eaton et al. 1980) and are often used for 
oncological research.  RAG1-/- mice have a blockade in lymphocyte differentiation 
at the pro-B to pre-B cell stage in development, similar to that described in severe 
combined immunodeficient  (SCID) mice. RAG genes are also responsible for 
  51 
TCR rearrangement, and therefore RAG1-/- mice have no mature B and T 
lymphocytes (Mombaerts et al. 1992), and an impaired immune system.   
In preparation for isolation of FL derived HPCs, timed pregnant mice were 
generated, and FL was extracted at day 14 of gestation. 
2.3.2 In vivo adoptive transfer 
Lymphocytes were isolated from retrovirally transduced HPC FL cultures by 
centrifugation over Lympholyte-Mammal.  Briefly, HPCs were isolated from day 14 
gestation FL (as described in section 2.2.1), retrovirally transduced overnight (as 
described in section 2.2.2), collected, washed and re-suspended in 5 ml, underlaid 
with Lympholyte-Mammal and centrifuged for 30 min (623g; RT).  Cells were 
isolated from the interphase, washed twice in PBS and re-suspended in PBS at a 
concentration of 1x106 cells/ml.  Neonatal RAG1-/- mice were injected intra-
peritoneally (i.p.) with the cell suspension at a desired concentration of cells and 
monitored for the development of disease.   Mice were sacrificed by cervical 
dislocation 4-8 weeks post-injection and organs (BM, LN, spleen), blood, 
peritoneal wash and any present tumours were harvested for processing and 
analysis or storage for later analyses.  
2.3.2.1 Processing of blood and organs from injected RAG1-/- mice 
Lymphoid organs were removed from injected RAG1-/- mice and placed into 
separate tubes containing 2 ml PBS.  The organs were crushed in order to 
generate a cell suspension.  Cells were filtered through a 70 µM nylon mesh 
(Biodesign Inc., NY, USA) and pelleted by centrifugation for 5 min at 400 g at RT.  
The cell pellet was re-suspended in 5 ml PBS and underlaid with 2.5 ml 
Lympholyte-Mammal (as described in Section 2.1.1) in order to remove red and 
dead cells.  Cells were re-suspended in FACS buffer and stained with antibodies 
for FACS analysis.   
2.4 Normal human B cells and CLL blood samples 
Normal B lymphocytes were isolated from buffy coat samples acquired from 
healthy individuals through the Scottish National Blood Transfusion Service 
(SNBTS), with approval from SNBTS ethics committee.  Samples were received 
within 24 hr after bleeding of donor, after standard virology screening was 
completed. B cells were isolated using MACS human CD19 MicroBeads according 
to the manufacturer’s protocol (Miltenyi Biotec, Surrey, UK).  CLL lymphocytes 
were isolated from peripheral blood of patients with a clinically confirmed diagnosis 
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of B-CLL, after informed consent.  Patients had not received treatment within the 
preceding three months.  CLL B cells were isolated using RosettesepTM human B 
cell enrichment cocktail (Stemcell Technologies, Grenoble, France) according to 
the manufacturer’s protocol.  After separation, B cell purity was >90% assessed by 
FACS in both normal and CLL samples. For a list of clinical characteristics CLL 
samples used see Table 2.3.  CLL patients were anonymised and linked through 
acquisition of a field of clinical data. 
2.5 Western Blotting 
B lineage cells were removed from OP9 co-cultures and placed on empty 6-well 
plates in complete medium for 2 hr in order to separate B cells from adherent OP9 
layers.  1 x 107 cells were washed twice in ice-cold PBS with phosphatase 
inhibitors (Roche, West Sussex, UK) and re-suspended in 100 µl lysis buffer (20 
mM Tris pH7.5, 137 mM NaCl, 10% glycerol, 1% NP40) containing protease 
inhibitor cocktail  (Roche, West Sussex, UK) and phosphatase inhibitor cocktail 
(Roche) on ice for 30 min. Lysates were then spun at 14 000 rpm for 30 min at 4°C 
and supernatant collected.   
Quantification of lysates was conducted with a bicinchoninic acid (BCA) Protein 
Assay Kit (Pierce, Northumberland, UK). Bovine albumin serum (BSA) protein 
standards were prepared in sterile water at concentrations of: 2000, 1500, 1000, 
750, 500, 250, 125, 26 and 0 µg/ml and stored at -20°C until use.  2 µl of BSA 
protein standard or sample lysate was pipetted per well of 96-well plate in triplicate 
and 200 µl of 50:1 solution of kit reagent A:B was pipetted to each well and the 
plate was incubated at 37°C for 30 min.  Absorbance was read at 562 nM on a 
Spectramax M5 plate reader (MDS Analytical Technologies, Berkshire, UK) and 
analysed with SoftMax Pro 5.2 software (MDS Analytical Technologies).   
Equal amounts of protein (typically 10-20 µg) were incubated with NuPage LDS 
Sample buffer (10 % (w/v) Glycerol, 1.7% (w/v) Tris-Base, 1.7% Tris-HCl, 2% (w/v) 
lithium dodecyl sulfate (LDL), 0.15% (w/v) EDTA, 0.019% Serva Blue G250 and 
0.063% Phenol Red (pH 8.5) (Invitrogen) and sample reducing agent (Invitrogen) 
at 72ºC for 15 min.  Proteins were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-12% NuPAGE Novex Bis-
Tris precast gel (Invitrogen) (unless otherwise stated), using MOPS SDS Running 
Buffer buffer (50 mM 3-(N-morpholino) propane sulfonic acid (MOPS), 50 mM Tris-
Base, 3.5 mM SDS and 1.0 mM EDTA (pH 7.7)) supplemented with NuPAGE 
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antioxidant (Invitrogen).  Samples were run alongside SeeBlue® Plus2 Pre-
Stained Standard (Invitrogen) at 150 volts (V) for 1 hr.  
Gels were then transferred onto an Immun-Blot polyvinyliden difluoride (PVDF) 
membranes (BioRad Laboratories, West Sussex, UK) using a 1 x solution of 20 x 
NuPAGE transfer buffer (25 mM Bicine, 25 mM Bis-Tris, 1.0 mM EDTA, 50 µM 
Chlorobutanol (pH 7.2)) supplemented with 20% (v/v) methanol (Sigma-Aldrich).  
Briefly, the PVDF membrane was soaked in 100% methanol for 1 min, rinsed in 
distilled water (dH20) and equilibrated in transfer buffer prior to assembly of 
gel/membrane sandwiches using 1.0 mm gel blotting paper (Whatman plc, Kent, 
UK) and sponges in an XCell IITM Blot Module (Invitrogen).  Transfer was 
performed at 30 V for 1 hr.    
Blots were washed with 1 x TBST (20 mM Tris HCl pH 7.4, 150 mM NaCl, 0.01% 
Tween 20), blocked in TBST containing 5% BSA (Sigma-Aldrich) or 5% milk for 1 
hr at RT, and incubated with primary antibody overnight at 4ºC. Thereafter, the 
blots were washed 4 times with TBST and incubated with horseradish-peroxidase 
(HRP)-labelled secondary antibodies for 1 hr at RT. After 4 washes with TBST, the 
blots were developed with Immun-StarTM Western CTM HRP chemiluminescent kit 
for one minute, and imaged with the Molecular Imager® ChemiDocTM XRS system 
(BioRad Laboratories). Western blot antibodies were purchased from Cell 
Signaling Technology unless otherwise stated.  Refer to Table 2.4 for a list of 
antibodies used. 
2.5.1 Membrane stripping and re-probing 
When multiple proteins or proteins of similar sizes were viewed on the same gel, 
PVDF membranes were stripped.   Blots were incubated for 5 - 10 min in mild 
stripping buffer (200mM Glycine, 01% SDS, 1% Tween 20), 2 x 10 min in PBS, 2 x 
5 min in TBST and subsequently re-blocked in 5% BSA (TBST) or 5% milk (TBST) 
for 1 hr at RT prior to incubation with primary antibody. 
2.6 Genomic DNA extraction 
Cells were sorted, pelleted by centrifugation at 4°C and re-suspended in PBS.   
DNA was isolated using the Easy-DNA kit according to the manufacturer’s protocol 
(Invitrogen) and then dissolved in DNase-free H20. 
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2.6.1 Genomic DNA PCR 
For each reaction, DNA from 1 - 5 x 103 cells was used.  DNA was amplified in a 
PCR reaction with a hot start at 94°C for 2 min, 35 cycles of: 10 sec denaturation 
at 94°C, 30 sec annealing at 59°C, 2 min extension at 68°C; and a final extension 
at 68°C for 6 min.    TCR Dβ-Jβ, IgH D-J and IgH V-J primers used for gene 
rearrangement analysis have been previously described (Pennycook et al. 1993; 
Michie et al. 2001). Genomic DNA from wildtype mouse splenocytes was used as 
the positive control, H20 as the negative control, and β2M was used as the loading 
control. Refer to Table 2.5 for primer sequences and PCR conditions. All primers 
were made by Eurofins MGW Operon (London, UK).  Products were separated by 
1% agarose gel electrophoresis and visualized by addition of Ethidium Bromide 
(EtBr) and imaging with the Molecular Imager® ChemiDocTM XRS system. 
2.7 Total RNA extraction 
RNA was purified using RNeasy mini kit columns (Qiagen, West Sussex, UK) 
according to the manufacturer’s protocol. Samples were re-suspended in RNase-
free H20 and quantified with a spectrophotometer (Nanodrop ND1000 
Spectrophotometer; Labtech International Ltd, East Sussex, UK). 
2.7.1 Measuring mRNA levels using qRT-PCR 
Up to 1 µg RNA was used as a template per 20 µl reverse transcription reaction 
using the First Strand cDNA Synthesis Kit for RT-PCR (Roche, West Sussex, UK).  
Quantitative PCR was performed using Taqman® Gene Expression Assays 
(Applied Biosystems, Warrington, UK; see list of assay IDs in Table 2.6). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the 
housekeeping gene unless otherwise stated.  1 µl cDNA was used per 20 µl PCR 
reaction containing 1 x TaqMan® Gene Expression Mastermix (AmpliTaq Gold® 
DNA Polymerase (Ultra Pure), Uracil-DNA glycosylase, dNTPs with deoxyuridine 
triphosphate, ROX™ Passive Reference; Applied Biosystems).  All reactions were 
performed in technical triplicates and at least three biological replicates using the 
7900HT Fast Real-Time PCR system (Applied Biosystems) programmed to 
complete 40 cycles as follows: 50°C for 2 min, 95°C for 10 min, 95°C for 15 sec, 
and 60°C for 1 min. After normalization to the endogenous control gene GAPDH, 
levels of gene mRNA expression in each sample were determined by the 2-ΔΔCT 
method of relative quantification (Schmittgen & Livak 2008).  
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2.8 Cell proliferation by 5-bromo-2’-deoxyuridine (BrdU) incorporation  
Cell proliferation was indirectly measured by monitoring of DNA synthesis by 
relative incorporation of BrdU using the Cell Proliferation ELISA, BrdU 
(colorimetric) kit as per manufacturer’s protocol (Roche).  Briefly, cells from 
OP9:FL co-cultures were passed through lympholyte mammal to isolate live 
lymphocytes and consequently plated in 96-well plates at a confluence of 1 x 104 – 
5 x 104 cells/well in complete medium +/- drug treatments. Prior to the termination 
of a time point of an experiment, cells were labelled with 10 µl of 100 µM BrDU 
and cultured for an additional 2 hr.  Plates were then centrifuged at 300g for 10 
min at RT and medium was removed by flicking.  Cells were consequently dried 
with a hair-dryer for 15 min and fixed with 200 µl/well of FixDenat reagent (ethanol 
based) for 30 min at RT.  FixDenat reagent was then removed by flicking and 
peroxidase-conjugated anti-BrdU antibody was added to the wells and cells 
incubated for 90 min at RT.  Anti-BrdU antibody was removed by flicking and wells 
washed three times prior to addition of 100 µl per well of 3,3′,5,5′-
tetramethylbenzidine (TMB) substrate. Absorbance was read at 370 nM and 492 
nM on a Spectramax M5 plate reader and analysed with SoftMax Pro 5.2 software.   
2.9 Assessment of surface antigen expression 
Cells were harvested by gentle pipetting and washed in flow cytometry (FACS) 
buffer (Hank’s Balanced Salt Solution (HBSS) supplemented with 1% BSA and 
0.05% sodium azide (Sigma-Aldrich)).  Cells were then incubated with anti-
CD16/CD32 antibody (1/200 dilution) to block Fc receptors and non-specific 
binding.  Cells were washed again in FACS buffer and stained with fluorochrome-
conjugated antibodies (in 100 µl FACS buffer) at 4°C in the dark for 30 min.  When 
biotin antibodies were used, cells were incubated with fluorescent-conjugated SA 
for 30 min at 4°C in the dark.  Cells were then washed twice (in FACS buffer), re-
suspended in 100 µl FACS buffer and passed through a 70 µM nylon mesh prior to 
FACS analysis. FACS analysis was performed using a FACSCanto II flow 
cytometer (BD Biosciences), data was acquired using BD FACSDiva (BD 
Biosciences) software and analysed using FlowJo (Tree Star Inc., Ashland, USA) 
software.   
2.10 Analysis of intracellular proteins by flow cytometry 
ZAP70 protein levels were measured by intracellular flow cytometry. Cells were 
washed once in FACS buffer, fixed using Cytofix/Cytoperm (BD Biosciences) 
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solution, and incubated for 20 min at 4°C.  Cells were washed twice in BD 
Perm/Wash solution (BD Biosciences) and subsequently stained with PE-
conjugated ZAP70 (ZAP70-PE) antibody. Cells were acquired on FACSCanto II 
flow cytometer as mentioned above (section 2.9).  
2.11 Detection of apoptosis using Annexin V  
Following drug treatments, 1 x 106 cells were washed once in ice-cold PBS, and 
re-suspended in 100 µl HBSS (Sigma-Aldrich) containing 5 µl Annexin V APC and 
5 µl Viaprobe (BD Biosciences) per test, and incubated for 15 min in the dark at 
RT. To stop the reaction, 400 µl HBSS was added to the samples, and the cells 
were analysed on a FACS CantoII flow cytometer. When autofluorescent drugs 
such as enzastaurin and hispidin were used, diamidino-2-phenylindole (DAPI, 10 
µg/ml final concentration) was used instead of Viaprobe, and was added just prior 
to FACS analysis.  Control tubes containing unstained cells, Annexin V or DNA 
stain (Viaprobe/DAPI) single-stained cells were recorded to set FSC/SSC voltages 
and compensation.  FCS analysis was performed as described above (section 
2.9).  Viable cells were considered to be Annexin V-/DNA stain- (Figure 2.8).  
2.12 Cell Cycle Analysis using Propidium Iodine (PI) staining  
All solutions used for PI staining were ice cold.  1 x 106 cells were harvested and 
suspended in 1 ml PBS and centrifuged for 5 min at RT. After aspiration of PBS, 
cells were re-suspended in 500 µl PBS and fixed by adding 4.5 ml 70% (v/v) 
ethanol. Cells were centrifuged (400g for 5 min), washed in 5 ml PBS and re-
suspended in DNA staining solution (20 µg/ml PI in PBS containing 0.2 mg/ml 
Dnase free RNase) for 30 min at RT in the dark (Riccardi & Nicoletti 2006). FACS 
data was acquired using a FACSCantoII flow cytometer. Figure 2.9 illustrates an 
example of cell cycle analysis pattern.   
2.13 Sorting of Cells 
Cells were harvested, washed once in PBS, once in sorting buffer (HBSS; 1 % 
BSA), incubated with anti-CD16/CD32 antibody as described above for 10 min on 
ice, and then incubated with appropriate antibodies on ice in the dark for 30 min. 
Cells were then washed and re-suspended in 500 µl sorting buffer in order to dilute 
out sodium azide present in antibody solutions, and passed through a sterile 70 
µm nylon mesh prior to sorting. All sorting was performed using a BD FACSAria 
and data acquired using FACSDiva software.  
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2.14 Immunohistochemistry 
Paraffin embedded sections were cut into 3 µm slices and placed on slides (Leica 
Microsystems, Buckinghamshire, UK) that were dewaxed with 2 washes with 
xylene, followed by 4 washes in 100% alcohol (to remove excess xylene), and 
finally water.  Heat antigen retrieval was carried out by submerging slides into hot 
EDTA solution (10 mM Tris, 1 mM EDTA, pH 8.0) in a pressure cooker and 
subsequently microwaved on high for 3 min, and 6 min thereafter.  The solution 
was cooled with water and slides washed in 1 x EnvisionTM Flex wash buffer 
(DAKO UK Ltd, Cambridge, UK). All endogenous biotin was blocked using 
Avidin/Biotin Blocking Kit (Vector) and sections were blocked with a 3% H2O2  
peroxidase blocking solution  Thereafter sections were blocked with 5% horse 
serum (in DAKO wash buffer), incubated with primary antibody for 30 min, 
washed, and incubated with biotin-labelled secondary antibody (in all cases apart 
from biotinylated B220).  The sections were washed again in DAKO wash buffer 
incubated with the avidin-biotin-complex (ABC) using the Alkaline Phosphatase or 
HRP Vectastain ABC kit (DAKO UK Ltd).  Finally substrate was added (either 
ImmPACTTM diaminobenzidine (DAB) or Peroxidase Substrate) for 5 min, washed 
with DAKO buffer, washed with H2O, stained with haematoxylin solution and 
dipped into 1% HCl-alcohol solution, then Scot’s Tapwater, 0.5% Copper Sulphate 
solution, and finally H2O prior to mounting.  Tissue sections were scanned with 
SlidePath Digital Pathology Solutions system and uploaded to the University of 
Glasgow SlidePath server. Refer to Table 2.7 for a list of antibodies used. 
2.15 Data and statistical analysis 
All results are shown as mean ± standard error of mean (SEM). Statistical analysis 
was performed using GraphPad Prism 4 software (GraphPad Software Inc., CA), 
using the Students unpaired t-test.  
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Table 2.1 Supplier addresses 
 
Name of Company Address: 
Applied Biosystems, Warrington, 
UK 
Lingley House, 120 Birchwood Boulevard, Warrington, WA3 
7QH, UK 
BD Biosciences, Oxford, UK The Danby Building, Edmund Halley Road, Oxford, OX4 
4DQ, UK 
Enzo Life Sciences Ltd. Palatine House, Matford Court,  
Exeter, EX2 8NL, UK  
Biodesign Inc.  P.O. BOX 1050, Carmel, NY, USA 
BioRad Maxted Rd, Hemel Hempstead,  
West Sussex, HP2 7DX, UK 
Bioscience Lifescience Ltd. 10 Orchard Place, Nottingham Business Park, Nottingham 
NG8 6PX, UK 
Bristol-Myers Squibb Route 206, Provinceline Road, P.O. Box 4000 
08543 New Jersey, U.S.A. 
Carl Zeiss Ltd. 15 - 20 Woodfield Road, Welwyn Garden City 
Hertfordshire, AL7 1JQ, UK 
Cedarlane 4410 Paletta Court, Burlington, Ontario 
L7L 5R2, Canada 
Cell Signaling Technology 
c/o New England Biolabs  
75-77 Knowl Piece, Wilbury Way, Hitchin,  
Herts SG4 0TY, UK 
ClonTech Avenue du President Kennedy 
78100 Saint-Germain-en-Laye, France 
DAKO Ltd. Cambridge House, St. Thomas Place,  
Cambridge CB7 4EX, UK 
Eli Lilly and Co. Ltd. Lilly House, Priestley Road,  
Hampshire, RG24 9NL, UK 
Eppendorf UK Ltd. Endurance House, Vision Park,  
Histon, Cambridge, CB24 9ZR 
Eurofins MWG Operon  Westway Estate 28-32 Brunel Road   
Acton London W3 7XR, UK 
Fisher Scientific UK Bishop Meadow Road, Loughborough,  
Leicestershire, LE 1 5RG, UK 
Greiner Bio-One Ltd. Unit 5, Stroudwater Business Park, Gloucestershire, 
GL103SX, UK 
Harlan UK Ltd. Blackthorn, UK 
 
Invitrogen, Paisley, UK Ltd. 
Part of Life Technologies 
Invitrogen, Paisley, UK Ltd, 3 Fountain Drive, Paisley, UK 
Labtech International Ltd. Acorn House, The Broyle, Ringmer, East Sussex, BN8 5NN, 
UK 
Leica Microsystems Davy Avenue Knowlhill,  
Milton Keynes, MK5 8LB, UK 
LC Laboratories 165 New Boston Street, Woburn, MA 01801, USA 
Merck Chemicals Ltd. Boulevard Industrial Park, Padge Road, Beeston, 
Nottingham, NG9 2JR, UK 
Millipore (U.K.) Limited Suite 3 & 5, Croxley Green Business Park,  
Watford, WD18 8YH, UK 
Miltenyi Biotech Almac House, Church Lane, Bisley,  
Surrey, GU24 9DR, UK 
PeproTech EC Ltd  PeproTech House, 29 Margravine Road,  
London, W6 8LL, UK 
Pierce, 
c/o Perbio Science UK Ltd. 
Unit 9, Atley Way, North Nelson Industrial Estate, 
Cramlington, Northumberland, NE23 1WA, UK 
Qiagen Fleming Way, Crawley, West Sussex, RH10 9NQ, UK 
R&D Systems R&D Systems Europe Ltd., 19 Barton Lane, Abingdon 
Science Park, Abingdon, OX14 3NB, UK 
  59 
Supplier addresses continued 
 
Name of Company Address: 
Roche, West Sussex, UK Roche, West Sussex, Charles Avenue,  
Burgess Hill, RH15 9RY, UK 
Sigma-Aldrich  The Old Brickyard, New Rd, Gillingham,  
Dorset, SP8 4XT, UK 
Stemcell Technolgies 40 Rues des Berges, Miniparc Polytec, Bâtiment Sirocco, 
38000 Grenoble, France 
Tree Star, Inc. 340 A Street #101 Ashland, OR 97520, USA 
Vector Laboratories Inc. 3, Accent Park, Bakewell Road, Orton Southgate, 
Peterborough, PE2 6XS, UK 
Whatman plc Springfield Mill, James Whatman Way, Maidstone,  
Kent, ME14 2LE, UK 
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Table 2.2 FACS antibodies 
 
Name of Antibody Reactive 
Species 
Clone Format Manufacturer 
CD4 mouse RM4-5 PE BDBiosciences 
CD5 mouse 53-7.3 APC BDBiosciences 
CD8α mouse 53-6.7 APC BDBiosciences 
CD11b mouse M7/70 PE BDBiosciences 
CD16/32 mouse 2.4G2 Purified BDBiosciences 
CD19 mouse 1D3 APC-Cy7 BDBiosciences 
CD23 mouse M-L233 Pe-Cy7 BDBiosciences 
CD24 mouse J11d Purified BDBiosciences 
CD25 mouse PC61 PE BDBiosciences 
CD45 mouse 30-F11 PerCP BDBiosciences 
CD45R/B220 mouse RA3-6B2 PE BDBiosciences 
CD71 mouse C2 PE BDBiosciences 
CD90.2 mouse 53-2.1 PE BDBiosciences 
CD98 mouse RL-388 PE BDBiosciences 
CD117 mouse 2B8 APC BDBiosciences 
Ly-6A/E (Sca-1) mouse D7 APC-Cy7 BDBiosciences 
Ly-6G and Ly6C (Gr-1) mouse RB6-8C5 APC BDBiosciences 
NK1.1 mouse PK136 APC BDBiosciences 
H-2Kb mouse AF6-88.5 FITC BDBiosciences 
CD19 Human HIB19 APC BDBiosciences 
CD5 Human UCHT2 PE BDBiosciences 
CD23 Human M-L233 APC BDBiosciences 
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Table 2.3 Details of CLL samples 
  
Sample 
Number 
Age Sex Binet 
Stage 
Treated ZAP-70 
Status 
FISH 
7 74 M C yes pos 11q- 
13 77 M A no neg 13q- 
14 63 M C yes pos 17q- 
18 62 F B Yes pos 11q- 
21 66 F C Yes pos nil 
23 80 F A No n/a n/a 
32 66 F B + C No pos nil 
34 65 M B Yes pos 11q- 
41 60 M A No neg nil 
45 79 M B Yes pos 13q- 
46 53 F A No pos nil 
51 77 M A/C No neg nil 
52 79 F B Yes neg 11q- 
54 55 F A No neg nil 
56 92 F A/C No n/a n/a 
58 66 M A No n/a n/a 
60 60 F A No pos nil 
62 84 F A Yes n/a n/a 
69 45 M A Yes pos nil 
70 75 F C No neg nil 
 
 
neg = ZAP-70 negative,  pos = ZAP-70 positive 
n/a = not available 
nil = no abnormality detected by FISH 
Chromosomal deletions are indicated by (-) and trisomy denoted by (+) 
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Table 2.4 Western Blot Antibodies 
 
Name of Antibody Reactive 
Species 
Dilution  Block  Manufacturer 
4-EBP1 Rabbit 1:1000 5 % BSA Cell Signaling 
β-Tubulin Rabbit 1:1000 5 % BSA Cell Signaling 
c-Myc Rabbit 1:1000 5 % BSA Cell Signaling 
Cyclin D1 Rabbit 1:1000 5 % BSA Thermo Scientific 
E47 Mouse 1:250 5 % MILK BD Biosciences 
EIF4E Rabbit 1:1000 5 % BSA Cell Signaling 
GAPDH 
 
Rabiit 1:1000 5 % BSA Cell Signaling 
GFP Rabbit 1:1000 5 % BSA Cell Signaling 
HA 
 
Rabbit 1:250 5 % BSA Covance 
Lck Mouse 1:500 5 % BSA BD Biosciences 
Mcl-1 Rabbit 1:1000 5 % BSA Cell Signaling 
Phospho-IKBα 
 
Mouse 1:500 5 % BSA Cell Signaling 
Phospho-p70s6 kinase (Thr389) 
 
Rabbit 1:1000 5 % BSA Cell Signaling 
Phospho p44/42 MAPK 
(Thr202/Tyr204) (pERK1/2) 
 
Rabbit 1:1000 5 % BSA Cell Signaling 
PKCα 
 
Mouse 1:1000 5 % BSA BD Biosciences 
PKCβI 
 
Mouse 1:1000 5 % BSA Santa Cruz 
PKCβII 
 
Rabbit 1:1000 5 % BSA Santa Cruz 
ZAP70 
 
Mouse 1:500 5 % BSA BD Biosciences 
Anti-rabbit IgG (H+L) – HRP 
conjugated 
Goat 1:2000 5 % BSA Cell Signaling 
Anti-mouse IgG (H+L) – HRP 
conjugated  
Horse 1:2000 5 % BSA Cell Signaling 
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Table 2.5 DNA primer sequences 
 
Primer Name Sequence 
Internal Control β2M 
β2M forward 5’-GGCGTCAACAATGCTGCTTCT-3’ 
β2M reverse 5’-CTTTCTGTGTTTCCCGCTCCC-3’ 
TCR Dβ-Jβ 
Dβ forward 5’-GTAGGCACCTGTGGGGAAGAAACT-3’ 
Jβ reverse 5’-TGAGAGCTGTCTCCTACTATCGAT T-3’ 
IgH D-J 
DFS forward 5’-AGGGATCCTTGTGAAGGGATCTACTACTGTG-3’ 
JH4 reverse 5’-AAAGACCTGCAGAGGCCATTCTTACC-‘3’ 
IgH V-J 
VHF forward 5’-AGGT(CG)(AC)A(AG)CTGCAG(CG)AGTC(AT)G G-3’ 
JH4 reverse 5’-AAAGACCTGCAGAGGCCATTCTTACC-‘3’ 
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Table 2.6 RNA gene expression assays 
 
Name  ID NAME Manufacturer 
CD3ε Mm00599683_m1 Applied Biosystems 
CD79a Mm00432423_m1 Applied Biosystems 
Cyclin D1 (mouse) Mm00432358_m1 Applied Biosystems 
Cyclin D1 (human) Hs00765553_m1  
 
Applied Biosystems 
Deltex Mm00492297_m1 Applied Biosystems 
E2A Mm01175588_m1 Applied Biosystems 
EBF1 Mm00395519_m1 Applied Biosystems 
GAPDH (mouse) 4352339E-0705012 Applied Biosystems 
GAPDH (human) Hs99999905_m1 Applied Biosystems 
GATA3 Mm00484683_m1 Applied Biosystems 
HPRT Mm01545399_m1 Applied Biosystems 
Id2 Mm00711781_m1  
 
Applied Biosystems 
Id3 Mm00492575_m1 Applied Biosystems 
PAX5 Mm00435501_m1  
 
Applied Biosystems 
PKCα (mouse) 
 
Mm00440858_m1 Applied Biosystems 
PKCα (human) 
 
Hs00925195_m1  
 
Applied Biosystems 
PKCβ (mouse) 
 
Mm00435749_m1 Applied Biosystems 
PKCβ (human) 
 
Hs00176998_m1  Applied Biosystems 
pTα Mm00478363_m1  
 
Applied Biosystems 
Sox9 Mm00448840_m1  
 
Applied Biosystems 
TCF1 Mm00481144_m1  
 
Applied Biosystems 
VEGFα Mm004377304_m1 Applied Biosystems 
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Table 2.7 IHC antibodies 
 
Name of 
Antibody 
Reactive 
Species 
Host 
Species 
Dilution Block Manufacturer 
 
B220 biotin Mouse Rat 1:200 5 % Horse Serum BD Bioscience 
 
GFP Mouse Rabbit 1:500 5 % Horse Serum Cell Signaling 
 
PKCβII Mouse Rabbit 1:200 5 % Horse Serum Santa Cruz 
 
Cyclin D1 
(clone SP4) 
Human/ 
mouse 
Rabbit 1:200 5 % Horse Serum Thermo Scientific 
2° antibody Host Species Dilution Manufacturer 
Biotin anti-
rabbit IgG 
Horse 1:50 DAKO 
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Table 2.8 Drugs 
 
Drug Name Stock 
Concentration 
Molar Mass Storage 
Conditions 
Diluent Manufacturer 
 
Enzastaurin 10 mM 552.0750 
g/mol 
-20°C DMSO Eli Lilly and 
Company 
Hispidin 5 mM 246.2 g/mol -20°C DMSO Sigma-Aldrich 
 
Ionomycin 1 mM  747.1 g/mol -20°C DMSO Sigma-Aldrich 
 
Okadaic Acid 60.8 µM 822 g/mol -20°C H2O Calbiochem  
 
PMA 1.62 mM 616.83 g/mol -20°C DMSO Sigma-Aldrich  
 
Rapamycin 1 mM 914.2 g/mol -20°C MeOH Calbiochem 
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Figure 2.1 Vector map of pHACE and pHANE constructs 
pHACE and pHANE are mammalian expression vectors containing a CMV 
promoter, Kozak translational initiation sequence, ATG start codon, EcoRI cloning 
site and a stop codon.  In addition, pHACE has a C-terminal HA epitope tag whilst 
pHANE has an N-terminal HA epitope tag.    
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Figure 2.2 Vector map of pHACB and MIEV constructs 
pHABE is a mammalian expression vector containing a CMV promoter, Kozak 
translational initiation sequence, ATG start codon, BamHI cloning site, C-terminal 
HA epitope tag and a stop codon.  MIEV is a retroviral vector containing a CMV 
promoter and 5’ IRES, allowing for the bicistronic expression of the gene of 
interest along with GFP.   
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Figure 2.3 Vector map of MIEV-PKCα-KR, MIEV-PKCβI-CAT, MIEV-PKCβII-
CAT and MIEV-PKCβI-WT 
MIEV-PKCα-KR plasmid was generated by subcloning of full length open reading 
frame of PKCα with a point mutation at the ATP binding site out of pHACE and into 
MIEV at BglII, NotI sites.  MIEV-PKCβI-CAT and MIEV-PKCβII-CAT were 
generated by subcloning of cDNA fragments encoding the catalytic domains of 
PKCβI or PKCβII  out of pHANE and into MIEV at BglII, NotI sites. MIEV-PKCβI-WT 
plasmid was generated by subcloning of full-length open reading frame of PKCβI 
out of pHACE and into MIEV at XhoI, NotI sites. 
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Figure 2.4 Vector map of MIEV-PKCβII-WT 
MIEV-PKCβII-WT plasmid was generated by digesting full-length open reading 
frame of PKCβII out of pHACB with XhoI, EcoRV and subcloned into MIEV at XhoI, 
SnaBI sites.   
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Figure 2.5 Vector map of pCMV-Sport6 and MIEV-CyclinD1 
pCMV-Sport6 is a mammalian expression vector containing a CMV promoter, and 
a multiple cloning site in which Cyclin D1 was cloned in at SalI, NotI sites.  MIEV-
CyclinD1 was generated by subcloning of Cyclin D1 into MIEV at EcoRI, NotI 
sites.   
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Figure 2.6 Generation of retroviral packaging lines 
Retroviral packaging lines were generated by transfecting DNA into PT67 cells 
using CaCl2 or Lipofectamine, collecting and concentrating the virus by 
ultracentrifugation, and subsequently transducting GP+E.86 cells.  GFP+ GP+E.86 
cells were sorted twice and grown for at least two weeks before HPCs were 
transduced by co-culture with GP+E.86 cells.   
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Figure 2.7 In vitro OP9 and OP9-DL1 system 
HPCs were prepared from d14 gestation FL and were co-cultured on OP9 cells 
with growth factors to generate B cells (OP9 system).  In order to generate T cells, 
pro-B cells from FL:OP9 co-cultures were sorted and subsequently co-culture with 
growth factors and OP9-DL1 cells that express Notch ligand allowing for Notch 
ligation.  
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Figure 2.8 Apoptosis assessed by Annexin V/Viaprobe 
Cells were stained with Annexin V and Viaprobe as described in Section 2.8.3 and 
gated as shown above.  Annexin V-/Viaprobe- gate represents viable cells, Annexin 
V+/Viaprobe- gate represents early apoptotic cells, and Annexin V+/Viaprobe+ gate 
indicates late apoptotic cells.   
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Figure 2.9 Cell cycle analysis using PI 
PI incorporation was analysed by FACS and a typical histogram is shown above. 
SubG0 population represents apoptosing cells; G0 represents quiescent cells; G1 
represents cells that are growing and preparing chromosomes for replication; S 
phase indicates DNA synthesis; G2 phase is where mitosis preparation occurs; M 
phase is where mitosis occurs.   
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 Chapter 3 
Over-expression of PKCα-KR in murine haematopoietic progenitor cells 
results in the generation of a CLL-like disease marked by the upregulation of 
PKCβII 
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3.1 Introduction 
The use of murine CLL models has proven to be very beneficial in gaining 
understanding of the human disease.  In fact, the importance of oncogenes like 
TCL1 was highlighted by transgenic mouse models expressing TCL1, indicating 
that deregulation of this gene may be a key event in the pathogenesis of CLL 
(Herling et al. 2005; Hamblin 2010; Gorgun et al. 2009).  Similarly, deregulation of 
human PKCα in a murine model was shown to generate a disease similar to 
human CLL ( Michie & Nakagawa 2006; Nakagawa et al. 2006).  This chapter 
aims to further develop the PKCα-KR CLL mouse model, investigating events that 
occur downstream of PKCα deregulation.  
3.2 Aims and Objectives 
The specific aims of this chapter were: 
i. To recapitulate the CLL mouse model; 
a. In vitro and  
b. In vivo 
ii.   To assess the similarities between human CLL and that generated within 
the PKCα-KR mouse model;  
iii. To investigate therapeutic targets in the PKCα-KR mouse model by 
treatment with drug.  
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3.3 Results 
3.3.1 Introduction of dominant negative human PKCα into murine HPCs 
results in a generation of cells with increased survival capacity and 
surface CLL phenotype expression profile. 
In order to reinforce previous findings that loss of PKCα may act as an oncogenic 
trigger within murine CLL (mCLL) ( Nakagawa et al. 2006; Michie & Nakagawa 
2006), HPCs were isolated from FL of day 14 gestation ICR wildtype mice and 
retrovirally transduced to express vector only (MIEV) or PKCα-KR containing 
vector.  The resultant cells were maintained in an in vitro B cell generating system 
containing stromal cells (OP9) with the addition of IL7 and FLT3L (Figure 3.1A). 
The PKC mutants used in this study which were constructed as described in 
Section 2.1.1, contain the bicistronic expression of GFP alongside the PKC gene 
of interest, thereby allowing GFP fluorescence to be monitored by FACS.  The 
PKC constructs are also tagged with HA at the C or N terminus which can be 
validated by Western blot using an anti-HA antibody. HA was detected in lystates 
of PKCα-KR containing B cells and not in MIEV control B cells (Figure 3.1B).  
MIEV and PKCα-KR cultures were maintained in the in vitro B cell generating 
system and GFP expression was assessed by FACS (Figure 3.2).  At day 1, the 
PKCα-KR transduced cells were less bright in GFP fluorescence and contained 
significantly less GFP+ cells (22%), compared to MIEV control that were brighter 
and already mostly GFP+ (80%). The difference in overall fluorescence intensity of 
GFP between the cultures is likely due to the presence of the CMV promoter 
driving IRES and GFP and lack of a 2 Kb gene (PKCα-KR) upstream of GFP 
within the MIEV vector (see Figure 2.2).  At day 10, there was a notable increase 
in the percentage GFP+ cells in the PKCα-KR cultures (68.3 % ± 13.3% n = 4) and 
by day 17, both MIEV and PKCα-KR cultures contained virtually no GFP- cells (<5 
%). The increase in GFP+ cells indicated a possible growth advantage of GFP+ 
cells over GFP- cells within the PKCα-KR culture. 
In order to assess the surface phenotype of MIEV and PKCα-KR cells, FACS 
analysis was carried out at day 10 and 17 of OP9 co-culture using cell surface 
markers indicative of B cell commitment (CD45 and CD19) and CLL phenotype 
(CD19, CD23, CD5). At day 10, both cultures contained almost 100% 
CD45+/CD19+ cells (Figure 3.3A) as expected within the in vitro B cell generating 
system.  When CLL surface markers were assessed, PKCα-KR cultures 
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expressed a notably higher level of CD19, CD5 and CD23 compared to MIEV 
control.  Also, IgM surface expression was downregulated within the PKCα-KR 
expressing B cells (Figure 3.3B and C).  Collectively, these findings indicate that 
murine PKCα-KR expressing B cells resemble human CLL B cells by surface 
marker expression profile.  
3.3.2 PKCα-KR cells express key CLL markers indicative of a poor 
prognostic outcome  
Once it was established that murine PKCα-KR expressing B cell phenotypically 
resemble human CLL B cells, the expression of key genes and proteins 
associated with CLL pathogenesis were assessed within the PKCα-KR cultures 
including Bcl-2, aicda (encodes for AID), ZAP70 and activated NFκB. 
At day 6 and 13 of OP9:FL cultures,  Bcl-2 transcript levels were significantly 
higher in PKCα-KR expressing cells compared to MIEV control (Figure 3.4A left). 
Similarly, PKCα-KR cells express significantly higher mRNA transcripts of aicda, 
another key CLL gene, similar to a more aggressive, unmutated form of human 
CLL (Heintel et al. 2004) (Figure 3.4A right). In accordance with human unmutated 
CLL cells, PKCα-KR cells also express higher ZAP-70 protein levels as 
determined by Western blot and intracellular FACS analysis (Figure 3.4B, 3.4C). 
Constitutive activation of the NFκB pathway has become one of the hallmarks in 
CLL (Frenzel et al. 2011). Phosphorylation of NFκB-dependent genes are 
associated with anti-apoptosis (Bcl-2, XIAP), cell proliferation (cyclins) and 
metastasis (VEGF) and collectively contribute to a worse overall prognosis 
(Pepper et al. 2009).  Similarly to human CLL, the NFκB pathway also seems to be 
active in PKCα-KR expressing cells as phosphorylation of IκBα protein, a classic 
activation marker of NFκB, is higher in PKCα-KR expressing cells compared to the 
MIEV control (Figure 3.4B left).   
3.3.3 RAG1-/- mice injected with PKCα-KR-HPCs exhibit shortened lifespan 
In order to evaluate the effects of subversion of PKCα signaling in vivo, neonatal 
RAG1-/- mice were subjected to i.p. in vivo adoptive transfer of MIEV or PKCα-KR 
retrovirally transduced HPCs (see section 2.3.2) and monitored for development of 
disease.  Four to six weeks post injection, PKCα-KR injected mice exhibited signs 
of distress marked by significant weight loss and development of subcutaneous 
tumours at injection sites. At this time, mice were sacrificed and time of death 
recorded. PKCα-KR-HPC injected mice had a significantly shorter lifespan than 
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their MIEV-HPC injected counterparts (Figure 3.5).  Importantly, lifespan was 
inversely dependent on number of PKCα-KR-HPCs injected. 
3.3.4 Evidence of expansion of haematopoietic lineage cells with CLL 
phenotype in lymphoid organs and blood of RAG1-/- mice injected with 
PKCα-KR cells 
At signs of distress, mice injected with PKCα-KR or MIEV HPCs were sacrificed 
and organs (BM, spleen, LN) and blood were processed (as described in section 
2.3.2.1) and analyzed by FACS to determine the percentage of GFP+ 
haematopoietic (CD45+) cells and B cells (CD19+). There was a significant 
increase in the haematopoietic lineage within the PKCα-KR-HPC injected mice 
evident in the blood, spleen and BM (Figure 3.6).  In addition, there was a 
significant increase of B cells within the spleen, BM and LN of PKCα-KR-HPC 
injected mice (Figure 3.6).   
Blood and spleen of mice injected with PKCα-KR or MIEV HPCs were also 
subjected to FACS analysis to evaluate expression CD19, CD23, IgM and IgD 
(Figure 3.7). Concurrent with in vitro surface phenotype of PKCα-KR expressing 
cells, B cells within the blood and spleen of RAG1-/- mice injected with PKCα-KR-
HPCs expressed surface IgM and IgD at lower levels than their MIEV-HPC 
injected counterparts (1.1% vs 76.2% of IgM+IgD+ B cells).  Co-expression of 
CD19 and CD23 revealed consistently lower expression of CD23 on CD19+ cells 
within the MIEV cohorts (Figure 3.7).  
3.3.5 PKCα-KR injected RAG1-/- mice develop splenomegaly and 
disorganized splenic architecture  
Analysis of the gross structure of spleen from PKCα-KR HPC-injected neonatal 
RAG1-/- mice revealed enlarged spleens and disorganized splenic architecture 
assessed by H & E staining of splenic tissue sections (Figure 3.8 and 3.9) 
indicative of tumour formation. As expected, MIEV HPC-injected harboured 
average sized spleens and displayed an organised splenic architecture.  Splenic 
tissue sections were also stained with antibodies specific for B cell (anti-B220) 
antigens and GFP to assess the location of GFP+ B cells within the spleen.  B cells 
were located within the follicles of the spleen in an organized fashion in MIEV 
injected mice, whereas PKCα-KR injected mice displayed disrupted follicular 
development (Figure 3.10; see appendix 3-A for staining controls).  Of note, before 
B220 was used to identify B cells within splenic sections, co-expression with CD19 
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was verified by FACS (see Figure 3.10B). Very few GFP+ cells were observed 
within the spleen tissue sections from MIEV injected RAG1-/- mice compared to a 
higher number of GFP+ cells within the PKCα-KR injected mice (Figure 3.10).  It 
appears that there are many GFP+ cells that are not B cells within the PKCα-KR 
injected mice, although their identities were not established. 
3.3.6 Downregulation of PKCα signaling results in a gradual and sustained 
upregulation of PKCβII 
Although the overall PKC kinase activity is reduced early on in the PKCα-KR 
expressing B cell cultures compared to their MIEV counterparts, at later stages 
(day 17), PKC kinase activity is elevated in the PKCα-KR cultures (see Appendix 
3-B; Nakagawa et al. 2006).  The elevation in overall PKC kinase activity within the 
PKCα-KR expressing B cells is coupled with an upregulation of particularly PKCβII 
protein, where as PKCβI protein expression remains constant (Figure 3.11A) and 
PKCβ mRNA (Figure 3.11C) expression specifically during the later stages of 
culture, similar to that noted in human CLL cells (Abrams et al. 2007a; 
Buschenfelde et al. 2009).  Of note, the primers and probes for determining mRNA 
expression are not specific to a particular isoform of PKCβ, but detects both 
isoforms. The upregulation in PKCβII coincides with an increase in transcript levels 
of VEGF which regulates and is regulated by PKCβII, and ERK signaling which, 
like PKCβII, is important in CLL B cell survival (Krysov et al. 2012; Calpe et al. 
2011)(Figure 3.11A; 3.11D). In vivo, PKCβII  expression is concentrated in B cell 
areas within spleens of MIEV and PKCα-KR injected RAG1-/- mice (Figure 3.12).  
3.3.7 Introduction of PKCβII into HPCs provides a survival advantage to B 
cells 
In order to determine whether PKCβII alone is sufficient to transform HPCs into 
CLL cells, PKCβI-WT, PKCβI-CAT, PKCβII-WT and PKCβII-CAT were cloned into 
MIEV backbone and virus was generated as described before (section 2.1.1). 
HPCs were isolated from d14 gestation FL and retrovirally transduced to express 
MIEV, PKCα-KR or PKCβ genes and subsequently co-cultured on OP9 in a B cell 
generating in vitro environment.  Cells were harvested at day 1, 14, 17 and 22 of 
co-culture and assessed by flow cytometry to determine the percentage of GFP+ 
cells within the culture (Figure 3.13).  As seen previously, MIEV cells transduced 
at a higher efficiency than the vectors containing a gene of interest.  Also, as seen 
before, the PKCα-KR culture showed a rapid increase in the percentage of GFP+ 
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cells over time, overtaking the culture completely by day 14.  All of the PKCβ 
constructs had a much lower transduction efficiency compared to MIEV and 
PKCα-KR.  Of interest, only the PKCβII transduced HPCs expanded over the time 
course of the experiment increasing from 7.84% GFP+ at day 1 to over 40% GFP+ 
at day 22 (Figure 3.13), indicating that these cells have a survival advantage.   
To determine whether PKCβII transduced B cells harbour CLL phenotypic surface 
markers as seen in the PKCα-KR cultures, B cells from day 22 FL:OP9 co-cultures 
were harvested and stained with CD45, CD19, CD5 and CD23 antibodies and 
analysed by flow cytometry.  When assessing CD19 and CD5 positivity (Figure 
3.14), only the PKCα-KR expressing cells displayed the CLL phenotype, with 31% 
of cells staining for both CD5 and CD19.  When CD23 expression was assessed 
(Figure 3.15), 15% of PKCα-KR cultures were highly co-expressing CD23 and 
CD19, similarly to what was seen previously.  Interestingly, a small but distinct 
population of cells (2.75%) co-expressing CD23 and CD19 was evident within 
PKCβII-WT cultures.  Collectively these results indicate that at this stage of the in 
vitro culture, PKCβII is alone not sufficient to transform HPCs into B cells 
resembling human CLL cells by phenotypic surface protein analysis, as seen 
within the PKCα-KR cultures, although it is possible that the transformation toward 
a CLL-like cell may just take longer.     
3.3.8 Inhibition of PKCβ does not cause preferential apoptosis of murine 
CLL cells 
To address whether inhibition of PKCβII can result in apoptosis of PKCα-KR 
expressing cells, B cells were harvested from MIEV and PKCα-KR FL:OP9 co-
cultures, centrifuged over lympholyte mammal to remove dead cells and OP9 
stroma, and subsequently treated with pan PKCβ inhibitors hispidin and 
enzastaurin.  Hispidin is an older agent (in comparison to enzastaurin) that targets 
mainly PKCβ, but also β-secretase, protein tyrosine phosphatase, α-glucosidase, 
aldose reductase and some NFκB pathways (Gonindard et al. 1997; Park et al. 
2004; Lee et al. 2010; Huang et al. 2011; Wu et al. 2011).  Enzastaurin is a 
selective PKCβ/PI3K inhibitor (Rizvi et al. 2006; S. Ma & Rosen 2007; Chen & 
LaCasce 2008; Willey et al. 2010). We used the drugs in the µM range based on 
previously published work within the field.  At 24 and 48 hr, cell viability was 
assessed by FACS by annexin V/DAPI staining.  Treatment with hispidin (Figure 
3.16) resulted in concentration-dependent apoptosis of both MIEV and PKCα-KR 
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cells expressed as percentage of annexin V- cells, similar for both cultures at 24 
hr, and a slightly higher for MIEV culture at 48 hr.  Enzastaurin treatment (Figure 
3.17) resulted in only a moderate drop in cell viability (around 20-30%) at 24 hr.  At 
48 hr, the drug was more potent, however even at 50 µM, the percentage of viable 
cells did not drop below 40%.  
To confirm results obtained with annexin V/DAPI, induction of cell death was also 
evaluated by considering the sub-G0 phase of cell cycle.  PI analysis was 
conducted on hispidin and enzastaurin treated MIEV and PKCα-KR cultures and 
apoptosis was assessed by observing the percentage of cells in sub-G0 phase of 
cell cycle. As seen with apoptosis measured by annexin V/DAPI, PI analysis 
indicated no preferential induction of cell death in either culture (Figure 3.18).  
3.3.9 Inhibiting PKCβ results in an attenuation of proliferation of murine 
CLL cells 
Although initially CLL was considered a disease of the accumulation of abnormal B 
cells that resist apoptosis, CLL is now considered a disease not only of 
accumulation, but also proliferation (Messmer et al. 2005; Chiorazzi 2007).  The 
murine PKCα-KR expressing cells exhibit notably higher proliferation rates than 
their MIEV counterparts (see Figure 3.2 and Chapter 4).  Since PKCβII is highly 
upregulated in the PKCα-KR cultures, it was of interest to investigate whether 
inhibition of PKCβ could result in the attenuation of proliferation within these 
highly-proliferative cultures.  Therefore, MIEV and PKCα-KR OP9:FL cultures were 
maintained as before, and 1 x 104 cells were plated (per well of 96 well plate) in 
the presence or absence (DMSO only) of hispidin and enzastaurin and labelled 
with BrdU two hours prior to endpoint (24 or 48 hr). As expected, the PKCα-KR 
expressing cells proliferate at a significantly higher rate than MIEV (**p<0.005 for 
24 hr and ***p<0.001 for 48 hr) as seen in the untreated cultures (Figure 3.19).  
The addition of hispidin at 10 µM resulted in a significant drop in proliferation levels 
of specifically the PKCα-KR containing cultures at both 24 and 48 hr (Figure 3.19).  
Similarly, inhibition of PKCβ with enzastaurin treatment at 10µM resulted in an 
even more dramatic drop in proliferation rates of particularly PKCα-KR containing 
cultures. 
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3.3.10 Inhibition of PKCβ results in an accumulation of cells in G0/G1 phase 
of cell cycle  
In order to confirm results obtained by BrdU analysis of MIEV and PKCα-KR 
cultures treated with PKCβ inhibitors, cell cycle analysis was conducted on these 
cultures at 24 and 48 hr after drug (hispidin and enzastaurin) treatment.  
Treatment of cells with hispidin for 24 hr (Figure 3.20) resulted in a significant 
increase in the percentage of cells arrested in G0/G1 phase of cell cycle at 20 µM 
hispidin for PKCα-KR expressing cultures and at 30 µM hispidin for the MIEV 
counterpart.  A significant decrease in the percentage of cells in S phase of cell 
cycle was only observed at 50 µM hispidin for both PKCα-KR and MIEV cultures at 
24 hr (Figure 3.20).  The percentage of cells in G2/M phase of cell cycle at 24 hr 
post hispidin treatment significantly decreased more prominently in MIEV cultures 
rather than the PKCα-KR cultures (20 µM for MIEV vs. 30 µM for PKCα-KR).  At 
48 hr, MIEV cells were more sensitive to hispidin as the percentage of G0/G1 
arrested cells significantly increased for MIEV cultures at 10 µM compared to 30 
µM for PKCα-KR cultures.  Similarly, percentage of cells in S phase significantly 
decreased for MIEV cultures at 10 µM compared to 30 µM in PKCα-KR cultures.  
Finally, a significant decrease in the percentage of cells in G2/M phase was seen 
at 30 µM for both MIEV and PKCα-KR cultures. 
Treatment with enzastaurin resulted in a significant increase in the percentage of 
cells arrested in G0/G1 phase of cell cycle at 10 µM enzastaurin particularly for the 
PKCα-KR expressing cultures at both 24 and 48 hr (Figure 3.21).  A significant 
drop in percentage of cells in S phase of cell cycle was only observed at 48 hr at 
10 µM within the PKCα-KR expressing cultures.  Finally the percentage of cells in 
G2/M phase of cell cycle significantly decreased in the PKCα-KR expressing 
cultures treated with 10 µM enzastaurin at both 24 and 48 hr.  Collectively, these 
data indicate that the PKCα-KR expressing cultures are sensitive specifically to 
more selective PKCβ inhibitor enzastaurin, as treatment with enzastaurin resulted 
in an accumulation of non-dividing cells within G0/G1 phase of cell cycle, and a 
decrease in the amount of cells preparing for and going through cell division (S 
and G2/M). 
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3.3.11 Enzastaurin decreases amount of CLL-like GFP+ cells in vivo 
In order to determine whether enzastaurin has an anti-proliferative effect of CLL-
like cells in vivo, neonatal RAG1-/- mice were injected with PKCα-KR retrovirally 
transduced HPCs as described above (section 2.3.2). Four weeks post injection, 
mice were either treated with vehicle only or 80 mg/kg enzastaurin twice daily for 
two weeks. At this time, mice were sacrificed and organs subjected to FACS 
analysis in order to determine apoptosis in vivo using annexin V/Viaprobe and 
CD19 staining.  A significant increase in the percentage of apoptosing GFP+ CLL-
like cells was noted upon treatment of mice with enzastaurin (Figure 3.22A).  In 
addition, there is an evident decrease in spleen size (Figure 3.22B) post 
enzastaurin treatment.  
3.3.12 PKCα is downregulated in transcript levels and protein levels in 
human CLL compared to normal human B cells 
In order to determine whether the findings in the murine PKCα-KR model translate 
to human CLL, it was necessary to consider RNA and protein levels of PKCα in 
human CLL compared to normal B cells.  Therefore normal B cells and human 
CLL cells were isolated from buffy coats and whole blood respectively (as 
described in section 2.4) and subjected to qRT-PCR analysis and Western blot.  
PKCα is down-regulated at the transcript level in most of the CLL samples 
examined (in 64% of cell samples tested), although the mean level of PKCα 
transcript levels is higher in CLL compared to normal B cells (Figure 3.23A left).  
As described previously (Abrams et al. 2007; Abrams et al. 2010), CLL cells 
express high levels of PKCβ mRNA (Figure 3.23A right).  When levels of protein 
were examined, it was evident that PKCα protein was downregulated in CLL cells 
compared to normal B cells (Figure 3.23B). PKCα was downregulated at the 
protein level in 75% of samples tested (n=16). However, no clear relationship was 
found between prognostics (age, treatment, Binet stage, cytogenetic 
abnormalities, mutational status of IgVH genes, ZAP70 expression) and PKCα 
expression.   
3.4 Discussion 
Further classification of the PKCα-KR murine CLL model has demonstrated its 
strength as a translational model because of its similarities to human CLL.   The 
introduction of kinase inactive PKCα into early murine HPCs results in a 
transformation event leading to a survival advantage.  The low percentage of 
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PKCα-KR retrovirally transduced cells soon overtake the in vitro B cell culture, 
resulting in a homogeneous GFP+ population.   
B lymphocytes from CLL patients also strongly and constitutively express the 
CD23 antigen which is an important prognostic marker (Fournier et al. 1992; Goller 
et al. 2002; Sarfati et al. 1996).   Surface IgM is characteristically low in expression 
on CLL cells, despite normal transcription and intracellular synthesis. This poor 
surface expression has been accounted for by a defect in the ability of the CLL 
cells to assemble BCR chains, resulting in unprocessed µ chains (Payelle-Brogard 
et al. 2003). In normal human B cells, repeated BCR simulation leads to anergy 
and CD5 expression which are both important in CLL.  In addition, CD5 
phosphorylation has been linked to enhanced signaling of anti-apoptotic pathways 
such as Bcl-2, NFκB, Wnt, Stat, TGFβ, VEGF, MAPKs and various chemokines 
and cytokines leading to increased cell survival (Gary-Gouy et al. 2007).  Indeed, 
PKCα-KR expressing B cells phenotypically resemble human CLL cells by surface 
protein expression whereby they are CD19hiCD23hiCD5+IgMlo.  
Bcl-2 is an anti-apoptotic protein that is a key player implicated in the resistance of 
CLL cells to chemotherapy and resistance to external microenvironmental signals 
that direct healthy B cells to undergo programmed cell death ( Adams & Cory 
2007). Like human CLL cells, PKCα-KR expressing cells express Bcl-2 at high 
levels, possibly indicating other intrinsic properties similar to human CLL such as a 
defect in apoptosis.   
Another gene that bears high importance in human CLL is aicda.  Aicda gene 
encodes AID which is essential for immunoglobulin SHM and CSR (Xu et al. 
2007).  CLL patients can either express mutated or unmutated variable IgVH 
genes, and this mutational status represents an important prognostic factor 
whereby unmutated VH carrying patients exhibit a poorer prognosis.  CSR also 
predominates within the unmutated VH group, however CLL B cells can undergo 
CSR without SHM (Oppezzo et al. 2003).   Unmutated CLL B cells have been 
shown to constitutively express AID which may promote genetic changes that may 
lead to a more aggressive disease (Leuenberger et al. 2009; Oppezzo et al. 2003; 
Albesiano et al. 2003; Reiniger et al. 2006; McCarthy et al. 2003; Heintel et al. 
2004). Expression of AID is also associated with proliferating cells.  Importantly, 
PKCα-KR cells express significantly higher mRNA transcripts of aicda and are 
therefore similar to a more aggressive, unmutated form of human CLL. Hi Ki67 
positivity within B cell proliferation centres was demonstrated to be positively 
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associated with AID expression in human CLL (Leuenberger et al. 2009). In our 
model it is plausible that the higher proliferative capacity of PKCα-KR cultures can 
be linked higher expression of aicda.   
Patients harbouring an unmutated form of IgVH genes also express ZAP70 at high 
levels.  In fact, ZAP70 is expressed in over 90% of unmutated CLL cases and is 
associated with an increased cell survival and inferior clinical outcome (Wiestner 
et al. 2003; Crespo et al. 2003). In accordance with human unmutated CLL cells, 
PKCα-KR cells express higher ZAP70 protein levels. The survival of CLL cells is 
also dependent on the NFκB pathway, which is constitutively active in CLL 
(Herreros et al. 2010). The phosphorylation status of IκBα, which binds and 
sequesters NFκB dimer to prevent binding of DNA and activation of transcription, 
is often used to indicate NFκB activity (Shih et al. 2011). IκBα is phosphorylated by 
IκB kinases (IKKs) and consequently targeted for proteosomal degradation, 
allowing for NFκB heterodimers to enter the nucleus and initiate transcription of 
key genes essential for survival and function of mature B cells (Pasparakis et al. 
2002; Gilmore 2006). As in human CLL, the NFκB pathway also seems to be 
active in PKCα-KR expressing cells as phosphorylation of IκBα protein is higher 
compared to the MIEV control.    
The aggressive characteristic of the PKCα-KR expressing cells is even more so 
evident when these cells are observed in vivo.  Indeed, adoptive transfer of PKCα-
KR-HPCs into RAG1-/- recipient mice quickly causes tumorigenesis, marked by 
enlarged spleens with disorganized B cell areas.  This results in a shortened 
lifespan of PKCα-KR-HPC injected mice compared to their MIEV counterparts.  
The PKCα-KR expressing cells quickly proliferate within the mice evident from the 
increase in the percentage of GFP+ CD45+ cells, and more specifically CD19+ B 
cells within the blood, spleen, BM and LN, resembling human CLL.  Of note, when 
spleen sections of PKCα-KR-HPC injected mice were examined by IHC, it was 
evident that not all GFP+ cells were B220+, and therefore implies an expansion of 
other lineages that can result from PKCα subversion in HPCs (see Chapter 5).   
PKCα has been implicated as a tumour suppressor previously, whereby its 
expression/activity is downregulated (Gökmen-Polar et al. 2001; Kahl-Rainer et al. 
1994; Detjen et al. 2000).  Similarly within the PKCα-KR mouse model, PKCα acts 
as a tumour suppressor in B lymphocyte progenitors.  Although initially, overall 
PKC kinase activity is lowered within the PKCα-KR expressing cells, at later 
stages of culture overall PKC kinase activity is elevated, coupled by a dramatic 
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elevation in PKCβII expression specifically. In vivo, PKCβII is expressed within the 
B220+ B cell areas, however comparative quantification of protein in vivo between 
MIEV and PKCα-KR HPC injected mice was not possible because of the 
limitations set by this technique.  Of note, upregulation in PKCβII expression and 
activity has been strongly linked to poor prognosis in human CLL and disease 
progression (Abrams et al. 2010; Buschenfelde et al. 2009; Abrams et al. 2007). 
Similarly, within the TCL1 transgenic mouse model, PKCβ was shown to be 
essential for the development of CLL because PKCβ deleted TCL1 transgenic 
mice did not develop a CLL disease (Holler et al. 2009). 
It is therefore possible that the downregulation of tumour suppressor PKCα is 
linked to the upregulation of PKCβII and that PKCβII aids in the poor prognosis 
associated with the PKCα-KR mouse model. In fact PKCβII activation has been 
shown to be stimulated by oncogenic pathways such as VEGF signaling which can 
drive its expression, contributing to the malignant phenotype of CLL cells (Abrams 
et al. 2010).  In the PKCα-KR mouse model, VEGF transcript levels are elevated 
compared to control and could possibly correlate to increased PKCβII signaling, 
however further experiments need to be conducted to validate this relationship.   
It is clear that introduction of PKCβII into HPCs provides them with a survival 
advantage because HPCs transduced with PKCβII expand over time compared to 
untransduced HPCs within the same culture.  This survival advantage, however, is 
not enough to immediately transform HPCs into B cells that phenotypically 
resemble human CLL cells, as seen with introduction of PKCα-KR into HPCs. 
Perhaps PKCβII-transformed HPCs take longer to transform and thus analysing 
them at a later time point would be beneficial. The current data, however, suggest 
that the transformation of HPCs toward CLL-like cells does not depend on a single 
genetic event, but rather a combination of different events.   
The rationale behind targeting PKCβ in CLL is clear.  Targeting BCR signaling 
may prove beneficial because the mutational status of the IgVH and BCR 
downstream signaling molecules like ZAP70 are indicative of poor prognosis in 
CLL patients.  In fact, treatment of primary CLL cells with enzastaurin in vitro 
results in apoptosis regardless of mutational status (Holler et al. 2009).  In vivo, 
one study comprised of seven patients showed an ORR of 14.3% and a 
progression-free survival of 308 days (Forsyth et al. 2009). Within our PKCα-KR 
model, treatment with pan PKCβ inhibitors hispidin or enzastaurin did not 
preferentially induce apoptosis of PKCα-KR expressing cells in vitro, however it did 
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slow down their proliferation as assessed by a decrease in BrdU incorporation 
post treatment, most dramatically with enzastaurin treatment. The decrease in 
proliferation was coupled with an arrest in cell cycle post drug treatment, marked 
by an increase in percentage of cells in G0/G1 phase of cell cycle, and a decrease 
in percentage of cells in S and G2/M phases, particularly with enzastaurin 
treatment.  There was however, a relevant lack of effect of hispidin treatment on 
cell cycle as compared to BrdU, highlighting a difference in the two assay 
readouts.  In vivo, treatment with enzastaurin resulted in a decrease in the 
percentage of GFP+ CLL-like cells and a decrease in spleen size.  These results 
were encouraging, but do need to be repeated for validation purposes.   
Finally, PKCα seems to act as a tumour suppressor in human CLL because it is 
downregulated at the transcript and protein levels in most human CLL cases 
investigated.  Therefore, understanding the molecular events that lead to its down-
regulation could prove beneficial in developing new therapeutic approaches for the 
treatment of human CLL. 
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Figure 3.1 Isolation of HPCs from FL, retroviral transduction and in vitro B 
cell generating system 
A FL was excised from day 14 gestation mice and single cell suspensions were 
prepared by crushing of FL and filtering through a 70 µm nylon mesh.  The cells 
were incubated with anti-CD24 antibody and rabbit complement to allow for 
complement-mediated CD24+ cell lysis.  Viable CD24lo/- cells were isolated by 
Lympholyte-Mammal gradient centrifugation and subsequently retrovirally 
transduced over night on mitomycin C treated (10 µg/ml) GP+E.86 retroviral 
packaging lines producing either vehicle only (MIEV) or PKCα-KR virus. The cells 
were collected from the packaging lines, washed, and subsequently co-cultured on 
OP9 cells with 10 ng/ml IL7 and FLT3L.  Medium was replenished every second 
day and OP9 layers were replenished every fourth day.  B The construct 
containing PKCα-KR is tagged with HA at the C-terminus, therefore allowing 
PKCα-KR expression to be monitored by Western blot.  B cell lysates from MIEV 
and PKCα-KR cultures were prepared and examined for HA expression. 
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Figure 3.2 PKCα-KR expressing cells exhibit a growth advantage over their 
MIEV counterparts. 
The PKCα-KR construct bicistronically expresses GFP at the C-terminus, thus 
GFP fluorescence can be monitored by FACS. Cells were obtained from FL:OP9 
cultures at day 1, day 10, day 17 and consequently analysed by flow cytometry to 
determine the percentage of GFP+ cells over the duration of the culture. 
Haematopoietic (CD45+) cells were live and size gated (FSC vs SSC) prior to 
evaluation of GFP fluorescence.  
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Figure 3.3 PKCα-KR expressing cells phenotypically resemble human CLL 
cells by surface protein expression 
A Representative FACS plot of FL cultures around day 10.  Cells were live and 
size gated (FSC vs SSC) and CD45 and CD19 analysis shown. B Cells from day 
10 and 17 FL:OP9 MIEV and PKCα-KR cultures were stained with anti-CD19, anti-
CD5, anti-CD23 and anti-IgM antibodies in order to determine levels of surface 
protein expression.  These are representative plots of over 50 separate biological 
replicates. Haematopoietic (CD45+) cells were live and size gated (FSC vs SSC) 
and CD5 vs CD19, CD23 vs CD19, IgM vs CD19 analysis shown. C FL cultures 
were subjected to FACS analysis.  Haematopoietic (CD45+) cells were live and 
size gated (FSC vs SSC) and GFP, CD19, CD23, CD5 and IgM expression shown 
as an average of mean fluorescence intensity (MFI). GFP p < 0.0001 (n = 6); 
CD19 p = 0.0068 (n = 5); CD23 p = 0.0058 (n = 3); CD5 p = 0.0125 (n = 4); IgM p 
= 0.0003 (n = 3). Data are represented as mean (± SEM) of biological replicates. p 
values were generated using the student’s unpaired t-test to compare groups 
(*p<0.05, **p<0.005, ***p<0.001). 
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Figure 3.4 PKCα-KR expressing cells have higher levels of Bcl-2, aicda, 
ZAP70 and activated NFκB  
A RNA was isolated from MIEV and PKCα-KR cultures and subjected to qRT-PCR 
in order to determine transcript levels of CLL-associated genes Bcl-2 and aicda 
relative to housekeeping gene GAPDH. B Protein lysates were also prepared from 
MIEV and PKCα-KR cultures to determine levels of phospho-IκBα and ZAP70 
protein by Western blot and C intracellular ZAP70 protein by FACS.  Results are 
shown as mean ± SEM. p values were generated using the student’s unpaired t-
test to compare groups (n=3).  
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Figure 3.5 RAG1-/- mice injected with PKCα-KR-HPCs exhibit a shortened 
lifespan 
Neonatal RAG1-/- mice were subjected to i.p. in vivo adoptive transfer of MIEV or 
PKCα-KR retrovirally transduced HPCs. For MIEV-HPC injected mice, 1 x 106 
cells were used, whereas for PKCα-KR-HPC injected mice, either 1 x 106 or 4 x 
106 cells were injected.  Mice were sacrificed at signs of distress and day since 
injection was recorded.  The graph indicates a survival curve and each point 
marks a different mouse. n = 15 (1 x 106 PKCα-KR cells); n = 31 (4 x 105 PKCα-
KR cells); n = 20 (1 x 106 MIEV cells).  
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Figure 3.6 PKCα-KR-HPC injected mice express expansion of 
haematopoietic lineage and increase in percentage of GFP+ B cells. 
Neonatal RAG1-/- mice were subjected to in vivo adoptive transfer of MIEV or 
PKCα-KR retrovirally transduced HPCs.  Four to six weeks post injection, mice 
were sacrificed and organs and blood removed.  Single cell suspensions were 
generated from spleen, BM and LN.  FACS analysis was conducted on organs and 
blood stained with CD45 and CD19.  Each point on the graph represents a single 
mouse.  Averages are represented by lines and p values were generated using the 
student’s unpaired t-test to compare groups (*p<0.05, **p<0.005, ***p<0.001) n=13 
(MIEV) and n=21 (PKCα-KR). 
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Figure 3.7 PKCα-KR HPC-injected RAG1-/- mice exhibit CLL phenotype in 
vivo  
Lymphocytes were isolated from blood and spleen of MIEV and PKCα-KR HPC-
injected RAG1-/- mice (1 x 106 MIEV cells injected; 4 x 105 PKCα-KR cells injected) 
and subjected to FACS analysis.   Haematopoietic (CD45+) cells were live and 
size gated (FSC vs SSC) and CD23 vs CD19; CD45+CD19+ cells were gated and 
IgM vs IgD analysis shown. 
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Figure 3.8 PKCα-KR-HPC injected mice exhibit splenomegaly  
FL cells were prepared from wildtype mice and retrovirally transduced to express 
MIEV or PKCα-KR as described before.  After over-night transduction, 4 x 105 
cells were injected i.p. into neonatal RAG1-/- mice.  Four weeks post injection, mice 
were sacrified and spleens excised.   
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Figure 3.9 PKCα-KR-HPC injected mice exhibit disrupted splenic 
architecture 
Spleens from RAG1-/- mice injected with 4 x 105 MIEV or PKCα-KR HPCs were 
removed four weeks post injection and immediately embedded in paraffin. Three 
micron sections were cut and stained with H & E.  
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Figure 3.10 PKCα-KR-HPC injected mice display disrupted B cell follicular 
formation and more GFP+ cells within the spleen 
A Paraffin embedded spleens from RAG1-/- mice injected with 4 x 105 MIEV or 
PKCα-KR HPCs four weeks post injection were cut into three micron sections and 
subsequently stained for B220 antigen and GFP using anti-B220 and anti-GFP 
antibodies (for isotype controls, see Appendix A). B FL cultures were subjected to 
FACS analysis.  Haematopoietic (CD45+) cells were live and size gated (FSC vs 
SSC) and CD19 vs B220 analysis shown. 
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Figure 3.11 Attenuation of PKCα activity within the PKCα-KR expressing B 
cells leads to an upregulation of PKCβII  
A Protein lysates were prepared from MIEV and PKCα-KR cultures. Proteins were 
separated by gel electrophoresis and immunoblotted for PKCβII, PKCβI and 
phospho-ERK (pERK1/2).  GAPDH was included as a protein loading control.  B In 
order to determine when PKCβII protein is upregulated within the PKCα-KR 
cultures, protein lysates were taken at earlier (day 8, 10) and later (day 15, 17) 
time points of the B cell culture.  Immunoblotting for PKCβII and GAPDH (loading 
control) was performed. C RNA was isolated from MIEV and PKCα-KR cultures 
and subjected to qRT-PCR to evaluate the levels of PKCβ and D VEGFα mRNA 
transcripts. B and T cells sorted from wildtype spleen serve as additional controls.  
Results are expressed as 2(-ΔCT) relative to GAPDH housekeeping gene and 
represent mean ± SEM (*p<0.05, ***p<0.001). 
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Figure 3.12 PKCβII protein is expressed in vivo within the B cell follicles of 
the spleen 
Paraffin embedded spleen sections from MIEV and PKCα-KR HPC-injected mice 
were stained for B220 and PKCβII. 
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Figure 3.13 PKCβII transduced cells expand over time 
Full length PKCβI and PKCβII (PKCβI-WT and PKCβII-WT) and constitutively active 
PKCβI and PKCβII isoforms (PKCβI-CAT and PKCβII-CAT) were cloned into 
retroviral backbone MIEV. Retroviral packaging lines were generated as described 
in Section 2.1.2.2.1 and FL HPCs were transduced overnight.   FL HPCs were 
also transduced with MIEV and PKCα-KR for comparison.  Cells were then co-
cultured with OP9 and cytokines in a B cell generating system and subjected to 
FACS at different stages of culture (day 1, 14, 17, 22) to determine the percentage 
of GFP+ cells. B cells (CD45+CD19+) were live and size gated (FSC vs SSC) prior 
to GFP gating. 
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Figure 3.14 PKCβII transduced cell surface phenotype: CD5 expression 
HPCs that were retrovirally transduced to express MIEV, PKCα-KR, PKCβI-WT, 
PKCβII-WT, PKCβI-CAT and PKCβII-CAT were subjected to FACS analysis to 
determine expression of CD19 vs CD5 at day 22 of FL:OP9 co-culture. FACS 
analysis was carried out on GFP- and GFP+ populations. Haematopoietic (CD45+) 
cells were live and size gated (FSC vs SSC) and CD5 vs CD19 analysis shown.   
 
 
 
  104 
 
 
 
 
Figure 3.15 PKCβII transduced cell surface phenotype: CD23 expression 
HPCs that were retrovirally transduced to express MIEV, PKCα-KR, PKCβI-WT, 
PKCβII-WT, PKCβI-CAT and PKCβII-CAT (as in Fig 3.10) were subjected to FACS 
analysis to determine expression of CD19 vs CD23 at day 22 of FL:OP9 co-
culture. FACS analysis was carried out on GFP- and GFP+ populations. 
Haematopoietic (CD45+) cells were live and size gated (FSC vs SSC) and CD19 
vs CD23 analysis shown. 
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Figure 3.16 Inhibition of PKCβ with hispidin does not favour apoptosis of 
PKCα-KR cells compared to MIEV control 
Cells were harvested from MIEV and PKCα-KR FL:OP9 cultures at later stages 
(>14 days of in vitro culture) and treated with increasing concentrations of pan 
PKCβ inhibitor hispidin for 24 and 48 hr. Apoptosis was assessed by annexin 
V/DAPI staining. Data are represented as means (± SEM) of at least 3 biological 
replicates.  The graphs on the left represent cell percentage; whereas the graphs 
on the right represent percentage of no drug control (NDC). p values were 
generated using the student’s unpaired t-test to compare groups (*p<0.05, 
**p<0.005, ***p<0.001).   
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Figure 3.17 Inhibition of PKCβ with enzastaurin does not favour apoptosis of 
PKCα-KR cells compared to MIEV control 
Cells were harvested from MIEV and PKCα-KR and treated with increasing 
concentration of more selective PKCβ inhibitor enzastaurin for 24 and 48 hr and 
apoptosis was assessed by FACS using annexin V/DAPI staining. Data are 
represented as mean (± SEM) of at least 3 biological replicates.  The graphs on 
the left represent cell percentage; whereas the graphs on the right represent 
percentage of NDC. p values were generated using the student’s unpaired t-test to 
compare groups (*p<0.05, **p<0.005, ***p<0.001).   
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Figure 3.18 Representation of apoptosis by assessment of SubG0 population 
in hispidin and enzastaurin treated cells  
Cells were harvested from MIEV and PKCα-KR cultures and treated with 
increasing concentration of hispidin or enzastaurin for 24 and 48 hr. Cells were 
then washed in PBS and re-suspended in PBS containing 20 µg/ml PI in the 
presence of DNAse-free-RNAse.  Cell cycle profile was assessed by FACS.  Data 
are represented as mean (± SEM) of at least 3 biological replicates. p values were 
generated using the student’s unpaired t-test to compare groups (*p<0.05, 
**p<0.005, ***p<0.001).   
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Figure 3.19 Inhibition with hispidin and enzastaurin causes a decrease in 
proliferation of specifically PKCα-KR cultures as assessed by BrdU 
incorporation  
Cells were harvested from MIEV and PKCα-KR cultures and treated with 
increasing concentrations of hispidin or enzastaurin for 24 and 48 hr. Cells were 
incubated with BrdU for 2 hr prior to end point, and fixed.  Absorbance is 
represented as values read at 492 nm - 370 nm after addition of TMB substrate.  
Data are represented as mean (± SEM) of at least 3 biological replicates, each 
carried out in technical triplicates. p values were generated using the student’s 
unpaired t-test to compare groups (*p<0.05, **p<0.005, ***p<0.001).   
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Figure 3.20 Cell cycle analysis after treatment with hispidin shows no 
preference for PKCα-KR cultures in terms of cell cycle arrest 
Cells were harvested from MIEV and PKCα-KR cultures and treated with 
increasing concentration of hispidin for 24 and 48 hr. Cells were then washed in 
PBS and resuspended in PBS containing 20 µg/ml PI in the presence of DNAse-
free-RNAse.  Cell cycle profile was assessed by FACS. The sub-G0 population 
was gated out prior to analysis.  Data are represented as mean (± SEM) of at least 
3 biological replicates. p values were generated using the student’s unpaired t-test 
to compare groups (*p<0.05, **p<0.005, ***p<0.001).   
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Figure 3.21 Treatment of PKCα-KR cultures with enzastaurin causes cell 
cycle arrest  
Cells were harvested from MIEV and PKCα-KR cultures and treated with 
increasing concentration of enzastaurin for 24 and 48 hr. Cells were then washed 
in PBS and re-suspended in PBS containing 20 µg/ml PI in the presence of 
DNAse-free-RNAse.  Cell cycle profile was assessed by FACS. The sub-G0 
population was gated out prior to analysis.  Data are represented as mean (± 
SEM) of at least 3 biological replicates. p values were generated using the 
student’s unpaired t-test to compare groups (*p<0.05, **p<0.005, ***p<0.001).   
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Figure 3.22 Treatment of PKCα-KR-HPC injected mice with enzastaurin 
results in a reduction of CLL-like cells and spleen size  
RAG1-/- mice were injected with PKCα-KR-HPCs and treated with 80 mg/kg 
enzastaurin or vehicle control four weeks post injection.  A Cells were isolated 
from organs of mice and assessment of apoptosis was done by FACS using 
annexin V/Viaprobe.  Prior to annexin V+ gating, cells were gated on CD19 and 
GFP.   B Spleen size of control (RAG1-/-), PKCα-KR-HPC injected untreated, and 
PKCα-KR-HPC injected and enzastaurin treated mice. p values were generated 
using the student’s unpaired t-test to compare groups. 
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Figure 3.23 PKCα mRNA and protein is down-regulated in human CLL  
Normal human B cells and CLL cells were isolated from buffy coats and CLL 
patients respectively.  A qRT-PCR data showing expression of PKCα (left) and 
PKCβ (right) genes relative to GAPDH and represented as fold change over 
Normal B cells.  B PKCα and PKCβII protein expression by Western blot of 3 
normal and 6 CLL patients.  
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Appendix 3-A Isotype controls for immunohistochemistry 
Paraffin embedded spleens from RAG1-/- mice injected with MIEV or PKCα-KR 
HPCs were stained with secondary only and isotype controls. 
 
 
Appendix 3-B PKCα-KR expressing cells have decreased kinase activity in 
early (day 10) but not in late cultures (day 17)  
Cell lysates were prepared from FL:OP9 co-cultures of MIEV and PKCα-KR 
retrovirally transduced cells at day 10 and 17.  PKC activity was determined with 
32P PKC kinase kit.  The graphs express percentage of total PKC activity in PKCα-
KR  expressing cells relative to MIEV expressing cells. Statistics were generated 
using the student’s unpaired t-test (**p<0.005). Part of this figure was published 
previously in Nakagawa et al, 2006. 
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Chapter 4 
Attenuation of PKCα signaling in HPCs results in the activation of mTOR 
signaling and upregulation of Cyclin D1 
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4.1 Introduction 
The mTOR pathway is responsible for cell growth and proliferation and its 
deregulation is associated with human disease, including cancer (Sarbassov et al. 
2005).  The mTOR signaling pathway mediates signals from nutrients, growth 
factors and energy status in order to regulate bioprocesses such as metabolism 
and autophagy.  One of the many processes regulated by mTOR is nutrient 
metabolism. As cells grow, their requirement for nutrient intake is enhanced, 
resulting in an elevation of nutrient receptor expression.  CD98 is a cell surface 
protein that regulates amino-acid transport.  In murine fibroblasts, over-expression 
of CD98 is associated with malignant transformation (Shishido et al. 2000).  CD71 
is a transferrin receptor that is usually expressed on activated lymphocytes 
(among other cell lineages).  CD71 binds Fe(Apo)-transferrin  and delivers iron by 
internalization that is necessary for cellular metabolism of a growing cell (Sargent 
et al. 2005; Aisen 2004). 
mTOR consists of two distinct complexes, mTORC1 and mTORC2.  mTORC1 is 
comprised of mTOR, Raptor, GβL and Deptor, whilst mTORC2 is comprised of 
mTOR, Rictor, GβL, Sin1, PRR5/Protor-1 and Deptor (Laplante & Sabatini 2009).  
mTORC2 can promote cell survival by activating Akt. mTORC1 can promote cell 
growth if adequate nutrients, growth factors or energy are available, or can 
regulate catabolic processes under stress conditions.  Hormones such as insulin 
and growth factors signal via PI3K/Akt to mTORC1, inactivating tuberous sclerosis 
complex 2 (TSC2) and preventing mTORC1 inhibition.  In contrast, low ATP levels 
can activate TSC2 in order to inhibit mTROC1 signaling.  Ras-related GTPase 
(Rag) proteins are involved with signaling to mTORC1 in regard to amino acid 
availability.  Active mTORC1 can regulate downstream biological effects such as 
mRNA translation via downstream target 4EBP1.  Like ERK, mTORC1 can 
phosphorylate translational repressor 4EBP1, thereby releasing eIF-4E and 
allowing it to generate a complex with eIF-4A and eIF-4G that is responsible for 
cap-dependent translation (Figure 4.1) (Laplante & Sabatini 2009).  PKCα 
activates protein serine/threonine phosphatase A (PP2A) which in turn 
dephosphorylates 4EBP1, thus activating translational repressor 4EBP1 that binds 
eIF-4E, preventing it from forming the eIF-4F complex (Guan et al. 2007). 
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Figure 4.1 Regulation of cap-dependent translation by eIF-4E through 4EBP1 
phosphorylation 
 
4.2 Aims and Objectives 
One of the early notable features of HPCs that have been transduced with PKCα-
KR mutant is their ability to expand within the culture (Figure 3.2).  The attenuation 
of PKCα signaling leads to a survival advantage marked by an evident increase in 
the percentage of GFP+ cells in culture.  To gain a deeper understanding of the 
transformation characteristics of PKCα-KR transduced cells, the specific aims of 
this chapter were: 
i.   To investigate whether attenuation of PKCα signaling in HPCs leads to 
increased proliferation and changes in cell cycle; 
ii.   To delineate the molecular mechanisms responsible for the expansion of 
the PKCα-KR expressing cells over their control counterparts; 
iii.  To determine whether the signaling pathways associated with 
transformation in mCLL mirror those that occur in human CLL. 
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4.3 Results 
4.3.1 PKCα-KR expressing cells are bigger than their MIEV counterparts 
and have activated mTOR signaling 
PKCα-KR cells appeared larger in size in comparison to their MIEV counterparts. 
In order to determine whether there was a size difference between the PKCα-KR 
and MIEV cultures, the two cultures were photographed (Figure 4.2A) and 
analysed by FACS (Figure 4.2B) at day 13 of FL:OP9 co-culture.  The PKCα-KR 
expressing cells were larger than their MIEV counterparts as demonstrated in the 
picture (Figure 4.2A) and in the overlay histogram of forward scatter (Figure 4.2B; 
average of FSC mean for MIEV = 6.83 x 104 versus 8.91 x 104 for PKCα-KR, n = 
6; p = 0.0049).  A larger size of cell is correlated to an increased requirement for 
nutrients and elevation in cellular processes such as metabolism.  Therefore, the 
expression of two nutrient receptors, CD71 and CD98 was investigated on the 
surface of PKCα-KR and MIEV cultures by FACS (Figure 4.3A). PKCα-KR cells 
expressed both CD98 and CD71 at higher levels than their MIEV counterparts at 
day 14 of co-culture.  The increase in mammalian cell size and its growth has 
been attributed to the mTOR pathway (Sarbassov et al. 2005), so initial activation 
of the pathway was investigated by examining the phosphorylation state of p70 S6 
Kinase, a common downstream target of mTOR activity. Indeed, mTOR is active in 
PKCα-KR cultures at day 11 and day 18 (Figure 4.3B).  Phospho-p70 S6 Kinase 
was also present in day 11 MIEV cultures, however it was more pronounced in 
PKCα-KR cultures.  In addition to an elevation of mTOR activity, PKCα-KR 
expressing cells have constitutively active ERK signaling as demonstrated by early 
and sustained phoshorylation of ERK1/2 (Figure 4.3B).   
4.3.2 Treatment of PKCα-KR cells with mTORC1 inhibitor rapamycin does 
not cause preferential apoptosis compared to the control  
Since it was determined that mTOR signaling is active within PKCα-KR cultures, 
we investigated whether inhibition of mTOR signaling by rapamycin treatment 
would result in apoptosis of these cells.  Therefore MIEV and PKCα-KR cells were 
harvested from (> day 14) FL:OP9 co-cultures and treated with increasing 
concentrations of rapamycin in the presence or absence of OP9 stroma (Figure 
4.4).  The rationale behind testing drug efficacy on stroma was derived from recent 
studies indicating that drug resistance in vivo is correlated to the dependency of a 
leukaemic cell on its microenvironment that protects it from the effects of drug 
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seen in vitro in medium alone, rendering it chemoresistant (McCaig et al. 2011; 
Tabe et al. 2011).  There was a significant but modest decrease in the percentage 
of viable cells in both MIEV and PKCα-KR cultures treated with 10 nM at 24 hr 
(Figure 4.4A).  At 24 hr, this decrease was moderate even at highest concentration 
of rapamycin (300 nM) as percentage of decrease in viable cells was ≤25.  The 
presence of OP9 stroma had a slight protective effect for both MIEV and PKCα-KR 
cultures.  At 48 hr, a significant decrease in the percentage of viable cells was 
seen for rapamycin treated MIEV cultures only in the presence of stroma (Figure 
4.4B left). In the absence of stroma, a significant decrease in the percentage of 
viable cells was seen at 10 nM rapamycin for PKCα-KR cultures, and only at 300 
nM for MIEV cultures (Figure 4.4B right). 
4.3.3 Treatment of PKCα-KR cultures with mTORC1 inhibitor rapamycin 
results in the attenuation of proliferation as marked by BrdU 
incorporation 
Although treatment with rapamycin did not result in a preferential induction of 
apoptosis in PKCα-KR cultures compared to their control counterparts, we aimed 
to determine whether treatment with rapamycin would result in a decrease in 
levels of proliferation within these cells.  Thus, MIEV and PKCα-KR cells were 
treated with increasing concentrations of rapamycin and proliferation was 
assessed by BrdU incorporation (Figure 4.5).  There was a significant reduction in 
proliferation with addition of lowest concentration of rapamycin (10 nM) specifically 
in the PKCα-KR cultures. Treatment with higher concentrations of drug resulted in 
a further modest decrease in proliferation within these cultures.  
4.3.4 A higher percentage of PKCα-KR cells are undergoing cell division 
compared to MIEV cells, and are dependent on OP9 stroma 
In CLL, the microenvironment within the LN and BM has proven to be crucial for 
the survival and proliferation of a CLL cell.  Since it was demonstrated that PKCα-
KR cells proliferate more than their MIEV counterparts it was of interest to 
determine whether the in vitro microenvironment (stroma and cytokines) aid in the 
proliferation of PKCα-KR cells. Therefore, MIEV and PKCα-KR cells were cultured 
in medium alone (in the absence of stroma and IL7), with stroma alone, or with 
stroma and IL7 and cell cycle profile was analysed using FACS by PI staining 
(Figure 4.6A).  In medium alone, in comparison to MIEV cells, PKCα-KR cells 
displayed a significantly lower percentage of cells in subG0 phase and a trend of 
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an increase in percentage of cells in G2/M phase of cell cycle.  The addition of 
OP9 stroma resulted in a further decrease in the subG0 population (although not 
significant), a significant decrease in cells arrested in G0/G1 phase of cell cycle, 
and a significant increase in cells preparing for and undergoing cell division (S and 
G2/M) phase.  Finally, the addition of IL7 decreased the percentage of dead cells 
as marked by the subG0 population for both the MIEV and PKCα-KR cultures.  
Although not significant, the addition of IL7 and OP9 to PKCα-KR cultures further 
decreased the percentage of cells arrested in G0/G1 phase of cell cycle, and 
increased the percentage of cells in S and G2/M phases of cell cycle.    
To determine whether the increased proliferative capabilities of the PKCα-KR 
cultures occurred early on in the in vitro culture, or as a later event, two early (day 
9,10) and two late (day 24, 28) MIEV and PKCα-KR cultures were cultured on OP9 
with IL7 and labelled with BrdU (Figure 4.6 B).  It appears that the PKCα-KR 
cultures are proliferating more than the MIEV cultures at both early and late 
phases of cell culture (Figure 4.6B).  
4.3.5 PKCα-KR cells express cyclin D1 mRNA and protein in vitro and in 
vivo  
In the intestine, cyclin D1 was shown to be negatively regulated by PKCα (Pysz et 
al. 2009; Guan et al. 2007), therefore within the CLL mouse model, where PKCα 
signaling is attenuated, we hypothesised that cyclin D1 may be upregulated thus 
aiding in the proliferative characteristics of PKCα-KR cells.  As such, transcript 
levels of cyclin D1 mRNA were determined at day 6, 10 and 17 of FL:OP9 MIEV 
and PKCα-KR cultures (Figure 4.7A).  There was a notable increase in cyclin D1 
mRNA in PKCα-KR cultures compared to MIEV and control B and T cells.  In vivo, 
mRNA levels were determined within spleen, tumour and BM of PKCα-KR-injected 
mice and demonstrated to be higher than B or T controls (Figure 4.7B).  Since 
cyclin D1 mRNA was upregulated within the PKCα-KR cultures, protein expression 
was evaluated by Western blot analysis in early (day 6) mid (day 13) and late (day 
26) FL:OP9 co-cultures (Figure 4.7C). PKCα-KR cultures contained a higher 
amount of cyclin D1 protein even early on (day 6), and in correlation with the 
mRNA data obtained (Figure 4.7A) cyclin D1 protein levels were higher in the later 
cultures (Figure 4.7C).  In human embryonic stem cells, cyclin D1 was shown to 
be regulated by miR302 that is activated by Sox2 ( Card et al. 2008). Of interest, 
Sox2 mRNA is downregulated within the PKCα-KR cultures in vitro (Figure 4.7D).  
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As a result of the focus of the microenvironment in regard to CLL cell survival and 
proliferation, we determined whether cyclin D1 is expressed in B cells within the 
proliferation centres of PKCα-KR injected mice.  Therefore consecutive spleen 
sections of MIEV and PKCα-KR-injected mice were stained for B220 and cyclin D1 
(Figure 4.8).  Within the MIEV spleen, cyclin D1 was found outwith the B cell 
follicle, whereas within the PKCα-KR spleen, cyclin D1 and B220 were co-
localized within the B cell follicles as demonstrated by sequential staining of B220 
and cyclin D1 respectively. It is evident that other cells within both MIEV and 
particularly within the PKCα-KR spleens were positive for cyclin D1, although their 
identities were not clarified.    
In human CLL, cyclin D1 mRNA and protein is upregulated when CLL cells are co-
cultured with NTL cells and NTL cells expressing CD40L (CD154) as compared to 
medium alone (Appendix 4-A).  In addition, in human CLL LN biopsies, out of the 
seven samples tested, three revealed some positive staining for cyclin D1 
(Appendix 4-B). 
4.3.6 Over-expression of cyclin D1 does not result in an expansion of GFP+ 
cells, however the GFP+ cells do exhibit hallmark CLL markers  
Since it was demonstrated that cyclin D1 mRNA and protein are upregulated early 
within the PKCα-KR cultures, we determined whether expression of cyclin D1 
alone could transform HPCs into malignant cells by acting as an initiation factor.  
Therefore, cyclin D1 was cloned into retroviral backbone MIEV (see section 2.1.1) 
and retroviral packaging lines were generated as described in section 2.1.2.2.1.  
HPCs were isolated from FL as described previously, retrovirally transduced to 
overexpress cyclin D1, and analysed by FACS at day 1, 14, 17, and 22 (Figure 
4.9).  When assessing the percentage of GFP+ cells, no elevation in growth or 
survival advantage occurs in cells that over-express cyclin D1, as indicated by lack 
of expansion of GFP+ cells. However, when the cells were assessed by FACS at 
day 14 to determine the expression of surface makers CD19, CD5 and CD23 
indicative of CLL, the small populations of GFP+ B cells (CD19+) expressed both 
CD5 and CD23, however the cell number was minimal (Figure 4.10).  In fact, 
whereas 0% of B cells within MIEV GFP+ and cyclin D1 GFP- populations 
expressed CD23, 9.6% of B cells within the cyclin D1 GFP+ population expressed 
CD23 comparative to 7.28% within the PKCα-KR GFP+ population (Figure 4.10).  
Similarly, whereas B cells within MIEV GFP+ and cyclin D1 GFP- populations 
expressed CD5 at levels less than 4%, B cells within cyclin D1 GFP+ populations 
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expressed CD23 at levels above 20%, at even higher levels than the PKCα-KR 
GFP+ populations (7.4%) (Figure 4.10).   
4.3.7 Within mCLL cyclin D1 is regulated through transcriptional repressor 
4EBP1 
In order to determine how cyclin D1 expression is regulated within the PKCα-KR 
model, the phosphorylation state of translational repressor 4EBP1 was assessed 
since published work indicates a negative regulation of cyclin D1 by PKCα through 
4EBP1 in a PP2A-dependent manner (Figure 4.11) (Hizli et al. 2006; Guan et al. 
2007).  In addition mTOR signaling has been demonstrated to be important in 
4EBP1 regulation (Gingras et al. 2001; Averous et al. 2008).  Therefore, day 14 
MIEV and PKCα-KR cells were treated with pan-PKC activator PMA to activate 
PKCα (among other PKCs) and selective calcium ionophore agent Iono, mTORC1 
inhibitor rapa, and PP2A inhibitor OA.  Within the untreated cultures, 4EBP1 is 
hyperphosphorylated in PKCα-KR cultures compared to the MIEV cultures as 
demonstrated by the stronger expression of the higher band of 4EBP1.  Upon 
treatment with PMA/Iono, the middle band of 4EPB1 is lost, indicating a shift 
toward further 4EBP1 repression. Treatment with rapamycin causes a shift toward 
the lower bands of 4EBP1 (hypophosphorylated and therefore active state) in both 
MIEV and PKCα-KR cultures.  Finally treatment with OA within the PKCα-KR 
cultures results in an expression of the top (hyperphosporylated) band of 4EBP1, 
however it is unclear whether this band is stronger than that within the untreated 
PKCα-KR cultures.  Treatment of MIEV cultures with OA results in re-expression 
of the top band of 4EBP1.  Cyclin D1 expression is higher in untreated PKCα-KR 
cultures compared to MIEV control as demonstrated previously, and treatment 
with PMA and rapamycin results in a slight reduction of cyclin D1 protein levels.  
Activation of PKCs and attenuation of mTOR signaling results in a decrease of 
cyclin D1 protein.   
4.3.8 4EPB1 is hyperphosphorylated in human CLL cell line HG3 and  
human CLL and regulates expression of Mcl-1 and c-myc in a 
mTORC1 and PKC-dependent manner 
Cap-dependent translation and eIF-4E have been shown to regulate Mcl-1 and c-
myc expression ( Benedetti & Graff 2004; Huo et al. 2011).  To determine whether 
cyclin D1 expression is regulated through 4EBP1 as in the mCLL model, HG3 CLL 
cell line or human CLL cells were cultured on NTL stroma and treated with 
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rapamycin or PMA.  Untreated HG3 cells express hyperphosphorylated bands of 
4EBP1 indicating that it is inactive (Figure 4.12).  Treatment with rapamycin results 
in the shift toward the hypophosphorylated form and a reduction in pP70 S6K 
demonstrating the ability of rapamycin to inhibit mTORC1 signaling (Figure 4.12).  
In addition Mcl-1 and c-myc are down-regulated upon rapamycin treatment.  
Stimulation with PMA/Iono did not alter the phosphorylation state of 4EBP1, 
however it did result in an increase in levels of Mcl-1, pP70 S6K and c-myc (Figure 
4.12). No cyclin D1 protein was detected in this cell line under any condition.  In 
human CLL, 4EBP1 is hyperphosphorylated and therefore inactive (Figure 4.13 
left).  The regulation of 4EBP1 by mTOR signaling was indicated by a marked shift 
toward the hypophosphorylated form of 4EPB1 upon treatment with rapamycin 
(Figure 4.13 left). Treatment with rapamycin also results in a decrease in pP70 
S6K as expected, and a decrease in c-myc levels as seen in the HG3 cell line  
(Figure 4.13 right).  There was no change in cyclin D1 and Mcl-1 levels upon 
treatment with rapamycin.  Treatment with PMA resulted in a slight decrease in the 
inactive form of 4EBP1 (Figure 4.13 left).  A decrease in cyclin D1 levels was seen 
with PMA treatment as in the mCLL model, however this result did not occur in 
another CLL sample tested. Treatment with PMA/Iono resulted in an increase in 
Mcl-1 and c-myc, as seen in the HG3 cell line, (Figure 4.13 right).  Levels of p-
ERK were evaluated in the human CLL samples and demonstrated an elevation 
upon PMA/Iono treatment (Figure 4.13 left).  Cells treated with OA were removed 
from the analysis because a toxic effect was seen and thus little protein was 
detected.   
4.4 Discussion 
Co-culture of CLL cells with cytokines and stroma allows for the survival and 
proliferation of CLL cells in vitro (McCaig et al. 2011).   In fact, it was demonstrated 
that the LN and BM (more prominently LN) are sites of CLL active cell proliferation 
( Stevenson & Caligaris-Cappio 2004).  Within CLL LN and BM biopsies, a 
subpopulation of malignant lymphocytes are located within the proliferation centres 
surrounded by accessory cells such as stroma, T cells, macrophages and dendritic 
cells (see section 1.2.8). Similarly, within the mCLL model an early observation of 
the PKCα-KR cultures was their highly poliferative characteristic.  It was therefore 
hypothesised that attenuation of PKCα signaling results in a generation of CLL 
cells similar to those found within the proliferation centres of lymphoid organs 
responsible for the expansion of the CLL clone.  Therefore, we wanted to delineate 
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signaling molecules responsible for this proliferative capability of PKCα-KR cells, 
and in particular the mTOR signaling pathway. 
PKCα-KR expressing cells were larger than their MIEV counterparts and 
expressed nutrient receptors CD98 and CD71 at higher levels.  In addition, mTOR 
signaling was active in these cells by considering the levels of phosphorylation of 
p70 S6K, a common mTOR activation marker (Averous & Proud 2006). However, 
treatment of PKCα-KR cultures with rapamycin did not result in a dramatic 
preferential induction of apoptosis in these cultures compared to MIEV control 
cultures at 24 hr.  However, the decrease in the percentage of viable cells was 
more significant for the PKCα-KR cultures at 24 hr.  OP9 stroma had a slight 
protective effect on both MIEV and PKCα-KR cultures.  Rapamycin has been 
demonstrated to be relatively unstable under tissue culture conditions (37°C, 5% 
CO2), with a t1/2 of around 9.9 hr for degradation (Hosoi et al. 1999).  Perhaps 
repeated treatment with consistent low concentrations of rapamycin (10 nM) may 
result in preferential apoptosis of PKCα-KR cultures.  
mTOR is a multidomain protein that interacts with other proteins by forming 
complexes (Wullschleger et al. 2006).  Rapamycin only targets mTORC1 therefore 
using a pan mTOR inhibitor such as PP242 and AZD8055 that targets both 
mTORC1 and mTORC2 (Huo et al. 2011) may prove to be more effective in 
causing apoptosis preferentially within the PKCα-KR cultures.  
When cell cycle of MIEV and PKCα-KR cultures was examined in medium alone, 
stroma alone, or stroma with cytokine IL7, it was evident that PKCα-KR cells are 
more viable than MIEV cells without the microenvironment, demonstrating their 
survival advantage as seen in a significant decrease in the percentage of dead 
cells (subG0 population).  In addition, without stroma or IL7, PKCα-KR cells were 
still dividing, as indicated by a trend of an increase in the percentage of cells in 
G2/M phase.  It was evident that addition of stroma significantly decreased the 
percentage of non-dividing cells (G0/G1) and significantly increased the amount of 
dividing cells (S, G2/M). With the addition of IL7, similar viability was observed in 
both MIEV and PKCα-KR cells, and IL7 further increased the amount of 
proliferating PKCα-KR cells (as marked by an increase in percentage of S and 
G2/M and a decrease in G0/G1 phases of cell cycle).  Collectively these data 
indicate that indeed the increased capabilities of the PKCα-KR cells to proliferate 
are microenvironment dependent.  
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The process whereby a normal cell transforms into a leukaemic cell involves the 
progressive acquisition of genetic abnormalities leading to inhibition of tumour 
suppressors and overexpression or activation of oncogenes within a certain 
biological system.  An important group of genes, the cyclins are often deregulated 
in transformed cells.  In particular, cyclin D1 is often overexpressed in some 
cancers, including breast cancer, colorectal carcinoma and lymphoid malignancies 
such as mantle cell lymphoma (Weinstein 2000).  In these cancers, the 
overexpression of cyclin D1 plays a crucial role in cell transformation, leading to 
increased proliferation and tumorigenesis (Weinstein 2000). In CLL, cyclin D1 
mRNA is expressed, whereas it is not within normal B cells (Gladkikh et al. 2010).  
In concordance with these findings, within the mCLL model, cyclin D1 mRNA and 
protein were upregulated both in vitro and in vivo. Interestingly, there was a 
notably higher amount of cells that stained for cyclin D1 that were not B220+, 
perhaps implying an accessory oncogenic role for cyclin D1 whereby it is 
expressed within the epithelium and cells surrounding the CLL cells.  In human 
CLL, cyclin D1 mRNA and protein is upregulated upon co-culture with 
microenvironmental simulatory conditions (NTL and NTL-CD154).  In addition, 
some human CLL LN biopises were positive for cyclin D1, indicating that the 
findings within the mouse model translate at least partially to the human disease, 
implicating that cyclin D1 could be important within the proliferation centres of the 
lymphoid organs in CLL.   
Over-expression of cyclin D1 within HPCs did not result in an expansion of GFP+ 
cells as seen previously within the PKCα-KR cultures evident by a decrease in 
GFP+ cell population from 10.6% to 1.2%.  However the small population that 
remained GFP+ (1.2%), did display hallmark surface CLL phenotype makers.  
Although this experiment was conducted only once, with more reproducibility, it 
could indicate that cyclin D1 is important in the transformation of normal HPCs into 
CLL cells.  Perhaps over extended periods of time these cyclin D1 positive cells 
can accumulate and acquire further changes in order to generate CLL cells.   
To determine how cyclin D1 is regulated, we assessed the role of Sox2, one of the 
main transcription factors necessary for pluripotency during early embryogenesis 
and embryonic stem cell maintenance (Card et al. 2008). Sox2 was downregulated 
transcriptionally within the PKCα-KR in vitro cultures. Sox2 activates miR-302, 
which in turn negatively regulates cyclin D1 post-transcriptionally (Card et al. 
2008). The decreased expression of Sox2 mRNA within the PKCα-KR cultures 
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may be an indication of its reduced functionality, thereby its inability to activate 
miR-302 which represses cyclin D1, leading to an accumulation of cyclin D1.  
However, no protein analysis of Sox2 was conducted and further experiments 
should be considered before making such an assumption.  
In colon cancer cells, restored PKCα expression was shown to decrease cyclin D1 
levels through transcriptional and translational inhibition (Pysz et al. 2009).  In 
intestinal epithelial cells, PKCα can inhibit cyclin D1 expression through 
translational repressor 4EBP1 and attenuation of cap-dependent translation 
initiation (Hizli et al. 2006) in a PP2A dependent manner (Guan et al. 2007).  
4EBP1 is a binding partner of elF-4E, a known target of mTOR that has been 
documented to have a significant role in tumorigenesis and has a key role in 
mRNA translation and metabolism (Gingras et al. 2001; Averous et al. 2008).  
Often, the genes that are extensively translated are oncogenes that aid in 
transformation of normal cells, such as Mcl-1 and c-myc.  4EBP1 is regulated 
through phosphorylation at seven sites, four of which are associated with mTOR 
signaling (Mothe-Satney et al. 2000; Gingras et al. 2001). In its 
hyperphoshorylated form, 4EBP1 is not active and thus releases eIF-4E allowing 
for the formation of the eIF-4E complex that is responsible for cap-dependent 
translation.   
Within the PKCα-KR cultures, 4EBP1 is hyperphosphorylated and therefore not 
active. As such, it cannot repress translation of cyclin D1 which is highly 
expressed within the PKCα-KR cultures.  PKC activation with PMA/Iono results in 
an activation of 4EBP1 and reduction of cyclin D1 protein levels.  Pan-PKC 
activation includes PKCα reactivation, and thus it is plausible that reactivation 
leads to a downregulation of cyclin D1 as seen in other systems (Hizli et al. 2006; 
Guan et al. 2007). Inhibition of mTOR signaling with rapamycin treatment also 
results in a slight reduction of cyclin D1 levels, indicating that activated mTOR 
signaling within the PKCα-KR cultures is modulating 4EPB1 activity.  In fact, it has 
been demonstrated that mTORC1 is responsible for PP2A phosphorylation which 
inhibits PP2A activity leading to an accumulation of hyperphosphorylated (inactive) 
form of 4EBP1 (Gustafson & Weiss 2010).  Treatment with rapamycin, therefore, 
inhibits the ability of mTORC1 to inactivate PP2A resulting in hypophosphorylation 
and activation of translational repressor 4EPB1. A recent study shows that in 
mammalian cells, cell size and cell cycle progression are independent.  Whereas 
S6K is responsible for cell growth but not proliferation, 4EBPs were demonstrated 
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to be essential in control of mTORC1-dependent proliferation, but not cell growth 
(Dowling et al. 2010).  Similarly, in our mCLL model, an inhibition of mTORC1 via 
treatment with rapamycin results in a re-activation of 4EPB1 and an attenuation of 
proliferation.  It is unclear whether treatment with PP2A inhibitor OA in PKCα-KR 
cultures results in a greater hyperphosphorylation of 4EBP1 because in the 
untreated PKCα-KR cultures the top band is very highly expressed, and perhaps 
this method is not sensitive enough to see further changes in phosphorylation 
state.  
In human CLL cell line HG3 and primary human CLL cells 4EBP1 is 
hyperphosphorylated and therefore inactive.  Its phosphorylation state is regulated 
through mTOR signaling as seen through sensitivity to rapamycin treatment.   In 
two CLL samples tested cyclin D1 levels did not change upon treatment with 
rapamycin at 4 hr indicating that the protein is not regulated though mTORC1 in 
human CLL or that a longer time point is needed to see the effects of rapamycin 
treatment.  Again, a pan-mTOR inhibitor could prove to be more effective here.  A 
decrease in levels of c-myc was seen in HG3 cells and in one of the two CLL 
samples tested. Mcl-1 was only down-regulated in HG3 cells upon rapamycin 
treatment.  Indeed, both Mcl-1 and c-myc are known to be regulated by eIF-4E 
and cap dependent translation (Benedetti & Graff 2004; Huo et al. 2011).  
Treatment with PMA resulted in an increase of Mcl-1 and c-myc in both HG3 cells 
and primary CLL cells.  An increase in ERK activity was also seen in primary CLL 
samples that were analysed. Of note, ERK can also phosphorylate S6 kinases 
under specific conditions (Pende et al. 2004). These data suggest that inactivation 
of 4EBP1 through other PKCs or ERK could result in an increased translation or 
an accumulation of these proteins. A reduction in cyclin D1 protein was seen in 
one of the two CLL samples analysed after treatment with PMA.  Further studies in 
primary CLL samples are required to determine whether different patients differ in 
cyclin D1 expression, possibly correlated with prognostic data, and whether cyclin 
D1 expression is regulated through mTOR and PKC signaling.  
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Figure 4.2 PKCα-KR cells are larger than their MIEV counterparts. 
A Cells were cultured as described previously until day 13 of OP9:FL co-culture 
and subsequently photographed with an inverted light microscope under 10x 
magnification.   B Unstained cells were analysed by FACS, live-gated on 
FSC/SSC, and representative histographs were over-laid. 
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Figure 4.3 PKCα-KR cells express higher levels of CD98, CD71 and pP70 S6 
Kinase indicative of mTOR activation. 
A PKCα-KR and MIEV cells were incubated with CD98 and CD71 antibody and 
analyzed by FACS to determine levels of surface protein expression at day 13 
(PKCα-KR late culture was day 18).  Cells were first gated FSC/SSC, CD45+, 
GFP+ and CD19+ prior to CD98 and CD71 analysis. B Protein lysates were 
prepared from early, mid and late PKCα-KR and MIEV cultures prior to Western 
blot analysis of pP70 S6 Kinase and pERK.  GAPDH was used as a loading 
control. 
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Figure 4.4 Treatment with mTORC1 inhibitor rapamycin does not cause 
preferential induction of apoptosis in PKCα-KR cultures compared to their 
MIEV counterparts. 
Cells were harvested from MIEV and PKCα-KR cultures and treated with 
increasing concentrations of mTORC1 inhibitor rapamycin +/- OP9 for 24 hr (A) 
and 48 hr (B).  Apoptosis was assessed by Annexin V/7AAD staining.  Data are 
represented as means (± SEM) of 3 biological replicates.  The graphs are 
represented as percentage of no drug control (NDC).  p values were generated 
using the student’s unpaired t-test to compare groups (*p<0.05, ** p<0.005, 
***p<0.001). 
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Figure 4.5 Treatment with mTORC1 inhibitor rapamycin causes a significant 
attenuation of proliferation in PKCα-KR cultures. 
Cells were harvested from MIEV and PKCα-KR cultures and treated with 
increasing concentrations of mTORC1 inhibitor rapamycin for 24 hr (A) and 48 hr 
(B). Cells were incubated with BrdU for 2 hr prior to the endpoint. Data are 
represented as means (± SEM) of 3 biological replicates.  p values were 
generated using the student’s unpaired t-test to compare groups (*p<0.05, ** 
p<0.005, ***p<0.001). 
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Figure 4.6 A higher percentage of cells are undergoing cell division in PKCα-
KR cultures. 
A MIEV and PKCα-KR cells were cultured in medium alone, with OP9 stroma 
alone, or with OP9 stroma in the presence of cytokine IL7. Cells were stained with 
PI as described before and assessed by FACS. For percentage of cells in G0/G1, S 
and G2/M phases, the sub-G0 population was gated out prior to analysis. Data are 
represented as means (± SEM) of 3 biological replicates.  p values were 
generated using the student’s unpaired t-test to compare groups (*p<0.05, ** 
p<0.005, ***p<0.001). B Cells were harvested from MIEV and PKCα-KR cultures 
and incubated with BrdU for 2 hr.  Error bars represent S.D. of technical triplicates.   
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Figure 4.7 PKCα-KR cells express higher levels of cyclin D1 transcripts and 
protein in vitro compared to MIEV counterparts. 
A RNA was isolated from MIEV and PKCα-KR cultures and subjected to qRT-PCR 
to determine levels of cyclin D1 mRNA at early (day 6), mid (day 10) and late (day 
17) in vitro cultures.  B qRT-PCR analysis of cyclin D1 transcript levels in spleen, 
tumour and B.M. of PKCα-KR injected Rag 1-/- mouse.  C Protein lysates were 
prepared from early (day 6) mid (day 13) and late (day 26) MIEV and PKCα-KR 
cultures to determine levels of cyclin D1 protein by Western blot.  D qRT-PCR 
analysis of Sox2 mRNA in early (day 3, 6), mid (day 13, 14) and late (day 28) 
cultures.  For all qRT-PCR graphs, error bars represent S.D. of technical 
triplicates.  B and T cells isolated from wild type spleen were used as an additional 
control.     
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Figure 4.8 Cyclin D1 protein is found within B cell follicles of spleens of 
PKCα-KR HPC-injected mice. 
Consecutive paraffin embedded spleen sections from MIEV and PKCα-KR injected 
mice were stained for B220 and cyclin D1 respectively. 
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Figure 4.9 Over-expression of cyclin D1 in HPCs does not result in an 
expansion of GFP+ cells. 
Full length cyclin D1 was cloned into MIEV retroviral backbone and packaging 
lines were generated as described in (see section 2.1.1). FL HPCs were 
transduced with cyclin D1 and co-cultured with OP9 and cytokines in a B cell 
generating system and subjected to FACS at different stages of culture (day 1, 14, 
17, 22).  Haematopoietic (CD45+) cells were live and size gated (FSC vs SSC) 
and percentages of GFP+ cells are shown.   
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Figure 4.10 Overexpression of cyclin D1 in HPCs  results in generation of 
CLL surface phenotype. 
HPCs were retrovirally transduced to express MIEV, PKCα-KR or cyclin D1 and 
subjected to FACS analysis at day 14 of FL:OP9 co-culture to determine 
expression of CD19, CD5 and CD23. Haematopoietic (CD45+) cells were live and 
size gated (FSC vs SSC) and CD19 vs CD23, and CD19 vs CD5 analysis shown.  
For cyclin D1 transduced cells, GFP+ and GFP- populations are shown.  
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Figure 4.11 Cyclin D1 is regulated through 4EBP1 in PKCα-KR cultures in a 
mTORC1 and PKC-dependent manner. 
Western blot of day 14 MIEV and PKCα-KR cultures treated with 30 nM rapamycin 
(rapa), 100 nM PMA plus 1 µg/ml ionomycin (PMA/Iono), or 2.5 µM Okadaic Acid 
(O.A) for 1 hr. β tubulin was used as loading control. 
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Figure 4.12 Phosporylation of 4EBP1 is regulated by mTORC1, whereas PKC 
stimulation leads to upregulation of Mcl-1, pP70 S6 Kinase and c-myc in CLL 
cell line HG3. 
Western blot of HG3 cell line cultured with NTL mouse fibroblasts for 44 hr 
followed by treatment with 30 nM rapamycin (rapa) or 100 nM PMA plus 1 µg/ml 
ionomycin (PMA/Iono) for an additional 4 hr. β tubulin and actin were used as 
loading controls. 
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Figure 4.13 4EBP1 phosphorylation is sensitive to rapamycin treatment in 
human CLL, and PMA stimulation leads to upregulation of Mcl-1 and c-myc. 
Western blot of primary CLL sample cultured on NTL cells for 44 hr followed by 
treatment with 30 nM rapamycin (rapa) or 100 nM PMA plus 1 µg/ml ionomycin 
(PMA/Iono) for an additional 4 hr. β tubulin was used as loading control. 
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Appendix 4-A Co-culture of human CLL cells with stroma upregulates cyclin 
D1 mRNA and protein. 
Cyclin D1 mRNA (left) and protein (right) expression of a primary CLL sample 
cultured in in vitro with NTL cells or NTL-CD154 cells in the presence of IL4. This 
experiment was conducted by Dr. Emilio Cosimo.  
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Appendix 4-B Cyclin D1 is expressed in human lymph node of CLL patients.  
Paraffin embedded lymph node biopsies from CLL patients were stained with 
cyclin D1.  Two separate patients are shown. Out of 7 tested, 3 were positive for 
cyclin D1.  Isotype control is also depicted. This experiment was conducted by Dr. 
Mark Catherwood (Belfast City Hospital). 
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Chapter 5: 
PKCα-KR B cells exhibit ability to lineage switch to T cells upon Notch-
ligation 
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5.1 Introduction 
5.1.1 Plasticity of pluripotent HSCs 
Haematopoiesis is normally a highly regulated process whereby an HSC 
subsequentally commits toward a myeloid or a lymphoid lineage in a hierarchical 
manner, however lineage plasticity, although rare, is not impossible.  Cells can 
undergo transdifferentiation whereby the lineage-specific gene program of a cell is 
replaced by an alternate lineage-specific program.  Alternatively, differentiated 
cells can primarily dedifferentiate into a more primitive state and proceed to 
redifferentiate into another lineage (Figure 5.1) (Greer 2005).   
 
Figure 5.1 Transdifferentiation, dedifferentiation and redifferentiation 
 
Although ordered B cell development was thought of as unidirectional, more 
recently, attention has been brought to the apparent plasticity of B cells. Indeed, 
introduction of a nucleus from a fully differentiated B cell into an enucleated 
embryonic stem cell gave rise to a broad spectrum of cell lineages (Gurdon et al. 
1975; Hochedlinger & Jaenisch 2002). Similarly, reprogramming of differentiated B 
cell into macrophages through inhibition of PAX5 activity and subsequent 
downregulation of CD19 can occur when expression of C/EBPα and C/EBPβ is 
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enforced (Xie et al. 2004).  Also raf/ras oncogenes and activated M-CSF receptor 
are capable of reprogramming oncogene-immortalized B cell lines into 
macrophages (Klinken et al. 1988; Borzillo et al. 1990).  Therefore, although in the 
most probable scenario, the developmental pathway of an HSC to a fully 
functional, antigen-reactive B cell is usually directional, nevertheless it is incorrect 
to say that it is irreversible (Honjo & Neuberger 2004).  Indeed, redifferentiation 
can be induced by external stimuli or increases/decreases in levels of specific 
transcription factors that regulate cell fate (Honjo & Neuberger 2004).  
As mentioned previously (Section 1.1.4), PAX5 is a master B cell regulator that is 
present in all stages of B cell development apart from plasma cells.  Of note, 
PAX5-/- pro-B cells are very sensitive to environmental stimuli and their fate is 
heavily determined by cytokines and stroma.  For example, co-culture of PAX5-/- 
pro-B cells with stroma and IL7 retains their pro-B state.  Alternatively, removal of 
stroma and co-culture with alternative cytokines promotes differentiation of PAX5-/- 
pro-B cells into other lineages, such as NK cells, macrophages, dendritic cells, 
osteoclasts or granulocytes (Nutt et al. 1999; Schaniel et al. 2002; Carotta et al. 
2006).  Specifically, addition of IL15 causes a de-differentiation into the NK lineage 
(Carotta et al. 2006), whilst co-culture with M-CSF induces macrophage 
differentiation (Nutt et al. 1999).   The newly formed alternate fate cells (NK or 
myeloid) still carry immunoglobulin DJ rearrangements reminiscent of their pro-B 
cell origin.  In addition, in vivo adoptive transfer of PAX5-/- cells into RAG2-/- mice 
causes de-differentiation in CD8- or CD8+ dendritic cells.  Normal T cell 
development is also observed in the thymus and periphery (Rolink et al, 1999).  
Later analysis of these mice demonstrated the additional presence of myeloid cells 
and erythrocytes (Schaniel et al. 2002). Importantly, these PAX5-/- pro-B cells 
display self-renewal and long-term reconstitution potential whereby they travel to 
the BM prior to re-differentiating again (Schaniel et al. 2002).  Therefore deletion of 
PAX5 allows for the generation of cells that closely resemble pHSCs.   
5.1.2 T cell development 
T lymphopoiesis is characterised by a series of commitment events such as TCR 
V(D)J gene rearrangement (see Section 5.1.2.1), TCRβ selection and positive and 
negative selection of thymocytes (Ciofani & Zúñiga-Pflücker 2007).  These events 
are coupled by the ordered expression of specific phenotypic markers, namely 
CD4 and CD8 co-receptors.  BM derived HSCs within the thymus develop into 
immature thymocytes which are CD4-CD8- (DN) (Figure 5.2A).  These DN cells 
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are further characterised into four developmental stages that are present within the 
outer thymic cortex (DN1, DN2, DN3 and DN4) based on the surface expression of 
CD117 and CD25: CD117+CD25-(DN1), CD117+CD25+(DN2), CD117-CD25+(CD3) 
and CD117-CD25-(DN4) (Ciofani & Zúñiga-Pflücker 2007) (Figure 5.2B).  At DN3, 
thymocytes rearrange their TCRβ and thus commit toward the T cell lineage.  β-
selection allows for a functionally rearranged TCRβ to complexes with pTα and 
form the pre-TCR (Kearse 2000).  A dysfunctional TCRβ rearrangement results in 
apoptosis.  Signaling via the pre-TCR complex leads to proliferation and transition 
into the DP stage (CD4+CD8+) which is followed by selection toward the SP (CD4+ 
or CD8+) stage (Ciofani & Zúñiga-Pflücker 2007). The DP stage also marks the 
initiation of TCRα rearrangement.  CD3ε is also important at this stage in that it 
forms a complex with the TCR which is important in intracellular signal-
transduction (Gold et al. 1986).  A complete αβ-TCR/CD3 complex in DP 
thymocytes induces positive and negative selection resulting in mature SP 
thymocytes. Here, the second checkpoint occurs whereby recognition by DP cells 
of major histocompatibility complex (MHC) class I molecules leads to CD8 
committed SP cells and recognition of MHC class II molecules leads to CD4 
committed SP cells within the inner cortex of the thymus (Figure 5.2A)(Kearse 
2000).  Thymocytes that improperly rearrange TCRα or generate TCRα/β complex 
with high self-MHC affinity are negatively selected for resulting in apoptosis.  
Positively selected T cells can now move out of the thymic medulla and migrate 
into the periphery.   
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Figure 5.2 T cell development 
A T cell development within the thymus.  B Expression of surface molecules 
during T cell development; CD117+CD25-(DN1), CD117+CD25+(DN2), CD117-
CD25+(CD3) and CD117-CD25-(DN4). 
5.1.2.1 TCR rearrangement 
The α and β chains of the TCR consist of variable (V) amino-terminal and constant 
(C) regions.  Similarly to lights chains of IgM, TCRα contains V and joining (J) 
gene segments (Vα, Jα), whilst TCRβ contains V, J and D gene segments (Vβ, Jβ, 
D) (K. P. Murphy et al. 2008).  TCRα is located on chromosome 14 and consists of 
leader sequence (L) followed by 70-80 Vα segments (Figure 5.3).  61 Jα segments 
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are located a distance away from Vα segments followed by one C gene.  TCRβ is 
located on chromosome 7 and contains an L sequence followed by 52 functional 
Vβ segments, and two distal clusters of 6 or 7 Jβ segments, each preceded with a 
separate Dβ segment and followed by a separate C segment (Figure 5.3) (K. P. 
Murphy et al. 2008). 
 
 
 
Adapted from Murphy et al. 2008 
Figure 5.3 Germline organization of TCRα and TCRβ loci 
 
During T cell development TCR gene segments rearrange in the thymus to form 
complete V-domain exons.  For TCRα chain generation, Vα rearranges to Jα 
forming VJα (Figure 5.4).  Transcription and subsequent splicing of VJα to Cα 
generates mRNA that is subsequently translated to TCRα protein.  For TCRβ chain 
generation, similarly to IgMH, rearrangement of Vβ, Dβ, and Jβ forms a functional 
VDJβ V-region exon (Murphy et al. 2008). Transcription and splicing of VDJβ to Cβ 
generates mRNA that is subsequently translated to TCRβ protein.  The two chains, 
α and β join to form a α:β TCR heterodimer (Figure 5.4). 
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Adapted from Murphy et al. 2008 
Figure 5.4 TCRα and TCRβ loci rearrangement 
 
The key difference between IgM genes and genes encoding the TCR is effector 
function.  In B cells (see Chapter 1), secreted antibodies’ heavy chain C region 
isotypes trigger an effector mechanism, whereas in T cells cell-cell contact and not 
the TCR directly mediates effector mechanisms (Murphy et al. 2008).  The TCR’s 
main role is antigen recognition, and thus the C regions of the α and β TCR loci 
are less complex than IgMH.  
5.1.2.2 Role of Notch in T cell commitment 
T cell development is regulated via transcription factors such as GATA3, TCF1 
and Notch downstream transcription regulator Deltex (Joulin et al. 1991; Matsuno 
et al. 1998; Liu & Lai 2005; Weber et al. 2011).  Notch proteins belong to a family 
of type I transmembrane receptors that are involved in regulating cell fate (Deftos 
& Bevan 2000).  Notch signaling involves the interaction between one of five Notch 
ligands of the Jagged (1, 2) or Delta-like (1, 3, 4) families and one of four Notch 
receptors (1-4) (Sandy et al. 2012). When ligand binds receptor an S2 cleavage 
site is exposed to a metalloprotease which cleaves Notch within or in high 
proximity to its transmembrane domain.  An intra-membrane protease complex, or 
the ϒ-secretase complex conducts the final cleavage of Notch, releasing its 
intracellular domain to translocate to the nucleus allowing for interaction with the 
CBF1 transcription factor changing it from a repressor to an activator of gene 
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transcription (of for example Hes1, Deltex and Notch1).   In T cell development, 
deletion of Notch1 in BM stem cells (BMsc)s or newborn mice results in a block in 
T cell development and an upregulation of B cell markers on CD25-CD44+CD4-
CD8- (DN1) thymic cells, highlighting that Notch signaling is necessary for 
commitment toward the T cell fate (Tomita et al. 1999), and lack of Notch signals 
results in differentiation to a B cell lineage. Introduction of BMscs expressing 
constitutively active Notch1 into irradiated hosts gives rise to CD4+, CD8+ and Thy-
1+ thymus-independent T cells, whilst no B cells were observed (Pui et al. 1999).  
Therefore Notch signaling plays a crucial role in T or B cell lineage commitment.  
In addition to its role in T cell commitment, Notch1 is important in later stages of T 
cell development such as αβ T cell commitment versus Υδ T cell commitment 
(Washburn et al. 1997), and in maturation of CD4+ and CD8+ SP thymocytes 
(Deftos et al. 1998).   
5.1.2.3 In vitro system to assess T cell development 
Zúñiga-Pflücker and colleagues developed an in vitro T cell system using OP9-
DL1 cells.  OP9-DL1 cells are OP9 cells that ectopically express the Notch ligand 
DL1, thus losing the ability to support B cell lymphopoiesis and acquiring the ability 
to support T cell lymphopoiesis (Schmitt & Zúñiga-Pflücker 2002).  
Within a B cell environment, subversion of PKCα signaling in HPCs resulted in 
transformed B cells that resemble human CLL cells (see Chapter 3; Nakagawa et 
al. 2006).  Because lineage switching has been implicated in a number of B cell 
malignancies (Mikkola et al. 2002; Cobaleda et al. 2007), we were therefore 
interested in investigating whether PKCα-KR transformed B cells were capable of 
lineage trans-differentiation. 
5.2 Aims and Objectives: 
In order to assess whether PKCα-KR transduced B cells have the potential to 
lineage switch, the specific aims of this chapter were to: 
i.   Compare the expression of B cell specific genes between the MIEV and 
PKCα-KR B cells; 
ii. Assess the ability of MIEV and PKCα-KR B cells to differentiate into other 
lineages upon Notch ligation by co-culture with OP9-DL1;  
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iii. Investigate whether B and T cell specific genes are differently expressed 
between the MIEV and PKCα-KR cultures upon Notch ligation and assess 
implicated molecular mechanisms. 
5.3 Results 
5.3.1 PKCα-KR B cells express B cell specific genes at higher levels than 
MIEV counterparts 
In human CLL B cells, CD19 surface expression is diminished as compared to 
normal B cells (Ginaldi et al. 1998; Cabezudo et al. 1999; Yang et al. 2005). In 
contrast, one of the early notable features of PKCα-KR transduced B cells was the 
higher expression of surface marker CD19 (Figure 3.3 and Figure 5.5A) compared 
to MIEV control.  Hence it was of interest to determine whether other B cell 
specific genes are upregulated within the PKCα-KR expressing cells, particularly in 
vivo because of the importance of microenvironmental interactions for B cell 
development.  Therefore MIEV and PKCα-KR transduced HPCs were injected into 
neonatal RAG1-/- mice and spleens were excised 4 weeks post injection.  
Lymphocytes were isolated from the spleen and sorted for GFP+Lin-CD45+CD19+ 
B cells.  Similarly B and T cells were sorted from wildtype mice to be used as 
additional controls.  Analysis of B cell specific genes PAX5, EBF1, CD79a and T 
cell specific gene CD3ε was conducted with qRT-PCR and revealed that PKCα-KR 
cells express higher amounts of B cell specific genes PAX5, EBF1 and CD79a.  
As expected, only the T cells expressed CD3ε (Figure 5.5B).   
5.3.2 PKCα-KR B cells have the ability to lineage switch 
In order to determine whether PKCα-KR B cells have the potential to lineage 
switch as seen in other malignancies, MIEV and PKCα-KR transduced HSCs  
were isolated by cell sorting (GFP+Lin-CD45+B220-CD19-CD117hiSca1hi) and co-
cultured on OP9 stroma.  Thereafter, the late pro-B cell population was sorted 
(GFP+Lin-CD45+B220+CD19+CD117+) and subsequently co-cultured with OP9-
DL1 cells that ectopically express Notch ligand DL1, and thus support T cell 
development (Schmitt & Zúñiga-Pflücker 2002).  Unlike in MIEV-expressing CD19+ 
cells, co-culture of PKCα-KR-expressing CD19+ cells with OP9-DL1 resulted in the 
generation of cells expressing markers indicative of alternative lineages (Figure 
5.6). FACS analysis of CD19, CD11b, NK1.1, CD4 and CD8 surface markers 
demonstrates that whereas <0.2% of MIEV cultures expressed macrophage 
marker CD11b, >1% of PKCα-KR cultures expressed the myeloid marker (Figure 
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5.6).  In addition 2.7% of cells were CD19-CD11b- within the PKCα-KR cultures as 
compared to 0.8% in MIEV cultures, indicating lineage switching to other cell 
types.  When NK cell marker NK1.1 expression was assessed, MIEV cultures 
contained <0.1% NK1.1+ cells compared to 3.6% within the PKCα-KR cultures.  
FACS analysis of CD8 and CD4 revealed that 2.4% of PKCα-KR cells were SP 
CD8+, 3.7% CD4+ and 1.2% DP compared to no CD4 nor CD8 positive cells within 
the MIEV cultures. Collectively these data indicate that CD19+ PKCα-KR cells are 
capable of lineage switching upon Notch ligation to macrophages, NK cells and to 
T cells.  
5.3.3 CD19+ PKCα-KR lineage switching cells aberrantly express T cell 
specific genes  
Since it was demonstrated that PKCα-KR expressing B cells have the ability to 
lineage switch to T cells by surface marker expression analysis, we aimed to 
determine whether CD19-CD4+CD8+ T cells generated from OP9-DL1 co-cultures 
of CD19+ PKCα-KR cells express T cell specific genes.  Therefore CD19-Lin- 
progenitor MIEV cells and CD19+Lin- PKCα-KR B cells were sorted from OP9 co-
cultures and subsequently co-cultured with OP9-DL1. The MIEV CD19-Lin- cells 
developed into T cells (CD4+CD8+) as expected, and also into B cells 
(CD19+NK1.1-), indicating that the sorted CD19- progenitors were already primed 
toward the B cell lineage (Figure 5.7 left).  Within the PKCα-KR sorted CD19+Lin- 
cultures, some cells retained CD19 expression whilst others switched into T cells 
(Figure 5.7 left).  CD8+CD4+ T cells and CD19+NK1.1- B cells were subsequently 
sorted from the cultures using the indicated gates (Figure 5.7 left) and subjected to 
qRT-PCR in order to determine the expression of T cell specific genes (pTα, 
CD3ε), and B cell specific gene PAX5 (Figure 5.7 right).  Within the MIEV cultures, 
the sorted T cells expressed T cell specific genes (pTα, CD3ε) and GATA3, 
whereas they did not express PAX5, whilst the sorted B cells expressed PAX5 and 
not the T cell specific genes as expected.  Similarly, the lineage switched B cells 
(now T cells) within the PKCα-KR cultures expressed T cell specific genes, 
although at lower levels than T cells generated from progenitor cells within MIEV 
cultures (Figure 5.7 right), and did not express PAX5.  Interestingly the cells that 
remained CD19+ within the PKCα-KR cultures expressed low levels of T cell 
specific genes (Figure 5.7 right).  Collectively these data demonstrate the potential 
of CD19+ PKCα-KR expressing cells to lineage switch into T cells upon Notch 
  151 
ligation as marked by T cell specific surface protein expression and upregulation of 
T cell specific genes.    
5.3.4 Lineage switching of PKCα-KR CD19+ B cells occurs gradually via a 
transitional CD19+CD90+ stage 
Since it was demonstrated that PKCα-KR expressing CD19+ B cells were capable 
of lineage switching into T cells upon Notch ligation, we aimed to determine when 
this switch occurs.  Therefore retrovirally transduced MIEV and PKCα-KR HSCs 
were cultured on OP9 for 9 days and afterward sorted to isolate the pro-B cell 
population (GFP+CD19+B220+CD117+Lin-) which was subsequently cultured on 
OP9-DL1 stroma for an additional 10 days.  Surface expression of B cell maker 
CD19 and T cell marker CD90 revealed a large CD19+CD90+ population within 
PKCα-KRα-KR cultures, indicating that lineage switching of CD19+CD90- cells 
toward the T cell fate (CD19-CD90+) happens through a transitional CD19+CD90+ 
stage (Figure 5.8).  In fact, whereas the majority of sorted ProB cells within the 
MIEV cultures remained CD19+, 11% of sorted ProB cells within the PKCα-KR 
cultures expressed both CD19 and CD90 (compared to <2% within the MIEV 
cultures).  In addition, as previously demonstrated 1.5% of sorted ProB cells within 
the PKCα-KR culture lineage switched into T cells as demonstrated by loss of 
CD19 and upregulation of CD90.   
Previously it was demonstrated that PKCα-KR lineage switched B cells (now T 
cells) expressed T cells specific genes (Section 5.3.3).  Therefore it was of interest 
to determine whether the upregulation of these genes occurred sequentially, in line 
with the transitional stage of CD19+CD90+ cells within the PKCα-KR lineage 
switching cultures. Therefore, CD19+CD90-, CD19+CD90+ MIEV and PKCα-KR 
expressing cells and CD19-CD90+ PKCα-KR cells were isolated from  OP9-DL1 
cultures (post 9 day OP9 culture) as indicated in Figure 5.8, and analysed by qRT-
PCR to determine the expression of B cell specific genes (E2A, EBF1 and PAX5) 
and T cell specific genes (CD3ε, TCF1, Deltex and pTα). PKCα-KR expressing 
CD19+CD90- cells expressed B cell specific genes E2A, EBF1 and PAX5 at higher 
levels than their MIEV CD19+CD90- counterparts (Figure 5.9), similar to that noted 
in Figure 5.5.  The transitional CD19+CD90+ stage in both MIEV and PKCα-KR 
culture was marked by the decrease in B cell specific genes E2A, EBF1 and PAX5 
(significant for E2A within MIEV cultures and for E2A and PAX5 within PKCα-KR 
cultures).  The CD19-CD90+ population within the PKCα-KR expressing cells 
exhibit a further significant decrease in all three B cell specific genes investigated.  
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The sequential downregulation of B cell specific genes within the PKCα-KR 
transitioning cultures (CD19+CD90-!CD19+CD90+!CD19-CD90+) is coupled with 
a  sequential upregulation of T cell specific genes CD3ε, TCF1, Deltex and pTα 
indicating that expression of PKCα-KR allows the CD19+ B cells to become 
sensitive to Notch signaling through DL1 ligation.   
5.3.5 PKCα-KR transdifferentiated B cells (now T cells) maintain 
rearrangements of antibody producing Ig genes  
Although it was demonstrated that CD19+ PKCα-KR-expressing B cells can 
undergo lineage switching as a result of Notch ligation through analysis of surface 
markers and T-lineage associated genes, to demonstrate that these T cells 
originated from B cells, IgH rearrangement was investigated within these cells.  
Therefore, CD19+CD90-,CD19+CD90+ MIEV and PKCα-KR cells and CD19-CD90+ 
PKCα-KR cells were sorted from OP9-DL1 cultures (after OP9 cultures as 
described in 5.3.4) and subjected to genomic PCR to determine D-JH and V-DJH 
rearrangements (indicative of B cell origin) and TCRβ rearrangement at the D-Jβ 
level (indicative of T cell origin).  The analysis revealed that the CD19+CD90- and 
CD19+CD90+ populations within both MIEV and PKCα-KR cultures had completed 
IgH gene rearrangement at the D-JH and V-DJH level (Figure 5.10) as expected.  
CD19-CD90+ PKCα-KR cells also rearranged TCRβ at the D-Jβ level confirming 
that they are T cells. However D-JH and V-DJH gene rearrangement was also 
present in the lineage switched CD19-CD90+ PKCα-KR cells. Collectively these 
data confirm that the lineage switched T cells had a B cell origin.  Notably, no D-Jβ 
rearrangement occurred within the PKCα-KR CD19+CD90+ transitioning population 
suggesting that although these cells possess potential to convert into T cells, they 
have not yet fully committed to the T cell lineage.    
5.3.6 Lineage switching from B cells to T cells occurs by E2A and PAX5 
downregulation  
Since it was demonstrated that the gradual lineage switching from B cells into T 
cells occurs via a downregulation of B cell specific genes and upregulation of T 
cell specific genes at the transcript level (Figure 5.9), it was of interest to 
determine if the same occurs at a functional (protein) level. Therefore, 
CD19+CD90-,CD19+CD90+ MIEV and PKCα-KR cells and CD19-CD90+ PKCα-KR 
cells were sorted from OP9-DL1 cultures (after OP9 co-cultures as described in 
5.3.4) and subjected to western blot analysis to determine protein levels of E2A 
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protein product E47 and its downstream target PAX5, and T-cell specific protein 
Lck (Figure 5.11 and Appendix 5-A). Within the PKCα-KR cultures levels of PAX5 
and E47 protein are decreased in the CD19-CD90+ lineage switched cultures, 
whilst levels of Lck are increased. Total levels of ERK and β tubulin remained 
constant in all MIEV and PKCα-KR cultures (Figure 5.11; Appendix 5-A). 
5.3.7 ERK signaling is upregulated as B cells transition into T cells within 
the PKCα-KR cultures 
Since it was demonstrated that lineage switching within the PKCα-KR cultures 
occurred via a downregulation of E2A, it was of interest to determine the signaling 
pathways implicated in this phenomenon. E2A proteins are known to be negatively 
regulated by inhibitor of differentiation (Id) protein family members (Kee 2009).  Id2 
and Id3 expression was analysed within the cultures to determine levels of their 
transcripts.  Analysis shows that levels of Id2 are upregulated and levels of Id3 are 
downregulated within the lineage switched PKCα-KR cultures (Figure 5.12). 
Since ERK-MAPK signaling has also been shown to regulate E2A gene products 
in T and B cell progenitors ( Bain et al. 1994; King et al. 2007), pMEK and pERK 
levels were investigated in PKCα-KR lineage switched cultures. Western blot 
analysis of CD19+CD90- MIEV and CD19+CD90-, CD19+CD90+ and CD19-CD90+ 
PKCα-KR cells sorted from OP9-DL1 cultures (after OP9 co-cultures as described 
in 5.3.4) revealed an upregulation in MEK/ERK-MAPK signaling cascade within 
the lineage switching cultures, whilst total ERK and MEK mirrored the loading 
controls (Figure 5.13).  
5.4 Discussion 
The idea that commitment toward a mature cell type is unidirectional and 
irreversible can no longer be considered a dogma.  Recent studies suggest that 
committed B cells can reverse to other lineages (Cobaleda et al. 2007; Mikkola et 
al. 2002; Nakagawa et al. 2012). One study demonstrates that PAX5 inactivation 
gives differentiated B cells the ability to de-differentiate, and ultimately become 
macrophages in vitro or T cells in vivo (Mikkola et al. 2002). Another study 
demonstrated that conditional PAX5 deletion in mature B cells of mice allowed for 
de-differentiation into uncommitted progenitors in vivo and subsequent 
differentiation into T-cells within the thymus (Cobaleda et al. 2007).  Mice with 
PAX5 deleted B cells also developed aggressive progenitor cell lymphomas 
(Cobaleda et al. 2007).   
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Similarly, we show here that PKCα-KR cells display the ability of lineage plasticity, 
whereby fully differentiated B cells can reverse their lineage into T cells via a 
downregulation of B cell specific genes (CD19, PAX5, EBF1, E2A) and an 
upregulation of T cell specific genes (pTα, CD3ε, TCF1, Deltex).   
Upon notch ligation, PKCα-KR CD19+ cells can switch to macrophages, NK cells 
and T cells demonstrated by surface marker analysis. In order to determine 
whether the lineage switched CD19+ PKCα-KR expressing cells expressed T cell 
specific genes, mRNA from sorted B and T cells from MIEV progenitor cultures on 
OP9-DL1 and CD19+ PKCα-KR cultures on OP9-DL1 was analyzed by qRT-PCR.  
In fact, the T cells generated from CD19+ PKCα-KR cells expressed T cells 
specific genes pTα, CD3ε and upregulated GATA3.  By co-staining with CD19 and 
CD90 (a commonly used T cell marker expressed on mouse thymocytes and 
peripheral T cells), we demonstrated that CD19+ B cells within notch-ligated 
PKCα-KR cultures go through a transitional CD19+CD90+ stage before fully losing 
expression of CD19.   The transition from B cells into T cells is marked by the 
decrease in B cell specific genes E2A, EBF1 and PAX5, and an increase in T cell 
specific genes CD3ε, TCF1, Deltex and pTα at transcript levels. Importantly 
lineage switched PKCα-KR B cells (now T cells) maintain rearrangements of Ig 
genes indicative of their origin, whilst also demonstrating evidence of TCRβ 
rearrangement at the D-Jβ level.  However, PKCα-KR CD19+CD90+ cells show no 
TCRβ rearrangement, suggesting that although these cells have the potential of 
lineage converting, they have not entirely committed to the T cell lineage or that 
PAX5 is still inhibiting rearrangement of the TCRβ gene. 
We demonstrated that lineage conversion from B cells to T cells within the PKCα-
KR cultures upon Notch ligation occurs via degradation of E2A isoform E47 at the 
protein level. This is not surprising because although E2A is required in the early 
stages of T cell development, its activity is subsequently downregulated as 
thymocytes mature (Barndt et al. 1999; Gretchen Bain et al. 1999; Engel et al. 
2001; Pan et al. 2002; Taghon et al. 2006; Jones & Zhuang 2007). E2A 
degradation is coupled with PAX5 protein downregulation and upregulation of the 
protein tyrosine kinase Lck. Lck is important in the DN2-DN3 stage of T cell 
development (Buckland et al. 2000). The degradation of E2A could be a result of 
the increase in ERK-MAPK signaling activation within the PKCα-KR B cells as they 
transition into T cells in comparison to the control MIEV cells.  In fact, in T and B 
cell progenitors, ERK-MAPK signaling can regulate E2A gene products (Bain et al. 
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1994; King et al. 2007). E proteins, like E2A can also interact with antagonistic 
helix-loop-helix Id proteins that when activated inactivate E proteins’ DNA binding 
activity (Benezra et al. 1990; Kee 2009). Id protein expression is diminished as a B 
cell matures, correlating to Ig enhancer function (Saisanit & Sun 1995).  Id over-
expression in vivo was found to repress Ig enhancers implicating their inhibitory 
role in B cell development (Wilson et al. 1991). Within the PKCα-KR lineage 
switched cultures, Id2 expression was upregulated in the CD19-CD90+ cells while 
absent in the B lineage cells.  However, Id3 expression was reduced within the 
PKCα-KR CD19-CD90+ cells compared with the CD19+ cells.  This is surprising 
because others have shown that Id3 expression is activated in thymocytes by 
ERK-MAPK signaling which in turn results in a decrease in E2A’s DNA binding 
activity (Bain 2001). In addition Lck activity was shown to be able to induce Id3 
expression and decrease E12/E47 DNA binding activity (Bain et al. 2001). 
Collectively these data indicate that committed CD19+ cells within the PKCα-KR 
cultures are capable of lineage switching upon Notch ligation, by modulating E2A 
function.  The lineage switched T cells expressed T cells specific surface markers, 
T cell specific genes and carried TCRβ gene rearrangements. In addition, these 
lineage switched cells carried IgH gene rearrangements indicating their B cell 
origin.   
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Figure 5.5 PKCα-KR cells express B cell genes at higher levels than their 
control counterparts 
A MIEV and PKCα-KR transduced HPCs were co-cultured with OP9 as previously 
described and stained with CD45 and CD19. Haematopoietic (CD45+) cells were 
live and size gated (FCS vs SSC) and an over-lapping histogram of CD19 
expression is displayed.   B Neonatal Rag1-/- mice were injected with MIEV or 
PKCα-KR transduced HPCs and spleens were excised 4 weeks post injection.  
Lin-CD19+GFP+ haematopoietic (CD45+) cells were sorted from spleens and 
subjected to qRT-PCR to determine relative levels of B cell specific genes PAX5, 
EBF1 and CD79a and T cell gene CD3ε. Data are expressed as means of 
technical triplicates ± SD and are representative of (>3) biological replicates. 
Sorted B and T cells obtained from wildtype ICR mice were used as controls.   
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Figure 5.6 Co-culture of PKCα-KR CD19+ B cells with OP9-DL1 promotes 
differentiation into other lineages 
Sorted MIEV and PKCα-KR transduced HSC cells (GFP+Lin-CD45+B220-CD19-
CD117hiScaIhi) were cultured on OP9 for 9 days. Pro-B cells were then sorted from 
these cultures (GFP+CD19+B220+CD117+Lin-), subsequently cultured on OP9-DL1 
for an additional 9 days and analysed for expression of CD19, CD11b, NK1.1, 
CD4 and CD8 surface markers.   
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Figure 5.7 CD19+PKCα-KR cells express T cell specific markers 
MIEV and PKCα-KR transduced HSCs were co-cultured with OP9 for 9 days as 
previously described.  CD19-Lin- MIEV cells and CD19+Lin-PKCα-KR cells were 
sorted from these cultures and subsequently co-cultured with OP9-DL1 for an 
additional 20 days.  The resultant CD19+B cells and CD4+CD8+ T cells were sorted 
from the cultures using the gates indicated above and subjected to qRT-PCR  to 
determine transcript levels of T cell specific genes pTα, CD3ε and GATA3 and B 
cell specific gene PAX5. HPRT was used as the houskeeping gene and results are 
expressed as fold change normalized to T cells.  Data are expressed as mean ± 
SEM of 3 biological replicates.  p values were generated using the student’s 
unpaired t-test (*p<0.05, **p<0.005, ***p<0.001) 
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Figure 5.8 Lineage switching of PKCα-KR CD19+ occurs through a 
transitional CD19+CD90+ stage 
Retrovirally transduced MIEV and PKCα-KR HSCs were co-cultured with OP9 
cells for 9 days, proB cells were sorted and subsequently co-cultured on OP9-DL1 
for an additional 10 days.  Cells were then sorted according gates demonstrated 
above: 1=MIEV CD19+CD90-; 2=MIEV CD19+CD90+; 3=PKCα-KR CD19+CD90-; 
4=PKCα-KR CD19+CD90+; 5=PKCα-KR CD19-CD90+.   
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Figure 5.9 Lineage converted PKCα-KR cells downregulate B cell specific 
genes and upregulate T cell specific genes  
RNA was isolated from cells sorted in Figure 5.8 and expression of mRNA was 
analysed by qRT-PCR using GAPDH/HPRT as the housekeeping genes. 1=MIEV 
CD19+CD90-; 2=MIEV CD19+CD90+; 3=PKCα-KR CD19+CD90-; 4=PKCα-KR 
CD19+CD90+; 5=PKCα-KR CD19-CD90+.  Data are expressed as means ± SEM of 
at least 3 biological replicates.  p values were generated using the student’s 
unpaired t-test (*p<0.05, **p<0.005, ***p<0.001)   
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Figure 5.10 Lineage converted PKCα-KR B cells carry IgH gene 
rearrangements 
Cells were cultured and sorted as in Figure 5.8 (1=MIEV CD19+CD90-; 2=MIEV 
CD19+CD90+; 3=PKCα-KR CD19+CD90-; 4=PKCα-KR CD19+CD90+; 5=PKCα-KR 
CD19-CD90+) and DNA was analyzed by PCR to determine IgH D-J and V-DJ and 
TCRβ D-J rearrangement status. β2M was used as the loading control and 
genomic DNA from wildtype mouse splenocytes was used as the positive control.      
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Figure 5.11 Lineage converted PKCα-KR B cells downregulate PAX5 and E47 
and upregulate Lck 
Cells were cultured and sorted as in Figure 5.8 (1=MIEV CD19+CD90-; 2=MIEV 
CD19+CD90+; 3=PKCα-KR CD19+CD90-; 4=PKCα-KR CD19+CD90+; 5=PKCα-KR 
CD19-CD90+) and protein lysates were analysed by Western blot to determine 
expression of PAX5, E47, total ERK and Lck.  β tubulin was used as the loading 
control.  
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Figure 5.12 Lineage conversion in PKCα-KR B cells occurs by Id2 and Id3 
modulation  
Cells were cultured and sorted as in Figure 5.8 (1=MIEV CD19+CD90-; 2=MIEV 
CD19+CD90+; 3=PKCα-KR CD19+CD90-; 4=PKCα-KR CD19+CD90+; 5=PKCα-KR 
CD19-CD90+) and RNA was isolated.  Transcript levels of Id2 and Id3 were 
determined by qRT-PCR and expressed as fold change relative to GAPDH and 
normalized to sample 3 (PKCα-KR CD19+CD90- cells). Data are expressed as 
means ± SEM of at least 3 biological replicates.  p values were generated using 
the student’s unpaired t-test (*p<0.05, **p<0.005, ***p<0.001)    
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Figure 5.13 PKCα-KR B cells upregulate ERK signaling 
Cells were cultured and sorted as in Figure 5.8 (1=MIEV CD19+CD90-; 2=PKCα-
KR CD19+CD90-; 3=PKCα-KR CD19+CD90+; 4=PKCα-KR CD19-CD90+) and 
protein lysates were analysed by Western blot to determine expression of 
pERK1/2 and pMEK1/2, ERK and MEK.  β tubulin was used as the loading control.  
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Appendix 5-A Lineage converted PKCα-KR B cells downregulate E47 and 
PAX5, and upregulate Lck (example 2) 
Cells were cultured and sorted as in Figure 5.8 (1=MIEV CD19+CD90-; 2=MIEV 
CD19+CD90+; 3=PKCα-KR CD19+CD90-; 4=PKCα-KR CD19+CD90+; 5=PKCα-KR 
CD19-CD90+) and protein lysates were analysed by Western blot to determine 
expression of E47, PAX5, total ERK and Lck.  GAPDH was used as the loading 
control. Quantification of E47 signal strength as a ratio of loading control is shown 
(right) as mean ± S.D. of 4 biological replicates. p values were generated using the 
student’s unpaired t-test (*p<0.05).    
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6.1 Concluding Remarks 
CLL is a disease marked by the accumulation of malignant B cells that harbour a 
characteristic phenotype of CD19+CD5+CD23+IgMlo.  It is a disease of intraclonal 
heterogeneity and genetic homogeneity.  For example clinical course is highly 
varied between patient groups whereby two distinctive subgroups of CLL patients 
exist: those that harbour mutated IgVH genes and those that harbour unmutated 
IgVH genes. The mutational status of IgVH, alongside surrogate markers ZAP70 
and CD38 dictates prognosis, whereby an unmutated IgVH and ZAP70 and CD38 
positivity indicate a worse overall prognosis.  Unmutated IgVH CLL cells also have 
the ability to signal through the BCR at a stronger intensity than mutated CLL cells, 
thereby amplifying downstream signaling pathways including ERK, NFkB, mTOR, 
Akt and VEGF, and upregulating anti-apoptotic factors such as the Bcl-2 family. 
However, even though two distinct subsets of CLL patients exist with significant 
heterogeneity in clinical course, there is a remarkable genetic similarity in all CLL 
patients, implying a homogenous disease, and a common origin to all CLL cells.  
The microenvironment plays a key role in the survival and proliferation of CLL 
cells.  In fact, CLL cells spontaneously apoptose ex vivo, but survive and 
proliferate with addition of stroma and cytokines (Lagneaux et al. 1999; Chiorazzi 
& Ferrarini 2003).  The BM and secondary lymphoid tissues provide a 
microenvironment whereby CLL cells interact with stromal cells that protect and 
nurture.  NLCs, BMSCs within the microenvironment interact with CLL cells, 
safeguarding them from drug-induced apoptosis and cytotoxic agents (Burger et 
al. 2000; Tsukada et al. 2002) and play important roles in chemotaxis. In addition, 
T cells within the microenvironment have the ability to activate CLL cells through 
the CD40L, and induce proliferation (Buske et al. 1997; Kitada et al. 1999; 
Fluckiger et al. 1992).  Importantly, it is now evident that CLL is not simply a 
disease of accumulation, rather, a disease of active proliferation whereby CLL 
cells proliferate within specific compartments in the BM and LN, thereby causing 
the expansion of the leukaemic clone and resulting in a more aggressive CLL 
(Messmer et al. 2005). 
Our studies have led to the development of a murine model emulating an 
aggressive form of CLL.  Subversion of PKCα signaling in HPCs and subsequent 
in vitro B cell culture has resulted in the generation of B cells that phenotypically 
resemble CLL by the specific upregulation of surface markers CD19, CD5, CD23 
and downregulation of surface IgM. Like umutated CLL, our mCLL cells upregulate 
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anti-apoptotic protein Bcl-2, are ZAP70+ and express AID which promotes genetic 
changes through SHM and CSR, collectively leading to a more aggressive 
disease. Among the signaling pathways upregulated within our CLL model are 
NFκB-, ERK- and mTOR- mediated pathways. 
Injection of PKCα-KR expressing HPCs into RAG1-/- recipients results in 
development of disease coupled with a shorter lifespan as compared to MIEV 
control HPC injected mice.  In addition, there is evidence of enlarged spleens 
harbouring disorganized architecture within the PKCα-KR HPC injected mice. An 
expansion of GFP+CD45+CD19+ cells is evident within the blood, spleen BM and 
LN of these mice in vivo (there is however, IHC evidence of an expansion of B220-
GFP+ cells in vitro and in vivo implicating that subversion of PKCα signaling can 
drive HPCs toward other lineages in a micro-environment specific manner). Within 
such a complex biological system, HPCs can develop into any lineage depending 
on the environment.  Therefore, the expansion of GFP+ cells in vivo implies that 
subversion of PKCα signaling may be an oncogenic trigger for lineages other than 
B cells.   It would be interesting to downregulate PKCα within particular lineages 
through transgenic murine models with a lineage-specific promoter dictating 
deletion of PKCα.   
Downregulation of PKCα also results in a sustained upregulation of PKCβII without 
changes in PKCβI levels.  Similarly, in human CLL, PKCβII  is overexpressed and 
enzymatically active (Abrams et al. 2007; Abrams et al. 2010). In addition, PKCβII 
has been shown to be regulated by and to regulate VEGF aiding in development 
of the malignant phenotype of CLL (Abrams et al. 2010).  In our mouse model 
VEGF mRNA is upregulated, however no correlative links to PKCβII have been 
made thus far, and further experiments are necessary to determine whether a 
relationship between the two exists.  One study demonstrates that crossing of 
PKCβ-/- mice with Eµ-TCL1 mice results in the slowing down of CLL with loss of 
one PKCβ allele or complete abrogation of the disease with loss of both alleles 
(Holler et al. 2009).  However CD5+ B cells were present in mice lacking PKCβ 
especially after TCL1 overexpression suggesting that TCL1 can compensate for 
loss of PKCβ and that PKCβ is not essential of the development of CD5+ B cells 
that may become malignant. Additionally, some mice within the PKCβ-/+ cohorots 
developed disease, although different from that developed within the Eµ-TCL1 
mice (Holler et al. 2009). The authors of this study report significant induction of 
apoptosis of human CLL cells with PKCβ inhibitor enzastaurin, however CLL cells 
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were not isolated prior to treatment, rather a mixed population of MNCs was used.  
On the contrary, Abrams et al found that enzastaurin had little effect on isolated 
CD19+ CLL cells (Abrams et al 2007).  Similarly, in our study treatment with PKCβ 
inhibitor hispidin or with more selective PKCβ inhibitor enzastaurin even at high 
concentrations did not induce apoptosis preferentially within the mCLL cultures.  
However, treatment with hispidin, and more dramatically with enzastaurin induced 
an attenuation in proliferation of mCLL cells and caused them to enter cell cycle 
arrest, indicating that PKCβ is important for the expansion of the malignant clone 
within the proliferation centres.  
Importantly, introduction of PKCβII in HPCs and subsequent in vitro B cell co-
culture resulted in an expansion of GFP+CD19+ B cells over time, however not at 
the same rate as HPCs harbouring PKCα-KR. In addition, a small population 
CD19+CD23+ cells (2.75 %) was apparent within the PKCβII cultures, collectively 
implicating PKCβII as important for the survival and initiation of CLL cells.  Also, 
treatment with enzastaurin in vivo resulted in an increase in apoptosis of GFP+ 
CLL-like cells and a reduction in spleen size. However, limited biological 
replication within these experiments due to time limitations disallow for any 
concrete conclusions to be made.   
A key signaling pathway implicated in our mCLL model is mTOR.  In fact, PKCα-
KR cells upregulate nutrient receptors CD98 and CD71, are larger in size then 
their MIEV counterparts and begin to upregulate pP70 S6 kinase early on, 
implicating activation of mTOR as an oncogenic event. However, treatment of 
mCLL cells with mTORC1 inhibitor rapamycin does not result in dramatic induction 
of apoptosis, however similarly to PKCβ inhibition, treatment with rapamycin 
results in attenuation of proliferation of mCLL cells and increase in cell cycle 
arrest. Therefore mTOR signaling, like PKCβII signaling may be important in the 
generation of a more aggressive, highly proliferative CLL. Coupled with mTOR 
activation, is the activation of ERK which has been demonstrated to be capable of 
phosphorylating S6 kinases under certain conditions (Pende et al. 2004).  PKCβ 
has also been demonstrated to activate ERK (Guo et al. 2008; Lee et al. 2003).  
ERK signaling is important in cell survival and proliferation (Chuderland & Seger 
2005), and can phosphorylate and subsequently activate IKKα resulting in 
phosphorylation of IκBα, its proteosomal degradation and activation of NFκB 
(Chen & Lin 2001).  Indeed PKCα-KR cells exhibit higher levels of IκBα 
phosphorylation indicative of NFκB activation.   
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The oncogenic  transformation of PKCα-KR expressing cells is coupled with an 
upregulation of cyclin D1 mRNA and protein in vitro and in vivo.  It is localized 
within the leukemic B cell areas of the spleen of PKCα-KR injected mice, 
emulating a proliferation centre within human CLL. Importantly, when human CLL 
cells are cultured in the presence of stroma and IL4, cyclin D1 is upregulated, 
implicating it to be important within the microenvironment.  In accordance with this 
finding, we found that some human CLL LN biopsies were positive for cyclin D1.  
Over-expression of cyclin D1 in HPCs was alone insufficient to generate a 
leukaemic phenotype as seen with introduction of PKCα-KR.  The cells expressing 
cyclin D1 did not have an apparent survival advantage over untransduced cells 
within the same culture evident by a decrease in the percentage of GFP+ cells, 
however a small population of cells that expressed cyclin D1 also expressed 
hallmark CLL markers including CD23 and CD5.  This implicates cyclin D1 to be 
important for the CLL phenotype but not the progressive nature of CLL in the 
mCLL model. 
In mCLL, cyclin D1 was shown to be regulated through translational repressor 
4EPB1 that also regulates other key genes such as c-myc and Mcl-1.  4EBP1 was 
found to be inactive in PKCα-KR cultures and regulated by mTOR, as evidenced 
by sensitivity of its phosphorylation states in response to rapamycin treatment.  
Similarly to the findings from mCLL, we found 4EBP1 to be inactive in human CLL, 
and sensitive to phosphorylation in response to rapamycin, however no 
relationship with cyclin D1 was established.  Treatment with PMA resulted in an 
increase of Mcl-1 and c-myc in both HG3 cells and primarly CLL cells, coupled 
with an increase in ERK activity, suggesting inactivation of 4EBP1 through 
activation of other PKCs, such as PKCβII.  This mechanism could be responsible 
for the accumulation of oncogeneic proteins such as Mcl-1 and c-myc. 
Finally, PKCα-KR expressing differentiated B cells are capable of lineage 
switching into the NK, macrophage and T cell lineage upon Notch ligation.  We 
focused on their ability to switch into T cells and show that the transition of B to T 
cell occurs via degradation of E2A and PAX5.  B cell specific genes including 
PAX5, CD19 and EBF1 are downregulated whilst T cell specific genes including 
CD3ε, TCF1, Deltex and pTα become upregulated.  Importantly the lineage 
switched B cells (now T cells) still retain BCR rearrangement reminiscent of their 
origin.  Therefore, in our system, attenuation of PKCα signaling allows cells to fully 
differentiate down a given lineage according to internal and external environmental 
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stimuli, yet also allows for the ability to change lineage according to other stimuli.  
Although fully differentiated, our mCLL cells have preserved pluripotent quality.  
Recently, Kikushige et al. have highlighted the role of stem cells in CLL (Kikushige 
et al. 2011).  Although B and pro-B cells isolated from CLL patients failed to 
engraft into immunodeficient recipient mice, CD34+CD38-(CD90+) stem cells 
isolated from CLL patients not only engrafted stably but also gave rise to myeloid 
and lymphoid cells.  In particular, the engrafted stem cells biased toward a 
polyclonal pro-B cell population, and upon VDJ recombination analysis of more 
mature B cells, mono-and oligoclonaility was evident as well as CD5 expression, 
similarly to that found in monoclonal B cell lymphocytosis (MBL), a precursor to 
CLL. These mature B cells were also CD5+ and exhibited a biased V-gene 
repertoire. Collectively the authors imply a potential origin of a CLL cell to be a 
leukaemic HSC, that after antigen (or autoantigen) selection develops into mono- 
or oligoclonal leukaemic B cell populations that along with additional genomic 
abnormalities develop into CLL (Kikushige et al. 2011).  Given the finding that 
subversion of PKCα signaling in mCLL B cells allows for lineage plasticity, it would 
be interesting to investigate the expression and role of PKCα within different 
populations of human CLL cells, particularly within the CLL HSC population.   
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